: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Neoplasms of the CNS

Free Subscription

Articles published in Neuro Oncol
Retrieve available abstracts of 911 articles:
HTML format

Single Articles

October 2024

HUANG Y, Shan Y, Zhang W, Printzis C, et al
Sex differences in the molecular profile of adult diffuse glioma are shaped by IDH status and tumor microenvironment.
Neuro Oncol. 2024 Oct 5:noae207. doi: 10.1093.
PubMed Abstract available

TANG W, Dou H
Letter to the editor on "The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma".
Neuro Oncol. 2024 Oct 4:noae154. doi: 10.1093.
PubMed

BARTSCH R, Preusser M
Trastuzumab deruxtecan - defining a novel systemic treatment standard for HER2-positive breast cancer brain metastases?
Neuro Oncol. 2024 Oct 3:noae202. doi: 10.1093.
PubMed

HEGI ME, Oppong FB, Perry JR, Wick W, et al
No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients.
Neuro Oncol. 2024;26:1867-1875.
PubMed Abstract available

ZEYEN T, Bohm L, Paech D, Schafer N, et al
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with CCNU/TMZ.
Neuro Oncol. 2024 Oct 1:noae205. doi: 10.1093.
PubMed Abstract available

September 2024

EL SHAFIE RA, Bernhardt D, Welzel T, Schiele A, et al
Stereotactic Radiosurgery for 1-10 Brain Metastases to avoid Whole-Brain Radiotherapy - Results of the CYBER-SPACE Randomized Phase 2 Trial.
Neuro Oncol. 2024 Sep 28:noae201. doi: 10.1093.
PubMed Abstract available

NGUYEN MP, Morshed RA, Youngblood MW, Perlow HK, et al
A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence.
Neuro Oncol. 2024 Sep 28:noae198. doi: 10.1093.
PubMed Abstract available

MASSIMINO M, Barretta F, Dossena C, Minasi S, et al
Long-term outcome of the Milano-HART strategy for high-risk medulloblastoma, including the impact of molecular subtype.
Neuro Oncol. 2024 Sep 27:noae189. doi: 10.1093.
PubMed Abstract available

WU J, Wishart BD, Cohen SE, Orme P, et al
The Pediatric Physiatric Posterior Fossa Symptoms scale (3PFSs): Impairments and outcome in pediatric inpatient rehabilitation for posterior fossa brain tumors.
Neuro Oncol. 2024 Sep 25:noae199. doi: 10.1093.
PubMed Abstract available

Corrigendum to: Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer.
Neuro Oncol. 2024 Sep 21:noae197. doi: 10.1093.
PubMed

TOSEFSKY K, Yip S
"Splice of Life: How RNA is Rewriting the Meningioma Story".
Neuro Oncol. 2024 Sep 17:noae194. doi: 10.1093.
PubMed

Erratum to: The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?
Neuro Oncol. 2024 Sep 14:noae185. doi: 10.1093.
PubMed

SOUBERAN A, Jiguet-Jiglaire C, Toutain S, Morando P, et al
Brain tumoroids: treatment prediction and drug development for brain tumors with fast, reproducible and easy-to-use personalized models.
Neuro Oncol. 2024 Sep 10:noae184. doi: 10.1093.
PubMed Abstract available

REYES A, Stasenko A, Hopper A, Kohli JS, et al
Cognitive phenotypes: Unraveling the heterogeneity in cognitive dysfunction among patients with primary brain tumors receiving radiotherapy.
Neuro Oncol. 2024 Sep 9:noae183. doi: 10.1093.
PubMed Abstract available

AN Z, Fan QW, Wang L, Yoda H, et al
EGFR and EGFRvIII coopt host defense pathways, promoting progression in glioblastoma.
Neuro Oncol. 2024 Sep 9:noae182. doi: 10.1093.
PubMed Abstract available

SLOAN AE, Winter K, Gilbert MR, Aldape K, et al
NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma.
Neuro Oncol. 2024;26:1628-1637.
PubMed Abstract available

NOH MH, Kang JM, Miller AA, Nguyen G, et al
Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy.
Neuro Oncol. 2024;26:1602-1616.
PubMed Abstract available

PIPER K, Kumar JI, Domino J, Tuchek C, et al
Consensus review on strategies to improve delivery across the blood-brain barrier including focused ultrasound.
Neuro Oncol. 2024;26:1545-1556.
PubMed Abstract available

LASTRA ROMERO A, Seitz T, Zisiadis GA, Jeffery H, et al
EDA2R reflects the acute brain response to cranial irradiation in liquid biopsies.
Neuro Oncol. 2024;26:1617-1627.
PubMed Abstract available

MASSAAD E, Smith WJ, Bradley J, Esposito E, et al
Radical surgical resection with molecular margins is associated with improved survival in IDH wild-type glioblastoma.
Neuro Oncol. 2024;26:1660-1669.
PubMed Abstract available

MCAFEE SS, Robinson G, Gajjar A, Phillips NS, et al
Secondary cerebro-cerebellar and intra-cerebellar dysfunction in cerebellar mutism syndrome.
Neuro Oncol. 2024;26:1700-1711.
PubMed Abstract available

Corrigendum to: "Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis".
Neuro Oncol. 2024 Sep 2:noae156. doi: 10.1093.
PubMed

August 2024

SAHM F, Aldape KD, Brastianos PK, Brat DJ, et al
cIMPACT-NOW Update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas.
Neuro Oncol. 2024 Aug 30:noae170. doi: 10.1093.
PubMed Abstract available

PERESLETE AM, Hughes ME, Martin AR, Files J, et al
Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival.
Neuro Oncol. 2024 Aug 30:noae163. doi: 10.1093.
PubMed Abstract available

MAHOOTIHA M, Tak D, Ye Z, Zapaishchykova A, et al
Multimodal Deep Learning Improves Recurrence Risk Prediction in Pediatric Low-Grade Gliomas.
Neuro Oncol. 2024 Aug 30:noae173. doi: 10.1093.
PubMed Abstract available

SANTOS L, Tomatis F, Ferreira HRS, Almeida SFF, et al
ENPP1 induces blood-brain barrier dysfunction and promotes brain metastasis formation in HER2-positive breast cancer.
Neuro Oncol. 2024 Aug 30:noae169. doi: 10.1093.
PubMed Abstract available

ALVAREZ-BRECKENRIDGE C, Brastianos P, Cahill D
Thrombosis, brain metastasis formation, and the perivascular metastatic niche-novel insights from the tumor microvascular circulation.
Neuro Oncol. 2024 Aug 29:noae168. doi: 10.1093.
PubMed

SHEN S, Cui Y, Li M, Yu K, et al
TLR agonists promote formation of Tertiary Lymphoid Structure and improve anti-glioma immunity.
Neuro Oncol. 2024 Aug 27:noae167. doi: 10.1093.
PubMed Abstract available

PARK JE, Oh JY, Park DH, Lee HS, et al
Mapping Tumor Habitats in IDH-Wild Type Glioblastoma: Integrating MR Imaging, Pathologic, and RNA Data from Ivy Glioblastoma Atlas Project.
Neuro Oncol. 2024 Aug 23:noae161. doi: 10.1093.
PubMed Abstract available

Corrigendum to: LY6K promotes glioblastoma tumorigenicity via CAV-1-mediated ERK1/2 signaling enhancement.
Neuro Oncol. 2024 Aug 21:noae151. doi: 10.1093.
PubMed

GHOSH HS, Patel RV, Woodward E, Greenwald NF, et al
Contemporary Prognostic Signatures and Refined Risk Stratification of Gliomas: An Analysis of 4,400 Tumors.
Neuro Oncol. 2024 Aug 21:noae164. doi: 10.1093.
PubMed Abstract available

GARCIA-MOURE M, Laspidea V, Gupta S, Gillard AG, et al
The Emerging Field of Viroimmunotherapy for Pediatric Brain Tumors.
Neuro Oncol. 2024 Aug 16:noae160. doi: 10.1093.
PubMed Abstract available

GUPTA P, Dang M, Oberai S, Migliozzi S, et al
Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas.
Neuro Oncol. 2024 Aug 10:noae139. doi: 10.1093.
PubMed Abstract available

MONTOYA M, Collins SA, Chuntova P, Patel TS, et al
IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma.
Neuro Oncol. 2024 Aug 8:noae149. doi: 10.1093.
PubMed Abstract available

WELLER M, Albert NL, Galldiks N, Bink A, et al
Targeted radionuclide therapy for gliomas: emerging clinical trial landscape.
Neuro Oncol. 2024 Aug 6:noae125. doi: 10.1093.
PubMed Abstract available

KARSCHNIA P, Tonn JC
Shaping the future of molecular neurosurgery: Toward epigenetic precision in surgical neuro-oncology?
Neuro Oncol. 2024;26:1355-1356.
PubMed

BUDHIRAJA S, McManus G, Baisiwala S, Perrault EN, et al
ARF4-mediated retrograde trafficking as a driver of chemoresistance in glioblastoma.
Neuro Oncol. 2024;26:1421-1437.
PubMed Abstract available

ZHANG Y, Kang T, Wang Y, Song C, et al
Low level of tumor necrosis factor alpha in tumor microenvironment maintains self-renewal of glioma stem cells by Vasorin-mediated glycolysis.
Neuro Oncol. 2024 Aug 2:noae147. doi: 10.1093.
PubMed Abstract available

LECLAIR NK, Choudury A, Chen WC, Magill ST, et al
RNA splicing as a biomarker and phenotypic driver of meningioma DNA methylation groups.
Neuro Oncol. 2024 Aug 2:noae150. doi: 10.1093.
PubMed Abstract available

July 2024

LIM-FAT MJ, Cotter JA, Touat M, Vogelzang J, et al
A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients.
Neuro Oncol. 2024 Jul 31:noae142. doi: 10.1093.
PubMed Abstract available

LE RHUN E, Weller M
Tools and toys beyond RANO 2.0: digital flipbooks to monitor brain tumor growth dynamics?
Neuro Oncol. 2024 Jul 31:noae141. doi: 10.1093.
PubMed

SENER U, Sulman EP, Sarkaria JN
Temozolomide Use in Elderly Patients with MGMT Promoter Unmethylated Glioblastoma: Is It Finally Time to Dismount a Dead Horse?
Neuro Oncol. 2024 Jul 31:noae143. doi: 10.1093.
PubMed

KIM KS, Habashy K, Gould A, Zhao J, et al
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated BBB opening: A novel combinatorial immunotherapy regimen for gliomas.
Neuro Oncol. 2024 Jul 19:noae135. doi: 10.1093.
PubMed Abstract available

CHAN A, Zhang K, Martin G, Bano S, et al
Maternal obesogenic diet operates at the tumor cell of origin to increase incidence and decrease latency of Neurofibromatosis Type 1 optic pathway glioma.
Neuro Oncol. 2024 Jul 18:noae136. doi: 10.1093.
PubMed Abstract available

KETKAR M, Desai S, Rana P, Thorat R, et al
Inhibition of PERK mediated UPR acts as a switch for reversal of residual senescence and as senolytic therapy in glioblastoma.
Neuro Oncol. 2024 Jul 18:noae134. doi: 10.1093.
PubMed Abstract available

Erratum to: QOL-14. EPILEPTIC SEIZURES, ANTI-SEIZURE MEDICATIONS, AND NEUROCOGNITION IN SURVIVORS OF PEDIATRIC BRAIN TUMORS.
Neuro Oncol. 2024 Jul 17:noae129. doi: 10.1093.
PubMed

LUO X, Yang Y, Yin S, Li H, et al
Automated segmentation of brain metastases with deep learning: a multi-center, randomized crossover, multi-reader evaluation study.
Neuro Oncol. 2024 Jul 11:noae113. doi: 10.1093.
PubMed Abstract available

FIGG J, Chen D, Falceto Font L, Flores C, et al
In Vivo Mouse Models for Adult Brain Tumors: Exploring Tumorigenesis and Advancing Immunotherapy Development.
Neuro Oncol. 2024 Jul 11:noae131. doi: 10.1093.
PubMed Abstract available

HOU AJ, Shih RM, Uy BR, Shafer A, et al
IL-13Ralpha2/TGF-beta bispecific CAR-T cells counter TGF-beta-mediated immune suppression and potentiate anti-tumor responses in glioblastoma.
Neuro Oncol. 2024 Jul 10:noae126. doi: 10.1093.
PubMed Abstract available

GALLDIKS N, Lohmann P, Friedrich M, Werner JM, et al
PET imaging of gliomas: Status quo and quo vadis?
Neuro Oncol. 2024 Jul 6:noae078. doi: 10.1093.
PubMed Abstract available

LI B, Zhao S, Li S, Li C, et al
Novel molecular subtypes of intracranial germ cell tumors expand therapeutic opportunities.
Neuro Oncol. 2024;26:1335-1351.
PubMed Abstract available

ROZENBLUM L, Houillier C, Baptiste A, Soussain C, et al
Interim FDG-PET improves treatment failure prediction in primary central nervous system lymphoma: An LOC network prospective multicentric study.
Neuro Oncol. 2024;26:1292-1301.
PubMed Abstract available

PAPINI C, Mirzaei S S, Xing M, Tonning Olsson I, et al
Neurocognitive outcomes and functional independence in adult survivors of childhood medulloblastoma diagnosed over three decades.
Neuro Oncol. 2024 Jul 4:noae119. doi: 10.1093.
PubMed Abstract available

BARTSCH R, Berghoff AS, Furtner J, Marhold M, et al
FINAL outcome ANALYSIS FROM THE PHASE II TUXEDO-1 TRIAL OF TRASTUZUMAB-DERUXTECAN IN HER2-positive breast cancer PATIENTS WITH active brain metastases.
Neuro Oncol. 2024 Jul 4:noae123. doi: 10.1093.
PubMed Abstract available

MARQUEZ-RODAS I, Alvarez A, Arance A, Valduvieco I, et al
Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).
Neuro Oncol. 2024 Jul 1:noae116. doi: 10.1093.
PubMed Abstract available

June 2024

KINSLOW CJ, Roy S, Iwamoto FM, Brown PD, et al
The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wildtype and -mutant lower grade gliomas.
Neuro Oncol. 2024 Jun 29:noae102. doi: 10.1093.
PubMed Abstract available

LIU SJ, Raleigh DR, de Groot JF
Proteasome inhibition for glioblastoma: lessons learned and new opportunities.
Neuro Oncol. 2024 Jun 27:noae118. doi: 10.1093.
PubMed

SONKSEN M, Obrecht-Sturm D, Hernaiz Driever P, Sauerbrey A, et al
Medulloblastoma in children with Fanconi anemia: Association with FA-D1/FA-N, SHH type and poor survival independent of treatment strategies.
Neuro Oncol. 2024 Jun 26:noae111. doi: 10.1093.
PubMed Abstract available

NAKASE T, Guerra GA, Ostrom QT, Ge T, et al
Genome-wide Polygenic Risk Scores Predict Risk of Glioma and Molecular Subtypes.
Neuro Oncol. 2024 Jun 25:noae112. doi: 10.1093.
PubMed Abstract available

ABU-ARJA MH, Brown AL, Su JM, Okcu MF, et al
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma.
Neuro Oncol. 2024 Jun 25:noae114. doi: 10.1093.
PubMed Abstract available

VAN DEN BENT MJ, French PJ, Brat D, Tonn JC, et al
The biological significance of tumor grade, age, enhancement and extent of resection in IDH mutant gliomas: how should they inform treatment decision in the era of IDH inhibitors? Invited review.
Neuro Oncol. 2024 Jun 24:noae107. doi: 10.1093.
PubMed Abstract available

SEGURA-COLLAR B, Gargini R
Sex differences in glioblastoma based on tumor subtypes.
Neuro Oncol. 2024 Jun 17:noae089. doi: 10.1093.
PubMed

OFFI M, Gabriele L, Romagnoli G, Lauretti L, et al
The Sybil prophecy: Searching for predictors of response to bevacizumab in glioblastoma.
Neuro Oncol. 2024 Jun 17:noae088. doi: 10.1093.
PubMed

RENOULT O, Laurent-Blond M, Awada H, Oliver L, et al
Metabolic Profiling of Glioblastoma Stem Cells Reveals Pyruvate Carboxylase as a Critical Survival Factor and Potential Therapeutic Target.
Neuro Oncol. 2024 Jun 13:noae106. doi: 10.1093.
PubMed Abstract available

ZHOU L, van Bree N, Boutin L, Ryu J, et al
High-throughput neural stem cell-based drug screening identifies S6K1 inhibition as a selective vulnerability in SHH-medulloblastoma.
Neuro Oncol. 2024 Jun 11:noae104. doi: 10.1093.
PubMed Abstract available

DOBBER L, Geurts M, van den Bent MJ
Tumor growth in recurrent glioblastoma-RANO: when to plan the baseline scan?
Neuro Oncol. 2024 Jun 10:noae095. doi: 10.1093.
PubMed

MYNAREK M, Rossius A, Guiard A, Ottensmeier H, et al
Risk factors for domain-specific neurocognitive outcome in pediatric survivors of a brain tumor in the posterior fossa - Results of the HIT 2000 trial.
Neuro Oncol. 2024 Jun 5:noae092. doi: 10.1093.
PubMed Abstract available

ROESLER J, Spitzer D, Jia X, Aasen SN, et al
Disturbance in cerebral blood microcirculation and hypoxic-ischemic microenvironment are associated with the development of brain metastasis.
Neuro Oncol. 2024 Jun 4:noae094. doi: 10.1093.
PubMed Abstract available

GROGAN PT, Vogelbaum MA
Diffuse Midline (H3 K27M-Mutant) Glioma in Adults - Resection Fails to Matter.
Neuro Oncol. 2024 Jun 3:noae099. doi: 10.1093.
PubMed

LITA A, Sjoberg J, Pacioianu D, Siminea N, et al
Raman-based machine learning platform reveals unique metabolic differences between IDHmut and IDHwt glioma.
Neuro Oncol. 2024 Jun 3:noae101. doi: 10.1093.
PubMed Abstract available

NAYAK L, Bettegowda C, Scherer F, Galldiks N, et al
Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review.
Neuro Oncol. 2024;26:993-1011.
PubMed Abstract available

GALBRAITH K, Garcia M, Wei S, Chen A, et al
Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.
Neuro Oncol. 2024;26:1042-1051.
PubMed Abstract available

HASKELL-MENDOZA AP, Reason EH, Gonzalez AT, Jackson JD, et al
Automated segmentation of ablated lesions using deep convolutional neural networks: A basis for response assessment following laser interstitial thermal therapy.
Neuro Oncol. 2024;26:1152-1162.
PubMed Abstract available

LANG F, Cornwell JA, Kaur K, Elmogazy O, et al
Abrogation of the G2/M checkpoint as a chemosensitization approach for alkylating agents.
Neuro Oncol. 2024;26:1083-1096.
PubMed Abstract available

PARK YW, Jang G, Kim SB, Choi K, et al
Leptomeningeal Metastases in IDH-wildtype Glioblastomas Revisited: Comprehensive Analysis of Incidence, Risk Factors, and Prognosis Based on Post-contrast FLAIR.
Neuro Oncol. 2024 Jun 1:noae091. doi: 10.1093.
PubMed Abstract available

May 2024

BUCHNER JA, Kofler F, Mayinger M, Christ SM, et al
Radiomics-based prediction of local control in patients with brain metastases following postoperative stereotactic radiotherapy.
Neuro Oncol. 2024 May 30:noae098. doi: 10.1093.
PubMed Abstract available

CHO NS, Le VL, Sanvito F, Oshima S, et al
Digital "flipbooks" for enhanced visual assessment of simple and complex brain tumors.
Neuro Oncol. 2024 May 29:noae097. doi: 10.1093.
PubMed Abstract available

ZHANG Y, Hudson K, Abounader R
Unraveling the hypoxic puzzle: LncRNA LUCAT1 drives glioblastoma in cooperation with HIF1?.
Neuro Oncol. 2024 May 21:noae096. doi: 10.1093.
PubMed

FAMILIAR AM, Fathi Kazerooni A, Vossough A, Ware JB, et al
Towards Consistency in Pediatric Brain Tumor Measurements: Challenges, Solutions, and the Role of AI-Based Segmentation.
Neuro Oncol. 2024 May 21:noae093. doi: 10.1093.
PubMed Abstract available

O'HARE P, Cooney T, de Blank P, Gutmann DH, et al
Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition.
Neuro Oncol. 2024 May 14:noae074. doi: 10.1093.
PubMed Abstract available

LEON BE, Bayik D
A triad between sex, necrosis, and inflammation shapes glioblastoma outcomes.
Neuro Oncol. 2024 May 14:noae086. doi: 10.1093.
PubMed

LI M, Zhang Z, He L, Wang X, et al
SMYD2 induced PGC1alpha methylation promotes stemness maintenance of glioblastoma stem cells.
Neuro Oncol. 2024 May 9:noae090. doi: 10.1093.
PubMed Abstract available

NUSSBAUMER G, Benesch M, Grabovska Y, Mackay A, et al
Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile.
Neuro Oncol. 2024 May 8:noae080. doi: 10.1093.
PubMed Abstract available

Corrigendum to: The surgical management of diffuse gliomas: Current state of neurosurgical management and future directions.
Neuro Oncol. 2024 May 7:noae083. doi: 10.1093.
PubMed

PRICE M, Neff C, Nagarajan N, Kruchko C, et al
CBTRUS Statistical Report: American Brain Tumor Association & NCI Neuro-Oncology Branch Adolescent and Young Adult Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020.
Neuro Oncol. 2024;26.
PubMed Abstract available

MAIR MJ, Tabouret E, Johnson DR, Sulman EP, et al
Radioligand therapies in meningioma - evidence and future directions.
Neuro Oncol. 2024 May 4:noae069. doi: 10.1093.
PubMed Abstract available

POLLEY MC, Schwartz D, Karrison T, Dignam JJ, et al
Leveraging external control data in the design and analysis of neuro-oncology trials: Pearls and perils.
Neuro Oncol. 2024;26:796-810.
PubMed Abstract available

WAGNER A, Brielmaier MC, Kampf C, Baumgart L, et al
Fluorescein-stained confocal laser endomicroscopy versus conventional frozen section for intraoperative histopathological assessment of intracranial tumors.
Neuro Oncol. 2024;26:922-932.
PubMed Abstract available

DOTTERMUSCH M, Biabani A, Lempertz T, Schumann Y, et al
Integrated proteomics spotlight the proteasome as a therapeutic vulnerability in embryonal tumors with multilayered rosettes.
Neuro Oncol. 2024;26:935-949.
PubMed Abstract available

SURESH H, Morgan BR, Mithani K, Warsi NM, et al
Postoperative cerebellar mutism syndrome is an acquired autism-like network disturbance.
Neuro Oncol. 2024;26:950-964.
PubMed Abstract available

CHERNG HR, Sun K, Bentzen S, Armstrong TS, et al
Evaluating the heterogeneity of hippocampal avoidant whole brain radiotherapy treatment effect: A secondary analysis of NRG CC001.
Neuro Oncol. 2024;26:911-921.
PubMed Abstract available

WANG JZ, Landry AP, Raleigh DR, Sahm F, et al
Meningioma: International Consortium on Meningiomas (ICOM) consensus review on scientific advances & treatment paradigms for clinicians, researchers, and patients.
Neuro Oncol. 2024 May 2:noae082. doi: 10.1093.
PubMed Abstract available

HENDRIKSEN JD, Locallo A, Maarup S, Debnath O, et al
Immunotherapy drives mesenchymal tumour cell state shift and TME immune response in glioblastoma patients.
Neuro Oncol. 2024 May 2:noae085. doi: 10.1093.
PubMed Abstract available

April 2024

MURPHY ES, Yang K, Suh JH, Yu JS, et al
Phase I trial of dose escalation for preoperative stereotactic radiosurgery for patients with large brain metastases.
Neuro Oncol. 2024 Apr 24:noae076. doi: 10.1093.
PubMed Abstract available

PACKER RJ
Very long-term outcomes of pediatric patients treated for optic pathway gliomas: A longitudinal cohort study.
Neuro Oncol. 2024 Apr 17:noae079. doi: 10.1093.
PubMed

ANASTASAKI C, Chatterjee J, Koleske JP, Gao Y, et al
NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma.
Neuro Oncol. 2024 Apr 12:noae054. doi: 10.1093.
PubMed Abstract available

TOHIDINEZHAD F, Zegers CML, Vaassen F, Dijkstra J, et al
Predicting the risk of neurocognitive decline after brain irradiation in adult patients with a primary brain tumor.
Neuro Oncol. 2024 Apr 10:noae035. doi: 10.1093.
PubMed Abstract available

GEURTS M, Preusser M
Locoregional delivery of CAR-T cells - breaking the spell in glioblastoma?
Neuro Oncol. 2024 Apr 9:noae063. doi: 10.1093.
PubMed

ARRILLAGA-ROMANY I, Miller JJ
Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight.
Neuro Oncol. 2024 Apr 8:noae051. doi: 10.1093.
PubMed

OBRECHT-STURM D, Schomig L, Mynarek M, Bison B, et al
Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent MRI lesions after first-line treatment.
Neuro Oncol. 2024 Apr 5:noae071. doi: 10.1093.
PubMed Abstract available

CIOFFI G, Waite KA, Price M, Neff C, et al
The impact of COVID-19 on 2020 monthly incidence trends of primary brain and other CNS tumors.
Neuro Oncol. 2024;26:764-774.
PubMed Abstract available

APPIN CL, Hong C, Suwala AK, Hilz S, et al
Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression.
Neuro Oncol. 2024;26:640-652.
PubMed Abstract available

DUMOT C, Mantziaris G, Dayawansa S, Peker S, et al
Stereotactic radiosurgery for nonfunctioning pituitary tumor: A multicenter study of new pituitary hormone deficiency.
Neuro Oncol. 2024;26:715-723.
PubMed Abstract available

BUDHU JA, Chukwueke UN, Jackson S, Lee EQ, et al
Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort.
Neuro Oncol. 2024;26:596-608.
PubMed Abstract available

BROMBERG JEC, Issa S, van der Holt B, van der Meulen M, et al
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.
Neuro Oncol. 2024;26:724-734.
PubMed Abstract available

RICKLEFS FL, Wollmann K, Salviano-Silva A, Drexler R, et al
Circulating extracellular vesicles as biomarker for diagnosis, prognosis and monitoring in glioblastoma patients.
Neuro Oncol. 2024 Apr 3:noae068. doi: 10.1093.
PubMed Abstract available

March 2024

XIE H, Jiang Y, Xiang Y, Wu B, et al
Super-enhancer-driven LIF promotes the mesenchymal transition in glioblastoma by activating ITGB2 signaling feedback in microglia.
Neuro Oncol. 2024 Mar 30:noae065. doi: 10.1093.
PubMed Abstract available

DE LA NAVA D, Ausejo-Mauleon I, Laspidea V, Gonzalez-Huarriz M, et al
The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.
Neuro Oncol. 2024 Mar 30:noae066. doi: 10.1093.
PubMed Abstract available

IVANIDZE J, Chang SJ, Haghdel A, Kim JT, et al
[Ga68] DOTATATE PET/MRI-Guided Radiosurgical Treatment Planning and Response Assessment in Meningiomas.
Neuro Oncol. 2024 Mar 30:noae067. doi: 10.1093.
PubMed Abstract available

MCCORD M, Jamshidi P
Targeting the cell cycle to enhance chemotherapy efficacy in glioblastoma.
Neuro Oncol. 2024 Mar 22:noae062. doi: 10.1093.
PubMed

RAHMAN R, Shi DD, Reitman ZJ, Hamerlik P, et al
DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology.
Neuro Oncol. 2024 Mar 22:noae072. doi: 10.1093.
PubMed Abstract available

RYBA A, Ozdemir Z, Nissimov N, Honikl L, et al
Insights from a Multicenter Study on Adult H3 K27M-Mutated Glioma: Surgical Resection's Limited Influence on Overall Survival, ATRX as Molecular Prognosticator.
Neuro Oncol. 2024 Mar 20:noae061. doi: 10.1093.
PubMed Abstract available

ALVAREZ-VAZQUEZ A, San-Segundo L, Cervero-Garcia P, Flores-Hernandez R, et al
EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.
Neuro Oncol. 2024 Mar 20:noae060. doi: 10.1093.
PubMed Abstract available

Corrigendum to: Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
Neuro Oncol. 2024 Mar 20:noae055. doi: 10.1093.
PubMed

ROTH P, Gorlia T, Reijneveld JC, de Vos F, et al
Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial.
Neuro Oncol. 2024 Mar 19:noae053. doi: 10.1093.
PubMed Abstract available

LECHPAMMER M
Can confocal laser endomicroscopy replace frozen section in diagnosis of brain tumors? A definite maybe.
Neuro Oncol. 2024 Mar 15:noae042. doi: 10.1093.
PubMed

LAWLER S
Identification of transcriptomic signatures associated with glioblastoma recurrence.
Neuro Oncol. 2024 Mar 12:noae044. doi: 10.1093.
PubMed

STEVERS NO, Costello JF
Telomeres in glioma: Maintenance mechanisms to therapeutic potential.
Neuro Oncol. 2024 Mar 11:noae052. doi: 10.1093.
PubMed

GALLDIKS N, Kaufmann TJ, Vollmuth P, Lohmann P, et al
Challenges, Limitations and Pitfalls of PET and Advanced MRI in Patients with Brain Tumors - A Report of the PET/RANO Group.
Neuro Oncol. 2024 Mar 11:noae049. doi: 10.1093.
PubMed Abstract available

MOREIRA DC, Qaddoumi I, Spiller S, Bouldin TW, et al
Comprehensive analysis of MYB/MYBL1-altered pediatric-type diffuse low-grade glioma.
Neuro Oncol. 2024 Mar 11:noae048. doi: 10.1093.
PubMed Abstract available

MORIN A, Allodji R, Kariyawasam D, Touraine P, et al
Very long-term outcomes of pediatric patients treated for optic pathway gliomas: A longitudinal cohort study.
Neuro Oncol. 2024 Mar 11:noae045. doi: 10.1093.
PubMed Abstract available

NAGPAL S, Milano MT, Chiang VL, Soltys SG, et al
Executive Summary of the American Radium Society Appropriate Use Criteria for Brain Metastases in EGFR-mutated and ALK-fusion Non-Small Cell Lung Cancer.
Neuro Oncol. 2024 Mar 9:noae041. doi: 10.1093.
PubMed Abstract available

HUANG H, Shah H, Hao J, Lin J, et al
LncRNA LUCAT1 Promotes Glioblastoma Progression by Enhancing HIF1alpha Activity.
Neuro Oncol. 2024 Mar 8:noae036. doi: 10.1093.
PubMed Abstract available

TABOURET E, Furtner J, Graillon T, Silvani A, et al
3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.
Neuro Oncol. 2024 Mar 7:noae037. doi: 10.1093.
PubMed Abstract available

ARRILLAGA-ROMANY I, Lassman A, McGovern SL, Mueller S, et al
ACTION: A randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
Neuro Oncol. 2024 Mar 6:noae031. doi: 10.1093.
PubMed Abstract available

LEE MD, Jain R
Harnessing Generative AI for Glioma Diagnosis: A Step Forward in Neuro-Oncologic Imaging.
Neuro Oncol. 2024 Mar 5:noae043. doi: 10.1093.
PubMed

SHIXUE Y, Qi Z, Dongyuan S, Xiaoteng C, et al
HIF1alpha/ATF3 partake PGK1 K191/K192 succinylation by modulating P4HA1/succinate signaling in glioblastoma.
Neuro Oncol. 2024 Mar 5:noae040. doi: 10.1093.
PubMed Abstract available

TSENG CL, Zeng KL, Mellon EA, Soltys SG, et al
Evolving concepts in margin strategies and adaptive radiotherapy for glioblastoma: A new future is on the horizon.
Neuro Oncol. 2024;26.
PubMed Abstract available

PALMER JD, Perlow HK, Lehrer EJ, Wardak Z, et al
Novel radiotherapeutic strategies in the management of brain metastases: Challenging the dogma.
Neuro Oncol. 2024;26.
PubMed Abstract available

KOTECHA R, La Rosa A, Mehta MP
How proton therapy fits into the management of adult intracranial tumors.
Neuro Oncol. 2024;26.
PubMed Abstract available

BREEN WG, Aryal MP, Cao Y, Kim MM, et al
Integrating multi-modal imaging in radiation treatments for glioblastoma.
Neuro Oncol. 2024;26.
PubMed Abstract available

MAYO ZS, Billena C, Suh JH, Lo SS, et al
The dilemma of radiation necrosis from diagnosis to treatment in the management of brain metastases.
Neuro Oncol. 2024;26.
PubMed Abstract available

SAHGAL A, Chang S
Pushing the boundaries of radiation technology for the management of central nervous system tumors.
Neuro Oncol. 2024;26.
PubMed

COY S, Lee JS, Chan SJ, Woo T, et al
Systematic characterization of antibody-drug conjugate targets in central nervous system tumors.
Neuro Oncol. 2024;26:458-472.
PubMed Abstract available

February 2024

KIDWELL RL, Aghi MK
Lymphatic endothelial-like cells in the glioblastoma tumor niche drive metabolic alterations that promote stem cell proliferation and survival.
Neuro Oncol. 2024 Feb 28:noae020. doi: 10.1093.
PubMed

KE C, Huang B, Xiang J, Liang J, et al
Secreted Clusterin Inhibits Tumorigenesis by Modulating Tumor Cell and Macrophage in Human Meningioma.
Neuro Oncol. 2024 Feb 28:noae034. doi: 10.1093.
PubMed Abstract available

HILLER-VALLINA S, Mondejar-Ruescas L, Caamano-Moreno M, Comitre-Mariano B, et al
Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in Glioblastoma.
Neuro Oncol. 2024 Feb 27:noae033. doi: 10.1093.
PubMed Abstract available

ODIA Y, Koschmann C, Vitanza NA, de Blank P, et al
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3K27M-mutant glioma.
Neuro Oncol. 2024 Feb 24:noae001. doi: 10.1093.
PubMed Abstract available

Corrigendum to: Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial
Neuro Oncol. 2024 Feb 23:noae030. doi: 10.1093.
PubMed

SLOAN AR, Silver DJ, Kint S, Gallo M, et al
Cancer stem cell hypothesis 2.0 in glioblastoma: Where are we now and where are we going?
Neuro Oncol. 2024 Feb 23:noae011. doi: 10.1093.
PubMed Abstract available

ODIA Y, Hall MD, Cloughesy TF, Wen PY, et al
Selective DRD2 Antagonist and ClpP Agonist ONC201 in a Recurrent Non-midline H3 K27M-mutant Glioma Cohort.
Neuro Oncol. 2024 Feb 22:noae021. doi: 10.1093.
PubMed Abstract available

CHENG HS, Chong YK, Lim EKY, Lee XY, et al
Dual p38MAPK and MEK inhibition disrupts adaptive chemoresistance in mesenchymal glioblastoma to temozolomide.
Neuro Oncol. 2024 Feb 16:noae028. doi: 10.1093.
PubMed Abstract available

SILVESTRI VL, Tran AD, Chung M, Chung N, et al
Distinct uptake and elimination profiles for trastuzumab, human IgG and biocytin-TMR in experimental HER2+ brain metastases of breast cancer.
Neuro Oncol. 2024 Feb 13:noae025. doi: 10.1093.
PubMed Abstract available

MOREIRA DC, Bouffet E, Qaddoumi I
The greatest challenge for pediatric low-grade glioma.
Neuro Oncol. 2024 Feb 10:noae004. doi: 10.1093.
PubMed

PRINCE EW, Apps JR, Jeang J, Chee K, et al
Unraveling the Complexity of the Senescence-Associated Secretory Phenotype in Adamantinomatous Craniopharyngioma Using Multi-Modal Machine Learning Analysis.
Neuro Oncol. 2024 Feb 9:noae015. doi: 10.1093.
PubMed Abstract available

Expression of Concern: microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis.
Neuro Oncol. 2024 Feb 9:noae026. doi: 10.1093.
PubMed

LAUER EM, Riegler E, Mutter JA, Alig SK, et al
Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas.
Neuro Oncol. 2024;26:374-386.
PubMed Abstract available

January 2024

NELLAN A, Jackson S
Targeted therapy done right: direct SHH Inhibition for SHH medulloblastoma.
Neuro Oncol. 2024 Jan 30:noae018. doi: 10.1093.
PubMed

GHOSH S, Rothlin CV
TREM2 function in glioblastoma immune microenvironment: can we distinguish reality from illusion?
Neuro Oncol. 2024 Jan 30:noae019. doi: 10.1093.
PubMed

CHELLIAH A, Wood DA, Canas LS, Shuaib H, et al
Glioblastoma and Radiotherapy: a multi-center AI study for Survival Predictions from MRI (GRASP study).
Neuro Oncol. 2024 Jan 29:noae017. doi: 10.1093.
PubMed Abstract available

WAITKUS MS, Erman EN, Reitman ZJ, Ashley DM, et al
Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas.
Neuro Oncol. 2024 Jan 29:noae016. doi: 10.1093.
PubMed Abstract available

WANG S, Qi Y, Zhao R, Pan Z, et al
Copy number gain of FAM131B-AS2 promotes the progression of glioblastoma by mitigating replication stress.
Neuro Oncol. 2024 Jan 29:noae014. doi: 10.1093.
PubMed Abstract available

MACK SC, Bertrand KC
Understanding the Mechanisms of Diffuse Midline Glioma Cell Migration Towards Therapeutic Targeting.
Neuro Oncol. 2024 Jan 27:noad263. doi: 10.1093.
PubMed

DANKNER M, Maritan SM, Priego N, Kruck G, et al
Invasive growth of brain metastases is linked to CHI3L1 release from pSTAT3-positive astrocytes.
Neuro Oncol. 2024 Jan 25:noae013. doi: 10.1093.
PubMed Abstract available

RANDALL J, Sachdev S
A valuable glioblastoma prognostic maker driven by radiosensitivity.
Neuro Oncol. 2024 Jan 23:noad266. doi: 10.1093.
PubMed

MOON HH, Jeong J, Park JE, Kim N, et al
Generative AI in glioma: ensuring diversity in training image phenotypes to improve diagnostic performance for IDH mutation prediction.
Neuro Oncol. 2024 Jan 22:noae012. doi: 10.1093.
PubMed Abstract available

SUN Y, Mu G, Xue Z, Wang S, et al
Polyunsaturated fatty acid-binding protein FABP7, an attractive metabolic target for inhibition of glioblastoma stem cells.
Neuro Oncol. 2024 Jan 19:noad238. doi: 10.1093.
PubMed

LIU RZ, Choi WS, Godbout R
Nuclear translocation matters: Role of FABP7 in driving glioblastoma stemness and invasion: Reply to Mu et al.
Neuro Oncol. 2024 Jan 19:noad239. doi: 10.1093.
PubMed

ZIEGLER DS, Lehmann R, Eisenstat DD
A paradigm shift in how we treat pediatric low grade glioma - targeting the molecular drivers.
Neuro Oncol. 2024 Jan 19:noae008. doi: 10.1093.
PubMed

PESHOFF MM, Gupta P, Oberai S, Trivedi R, et al
Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma.
Neuro Oncol. 2024 Jan 18:noad257. doi: 10.1093.
PubMed Abstract available

FLIES CM, Friedrich M, Lohmann P, van Garderen KA, et al
Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide.
Neuro Oncol. 2024 Jan 14:noad247. doi: 10.1093.
PubMed Abstract available

WEN PY, van den Bent M, Vogelbaum MA, Chang SM, et al
RANO 2.0: The revised Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade glial tumors in adults designed for the future.
Neuro Oncol. 2024;26:2-4.
PubMed

DOHERTY C, Wilbanks B, Khatua S, Maher LJ 3rd, et al
Aptamers in neuro-oncology: An emerging therapeutic modality.
Neuro Oncol. 2024;26:38-54.
PubMed Abstract available

XING B, Lei Z, Wang Z, Wang Q, et al
A disintegrin and metalloproteinase 22 activates integrin beta1 through its disintegrin domain to promote the progression of pituitary adenoma.
Neuro Oncol. 2024;26:137-152.
PubMed Abstract available

BHUTADA I, Khambati F, Cheng SY, Tiek DM, et al
CDK7 and CDK9 inhibition interferes with transcription, translation, and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity.
Neuro Oncol. 2024;26:70-84.
PubMed Abstract available

Correction to: TSPO deficiency induces mitochondrial dysfunction, leading to hypoxia, angiogenesis, and a growth-promoting metabolic shift toward glycolysis in glioblastoma.
Neuro Oncol. 2024 Jan 4:noad251. doi: 10.1093.
PubMed

ALBERT NL, Preusser M
Measure what is measurable: PET RANO 1.0 criteria for interpretation of amino acid PET of diffuse gliomas.
Neuro Oncol. 2024 Jan 2:noad228. doi: 10.1093.
PubMed

KARSCHNIA P, Dono A, Young JS, Juenger ST, et al
Associations between recurrence patterns and outcome in glioblastoma patients undergoing re-resection: A complementary report of the RANO resect group.
Neuro Oncol. 2024 Jan 2:noad237. doi: 10.1093.
PubMed

December 2023

NEFF C, Price M, Cioffi G, Waite KA, et al
The impact of the COVID-19 pandemic on treatment patterns in glioblastoma.
Neuro Oncol. 2023 Dec 30:noad234. doi: 10.1093.
PubMed

LIU D, Zhu H, Cheng L, Li R, et al
Hypoxia induced Galectin-8 maintains stemness in glioma stem cells via autophagy regulation.
Neuro Oncol. 2023 Dec 30:noad264. doi: 10.1093.
PubMed Abstract available

FOLTYN-DUMITRU M, Kessler T, Sahm F, Wick W, et al
Cluster-based prognostication in glioblastoma: Unveiling heterogeneity based on diffusion and perfusion similarities.
Neuro Oncol. 2023 Dec 28:noad259. doi: 10.1093.
PubMed Abstract available

OBACZ J, Archambeau J, Lafont E, Nivet M, et al
IRE1 endoribonuclease signaling promotes myeloid cell infiltration in glioblastoma.
Neuro Oncol. 2023 Dec 28:noad256. doi: 10.1093.
PubMed Abstract available

RALEIGH DR
Radiotherapy dose escalation for high-risk meningiomas after subtotal resection.
Neuro Oncol. 2023 Dec 28:noad262. doi: 10.1093.
PubMed

MUELLER S, Fangusaro J, Thomas AO, Jacques TS, et al
Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group.
Neuro Oncol. 2023 Dec 26:noad227. doi: 10.1093.
PubMed Abstract available

YAN S, Melnick K, He X, Lyu T, et al
Developing a computable phenotype for glioblastoma.
Neuro Oncol. 2023 Dec 23:noad249. doi: 10.1093.
PubMed Abstract available

DE SAUVAGE MA, Torrini C, Nieblas-Bedolla E, Summers E, et al
The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis.
Neuro Oncol. 2023 Dec 22:noad248. doi: 10.1093.
PubMed Abstract available

MUELLER S, Kline C, Franson A, van der Lugt J, et al
Rational combination platform trial design for children and young adults with Diffuse Midline Glioma: a report from PNOC.
Neuro Oncol. 2023 Dec 20:noad181. doi: 10.1093.
PubMed Abstract available

Correction to: Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?
Neuro Oncol. 2023 Dec 18:noad241. doi: 10.1093.
PubMed

DUN MD, Odia Y, Arrillaga-Romany I
Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon.
Neuro Oncol. 2023 Dec 18:noad245. doi: 10.1093.
PubMed

VAN DEN BENT M, Saratsis AM, Geurts M, Franceschi E, et al
H3 K27M-altered Glioma and Diffuse Intrinsic Pontine Glioma: Semi-systematic Review of Treatment Landscape and Future Directions.
Neuro Oncol. 2023 Dec 15:noad220. doi: 10.1093.
PubMed Abstract available

PATEL J, Aittaleb R, Doherty R, Gera A, et al
Liquid Biopsy in H3K27M Diffuse Midline Glioma.
Neuro Oncol. 2023 Dec 14:noad229. doi: 10.1093.
PubMed Abstract available

PUGAZENTHI S, Price M, De La Vega Gomar R, Kruchko C, et al
Association of County-Level Socioeconomic Status with Meningioma Incidence and Outcomes.
Neuro Oncol. 2023 Dec 13:noad223. doi: 10.1093.
PubMed Abstract available

KIM D, Ko HY, Chung JI, Park YM, et al
Visualizing Cancer-Originating Acetate Uptake Through MCT1 in Reactive Astrocytes in the Glioblastoma Tumor Microenvironment.
Neuro Oncol. 2023 Dec 12:noad243. doi: 10.1093.
PubMed Abstract available

DENG MY, Maas SLN, Hinz F, Karger CP, et al
Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: prospective phase 2 MARCIE trial.
Neuro Oncol. 2023 Dec 11:noad244. doi: 10.1093.
PubMed Abstract available

ALBERT NL, Furtner J, van den Bent MJ, Preusser M, et al
The potential of amino acid PET imaging for prediction and monitoring of vorasidenib response in IDH-mutant gliomas.
Neuro Oncol. 2023 Dec 9:noad240. doi: 10.1093.
PubMed

ZHANG J, Liu B, Xu C, Ji C, et al
Cholesterol homeostasis confers glioma malignancy triggered by hnRNPA2B1-dependent regulation of SREBP2 and LDLR.
Neuro Oncol. 2023 Dec 9:noad233. doi: 10.1093.
PubMed Abstract available

KIM AE, Lou KW, Giobbie-Hurder A, Chang K, et al
Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.
Neuro Oncol. 2023 Dec 9:noad236. doi: 10.1093.
PubMed Abstract available

SUN Y, Mu G, Zhang X, Wu Y, et al
Metabolic Modulation of Histone Acetylation Mediated by HMGCL Activates the FOXM1/beta-catenin Pathway in Glioblastoma.
Neuro Oncol. 2023 Dec 9:noad232. doi: 10.1093.
PubMed Abstract available

NABORS B, Portnow J, Hattangadi-Gluth J, Horbinski C, et al
NCCN CNS tumor guidelines update for 2023.
Neuro Oncol. 2023;25:2114-2116.
PubMed

KARSCHNIA P, Arrillaga-Romany IC, Eichler A, Forst DA, et al
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
Neuro Oncol. 2023;25:2239-2249.
PubMed Abstract available

BOELDERS SM, Gehring K, Postma EO, Rutten GJM, et al
Cognitive functioning in untreated glioma patients: the limited predictive value of clinical variables.
Neuro Oncol. 2023 Dec 1:noad221. doi: 10.1093.
PubMed Abstract available

November 2023

XIN DE, Liao Y, Rao R, Ogurek S, et al
Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
Neuro Oncol. 2023 Nov 27:noad222. doi: 10.1093.
PubMed Abstract available

CHEN E, Ling AL, Reardon DA, Chiocca EA, et al
Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?
Neuro Oncol. 2023 Nov 23:noad211. doi: 10.1093.
PubMed Abstract available

RALEIGH DR, Preusser M
A 34-gene expression biomarker predicts meningioma outcomes and radiotherapy responses.
Neuro Oncol. 2023 Nov 15:noad212. doi: 10.1093.
PubMed

FANGUSARO J, Jones DT, Packer RJ, Gutmann DH, et al
Pediatric low-grade glioma: State-of-the-art and ongoing challenges.
Neuro Oncol. 2023 Nov 7:noad195. doi: 10.1093.
PubMed Abstract available

TURCAN S
SIRT2 inhibition as the Achilles' heel of ATRX-deficient gliomas.
Neuro Oncol. 2023 Nov 6:noad217. doi: 10.1093.
PubMed

LING AL, Chiocca EA
Oncolytic immunoactivation associates with survival in a glioblastoma clinical trial.
Neuro Oncol. 2023 Nov 6:noad216. doi: 10.1093.
PubMed

ZHENG J, Wang L, Zhao S, Zhang W, et al
TREM2 mediates MHCII-associated CD4+ T cell response against gliomas.
Neuro Oncol. 2023 Nov 6:noad214. doi: 10.1093.
PubMed Abstract available

DERBY S, Dutton L, Strathdee KE, Stevenson K, et al
Inhibition of ATR opposes glioblastoma invasion through disruption of cytoskeletal networks and integrin internalisation via macropinocytosis.
Neuro Oncol. 2023 Nov 4:noad210. doi: 10.1093.
PubMed Abstract available

DESISTO J, Donson AM, Griesinger AM, Fu R, et al
Tumor and immune cell types interact to produce heterogeneous phenotypes of pediatric high grade glioma.
Neuro Oncol. 2023 Nov 2:noad207. doi: 10.1093.
PubMed Abstract available

Erratum to: EPIC-1042 as a potent PTRF/Cavin1-caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma.
Neuro Oncol. 2023 Nov 1:noad200. doi: 10.1093.
PubMed

October 2023

SIEBENGA FF, van der Weide HL, Gelmers F, Rakers SE, et al
Emotion recognition in relation to tumor characteristics in patients with low-grade glioma.
Neuro Oncol. 2023 Oct 31:noad209. doi: 10.1093.
PubMed Abstract available

HOTCHKISS KM, Cho E, Khasraw M
A FIRST-IN-HUMAN PEPTIDE VACCINE TARGETING H3K27M; Encouraging Early Findings in Eight Adults with Diffuse Midline Glioma.
Neuro Oncol. 2023 Oct 31:noad203. doi: 10.1093.
PubMed

COSENZA-CONTRERAS M, Schafer A, Sing J, Cook L, et al
Proteometabolomics of initial and recurrent glioblastoma highlights an increased immune cell signature with altered lipid metabolism.
Neuro Oncol. 2023 Oct 26:noad208. doi: 10.1093.
PubMed Abstract available

GERSHON R, Polevikov A, Karepov Y, Shenkar A, et al
;Frequencies of four Tumor-infiltrating lymphocytes potently predict survival in glioblastoma, an immune desert.
Neuro Oncol. 2023 Oct 23:noad204. doi: 10.1093.
PubMed Abstract available

LEE JO, Ahn SS, Choi KS, Lee J, et al
Added Prognostic Value of 3D Deep Learning-Derived Features from Preoperative MRI for Adult-type Diffuse Gliomas.
Neuro Oncol. 2023 Oct 19:noad202. doi: 10.1093.
PubMed Abstract available

MCDONALD MF, Hossain A, Momin E, Hasan I, et al
Tumor-specific Polycistronic miRNA Delivered by Engineered Exosomes for the Treatment of Glioblastoma.
Neuro Oncol. 2023 Oct 17:noad199. doi: 10.1093.
PubMed Abstract available

ECKHARDT A, Drexler R, Schoof M, Struve N, et al
Mean global DNA methylation serves as independent prognostic marker in IDH wild type glioblastoma.
Neuro Oncol. 2023 Oct 11:noad197. doi: 10.1093.
PubMed Abstract available

SARATSIS AM, Knowles T, Petrovic A, Nazarian J, et al
H3K27M Mutant Glioma: Disease Definition and Biological Underpinnings.
Neuro Oncol. 2023 Oct 11:noad164. doi: 10.1093.
PubMed Abstract available

Corrigendum to: Isocitrate dehydrogenase wt and IDHmut adult-type diffuse gliomas display distinct alterations in ribosome biogenesis and 2'O-methylation of ribosomal RNA.
Neuro Oncol. 2023 Oct 10:noad192. doi: 10.1093.
PubMed

LOUGHAN AR, Lanoye A, Willis KD, Fox A, et al
Telehealth group Cognitive Behavioral Therapy for Insomnia (CBT-I) in primary brain tumor: Primary outcomes from a single-arm Phase 2 feasibility and proof-of-concept trial.
Neuro Oncol. 2023 Oct 5:noad193. doi: 10.1093.
PubMed Abstract available

OSTROM QT, Price M, Neff C, Cioffi G, et al
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020.
Neuro Oncol. 2023;25.
PubMed Abstract available

HANSFORD JR, Eisenstat DD
No safe harbors for recurrent posterior fossa group A ependymoma: A time for change in risk assignment?
Neuro Oncol. 2023;25:1868-1870.
PubMed

DONSON AM, Bertrand KC, Riemondy KA, Gao D, et al
Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter study.
Neuro Oncol. 2023;25:1854-1867.
PubMed Abstract available

September 2023

BOSKOVIC P, Wilke N, Man KH, Lichter P, et al
BCAT1 regulates glioblastoma cell plasticity and contributes to immunosuppression.
Neuro Oncol. 2023 Sep 28:noad190. doi: 10.1093.
PubMed Abstract available

KRESBACH C, Holst L, Schoof M, Leven T, et al
Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects.
Neuro Oncol. 2023 Sep 28:noad191. doi: 10.1093.
PubMed Abstract available

REMES TM, Suo-Palosaari MH, Arikoski PM, Harila M, et al
Radiotherapy-induced vascular cognitive impairment 20 years after childhood brain tumor.
Neuro Oncol. 2023 Sep 27:noad186. doi: 10.1093.
PubMed Abstract available

SAIJO A, Ogino H, Butowski NA, Tedesco MR, et al
A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.
Neuro Oncol. 2023 Sep 27:noad185. doi: 10.1093.
PubMed Abstract available

Correction to: Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
Neuro Oncol. 2023 Sep 26:noad180. doi: 10.1093.
PubMed

BIHN JR, Cioffi G, Waite KA, Kruchko C, et al
Brain Tumors in United States Military Veterans.
Neuro Oncol. 2023 Sep 22:noad182. doi: 10.1093.
PubMed Abstract available

ODDE D
Glioblastoma Cell Invasion: Go? Grow? Yes.
Neuro Oncol. 2023 Sep 22:noad178. doi: 10.1093.
PubMed

MILDE T, Fangusaro J, Fisher MJ, Hawkins C, et al
Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation.
Neuro Oncol. 2023 Sep 21:noad125. doi: 10.1093.
PubMed Abstract available

DESHPANDE K, Martirosian V, Nakamura BN, Das D, et al
SRRM4-mediated REST to REST4 dysregulation promotes tumor growth and neural adaptation in breast cancer leading to brain metastasis.
Neuro Oncol. 2023 Sep 16:noad175. doi: 10.1093.
PubMed Abstract available

KRAMER C, Kilian M, Chih YC, Kourtesakis A, et al
NLGN4X TCR transgenic T cells to treat gliomas.
Neuro Oncol. 2023 Sep 16:noad172. doi: 10.1093.
PubMed Abstract available

JOHNSON TS, MacDonald TJ, Pacholczyk R, Aguilera D, et al
Indoximod-based chemo-immunotherapy for pediatric brain tumors: a first-in-children phase 1 trial.
Neuro Oncol. 2023 Sep 16:noad174. doi: 10.1093.
PubMed Abstract available

TOBOCHNIK S, Dorotan MKC, Ghosh HS, Lapinskas E, et al
Glioma genetic profiles associated with electrophysiologic hyperexcitability.
Neuro Oncol. 2023 Sep 15:noad176. doi: 10.1093.
PubMed Abstract available

MISHRA DK, Popovski D, Morris SM, Bondoc A, et al
Preclinical Pediatric Brain Tumor Models for Immunotherapy: Hurdles and a Way Forward.
Neuro Oncol. 2023 Sep 15:noad170. doi: 10.1093.
PubMed Abstract available

Correction to: HGG-16. COMPARATIVE ANALYSIS OF AUTOPHAGY IN DRUG RESPONSES AND AGGRESSIVE BEHAVIOR OF ADULT VERSUS PEDIATRIC GLIOMA CELL LINES.
Neuro Oncol. 2023 Sep 13:noad168. doi: 10.1093.
PubMed

BRUSCHI M, Midjek L, Ajlil Y, Vairy S, et al
Diffuse Midline Glioma Invasion and Metastasis Rely on Cell-autonomous Signaling.
Neuro Oncol. 2023 Sep 13:noad161. doi: 10.1093.
PubMed Abstract available

Correction to: Mapping pediatric brain tumors to their origins in the developing cerebellum.
Neuro Oncol. 2023 Sep 12:noad167. doi: 10.1093.
PubMed

AVILA EK, Tobochnik S, Inati SK, Koekkoek JAF, et al
Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management.
Neuro Oncol. 2023 Sep 12:noad154. doi: 10.1093.
PubMed Abstract available

SHI DD, Kaelin WG
The INDIGO Trial: Precision Medicine Finally Comes to Glioma.
Neuro Oncol. 2023 Sep 12:noad162. doi: 10.1093.
PubMed

CAHILL DP, Dunn GP
Considering the Extent of Resection in Diffuse Glioma.
Neuro Oncol. 2023 Sep 7:noad165. doi: 10.1093.
PubMed

BROWN AL, Sok P, Raghubar KP, Lupo PJ, et al
Genetic susceptibility to cognitive decline following craniospinal irradiation for pediatric central nervous system tumors.
Neuro Oncol. 2023;25:1698-1708.
PubMed Abstract available

CHARBONNEAU M, Harper K, Brochu-Gaudreau K, Perreault A, et al
The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.
Neuro Oncol. 2023;25:1605-1616.
PubMed Abstract available

KARSCHNIA P, Dietrich J, Bruno F, Dono A, et al
Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement ('low grade appearance') - a report of the RANO resect group.
Neuro Oncol. 2023 Sep 4:noad160. doi: 10.1093.
PubMed Abstract available

August 2023

HONG B, Yang E, Su D, Ju J, et al
EPIC-1042 as a potent PTRF/Cavin1-Caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for Glioblastoma.
Neuro Oncol. 2023 Aug 31:noad159. doi: 10.1093.
PubMed Abstract available

PINSON H, Silversmit G, Vanhauwaert D, Vanschoenbeek K, et al
Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era.
Neuro Oncol. 2023 Aug 31:noad158. doi: 10.1093.
PubMed Abstract available

MALGULWAR PB, Danussi C, Dharmaiah S, Johnson W, et al
Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma.
Neuro Oncol. 2023 Aug 25:noad155. doi: 10.1093.
PubMed Abstract available

GU D, You H, Gao J, You Y, et al
Reply to "Targeting cholesterol homeostasis through inhibiting: An Achilles' heel for glioblastoma?".
Neuro Oncol. 2023 Aug 25:noad146. doi: 10.1093.
PubMed

SUN Y, Mu G, Xue Z, Wang S, et al
Targeting cholesterol homeostasis through inhibiting SREBP-2: An Achilles' heel for glioblastoma.
Neuro Oncol. 2023 Aug 25:noad145. doi: 10.1093.
PubMed

HUANG W, Li J, Zhu H, Qin X, et al
A novel EGFR variant EGFRx maintains glioblastoma stem cells through STAT5.
Neuro Oncol. 2023 Aug 24:noad153. doi: 10.1093.
PubMed Abstract available

KAN P, Srinivasan VM, Gumin J, Garcia R, et al
Development of a Rabbit Human Glioblastoma Model for Testing of Endovascular Selective Intra-Arterial Infusion (ESIA) of Novel Stem Cell-Based Therapeutics.
Neuro Oncol. 2023 Aug 21:noad152. doi: 10.1093.
PubMed Abstract available

PATEL KS, Yao J, Cho NS, Sanvito F, et al
pH-Weighted Amine Chemical Exchange Saturation Transfer Echo Planar Imaging (CEST-EPI) Visualizes Infiltrating Glioblastoma Cells.
Neuro Oncol. 2023 Aug 18:noad150. doi: 10.1093.
PubMed Abstract available

FRANCIS SS, Guerra G, Hansen HM, Wendt G, et al
Inherited polymorphisms in the Human Leukocyte Antigen Region modify the association between varicella-zoster virus antibody reactivity and glioma prognosis.
Neuro Oncol. 2023 Aug 18:noad122. doi: 10.1093.
PubMed

GALLO M
Prognostic value of integrative genomic approaches for IDH-mutant gliomas.
Neuro Oncol. 2023 Aug 17:noad151. doi: 10.1093.
PubMed

JACKSON ER, Persson ML, Fish CJ, Findlay IJ, et al
A review of the anti-tumor potential of current therapeutics targeting the mitochondrial protease ClpP in H3K27-altered, diffuse midline glioma.
Neuro Oncol. 2023 Aug 17:noad144. doi: 10.1093.
PubMed Abstract available

SHENOY G, Connor JR
A Closer Look at the Role of Iron in Glioblastoma.
Neuro Oncol. 2023 Aug 4:noad136. doi: 10.1093.
PubMed Abstract available

OKONECHNIKOV K, Joshi P, Sepp M, Leiss K, et al
Mapping pediatric brain tumors to their origins in the developing cerebellum.
Neuro Oncol. 2023 Aug 3:noad124. doi: 10.1093.
PubMed Abstract available

ROBERTS KF, Dahiya SM
Mitotic index is (still) important for grading isocitrate dehydrogenase (IDH)-mutant astrocytoma.
Neuro Oncol. 2023;25:1450-1451.
PubMed

FENG J, Duan Z, Yao K, Gui Q, et al
Primary papillary epithelial tumor of the sella and posterior pituitary tumor show similar (epi)genetic features and constitute a single neuro-oncological entity.
Neuro Oncol. 2023;25:1487-1497.
PubMed Abstract available

KOJIC M, Maybury MK, Waddell N, Koufariotis LT, et al
Efficient detection and monitoring of pediatric brain malignancies with liquid biopsy based on patient-specific somatic mutation screening.
Neuro Oncol. 2023;25:1507-1517.
PubMed Abstract available

KROS JM, Rushing E, Uwimana AL, Hernandez-Lain A, et al
Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.
Neuro Oncol. 2023;25:1443-1449.
PubMed Abstract available

ZUCCATO JA, Patil V, Mansouri S, Voisin M, et al
Cerebrospinal fluid methylome-based liquid biopsies for accurate malignant brain neoplasm classification.
Neuro Oncol. 2023;25:1452-1460.
PubMed Abstract available

PARAQINDES H, Mourksi NE, Ballesta S, Hedjam J, et al
IDHwt and IDHmut adult-type diffuse gliomas display distinct alterations in ribosome biogenesis and 2'O-methylation of ribosomal RNA.
Neuro Oncol. 2023 Aug 2:noad140. doi: 10.1093.
PubMed Abstract available

APFELBAUM A, Bandopadhayay P
The 'LOGGIC' of RNA-sequencing in enhancing diagnoses of pediatric low-grade gliomas.
Neuro Oncol. 2023 Aug 2:noad142. doi: 10.1093.
PubMed

Corrigendum to: USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5.
Neuro Oncol. 2023 Aug 1:noad135. doi: 10.1093.
PubMed

MONJE M, Cooney T, Glod J, Huang J, et al
A Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium (PBTC-047).
Neuro Oncol. 2023 Aug 1:noad141. doi: 10.1093.
PubMed Abstract available

July 2023

ROTH P
CARs in the brain: can we tackle glioblastoma with engineered NK cells?
Neuro Oncol. 2023 Jul 31:noad131. doi: 10.1093.
PubMed

CHIANG J, Bagchi A, Li X, Dhanda SK, et al
High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse-Results from the SJYC07 trial and institutional experience.
Neuro Oncol. 2023 Jul 28:noad130. doi: 10.1093.
PubMed Abstract available

YOUNG JS, Morshed RA, Hervey-Jumper SL, Berger MS, et al
The Surgical Management of Diffuse Gliomas: Current State of Neurosurgical Management and Future Directions.
Neuro Oncol. 2023 Jul 27:noad133. doi: 10.1093.
PubMed Abstract available

LIU RZ, Choi WS, Jain S, Xu X, et al
Stationary-to-migratory transition in glioblastoma stem-like cells driven by a FABP7-RXRalpha neurogenic pathway.
Neuro Oncol. 2023 Jul 27:noad134. doi: 10.1093.
PubMed Abstract available

WOLIN AR, Vincent MY, Hotz T, Purdy SC, et al
EYA2 Tyrosine Phosphatase Inhibition Reduces MYC and Prevents Medulloblastoma Progression.
Neuro Oncol. 2023 Jul 24:noad128. doi: 10.1093.
PubMed Abstract available

HALL MD, Kotecha R
Social Determinants of Health: A Forgotten Risk Factor for Neurocognition in Pediatric Brain Tumor Survivors.
Neuro Oncol. 2023 Jul 24:noad127. doi: 10.1093.
PubMed

PREUSSER M, Geurts M, Hainfellner JA, van den Bent MJ, et al
What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?
Neuro Oncol. 2023 Jul 21:noad113. doi: 10.1093.
PubMed

MAMATJAN Y, Voisin M, Nassiri F, Moraes FY, et al
Integrated molecular analysis reveals hypermethylation and overexpression of HOX genes to be poor prognosticators in IDH mutant glioma.
Neuro Oncol. 2023 Jul 20:noad126. doi: 10.1093.
PubMed Abstract available

HOU J, Huang P, Xu M, Wang H, et al
NCAPG promotes the progression of glioblastoma by facilitating PARP1-mediated E2F1 transactivation.
Neuro Oncol. 2023 Jul 9:noad111. doi: 10.1093.
PubMed Abstract available

LAPRIE A, Noel G, Chaltiel L, Truc G, et al
Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial).
Neuro Oncol. 2023 Jul 7:noad119. doi: 10.1093.
PubMed Abstract available

CHANG SM
Increasing growth and impact of Neuro-Oncology.
Neuro Oncol. 2023;25:1199.
PubMed

Erratum to: METB-13. A SINGLE-CELL GENETIC IN VIVO LINEAGE-TRACING PLATFORM FOR MEDULLOBLASTOMA.
Neuro Oncol. 2023 Jul 6:noad116. doi: 10.1093.
PubMed

POON MTC, Piper RJ, Thango N, Fountain DM, et al
Variation in postoperative outcomes of patients with intracranial tumors: insights from a prospective international cohort study during the COVID-19 pandemic.
Neuro Oncol. 2023;25:1299-1309.
PubMed Abstract available

WELLER M, Le Rhun E, Van den Bent M, Chang SM, et al
Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults.
Neuro Oncol. 2023;25:1200-1224.
PubMed Abstract available

TRAGER M, Schweizer L, Perez E, Schmid S, et al
Adult intracranial ependymoma-relevance of DNA methylation profiling for diagnosis, prognosis, and treatment.
Neuro Oncol. 2023;25:1286-1298.
PubMed Abstract available

RAMMOHAN N, Ho A, Besson P, Kruser TJ, et al
Whole-brain radiotherapy associated with structural changes resembling aging as determined by anatomic surface-based deep learning.
Neuro Oncol. 2023;25:1323-1330.
PubMed Abstract available

SMOLL NR, Brady Z, Scurrah KJ, Lee C, et al
Computed tomography scan radiation and brain cancer incidence.
Neuro Oncol. 2023;25:1368-1376.
PubMed Abstract available

NOCH EK, Palma LN, Yim I, Bullen N, et al
Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma.
Neuro Oncol. 2023 Jul 3:noad117. doi: 10.1093.
PubMed Abstract available

June 2023

VAN SCHAIK J, Schouten-van Meeteren AYN, Vos-Kerkhof E, Janssens GO, et al
Treatment and outcome of the Dutch Childhood Craniopharyngioma Cohort study; first results after centralization of care.
Neuro Oncol. 2023 Jun 29:noad112. doi: 10.1093.
PubMed Abstract available

ZHAO Y, Gu S, Li L, Zhao R, et al
A novel risk signature for predicting brain metastasis in patients with lung adenocarcinoma.
Neuro Oncol. 2023 Jun 28:noad115. doi: 10.1093.
PubMed Abstract available

KOLODZIEJCZAK AS, Guerrini-Rousseau L, Planchon JM, Ecker J, et al
Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome.
Neuro Oncol. 2023 Jun 28:noad114. doi: 10.1093.
PubMed Abstract available

HANSCH L, Peipp M, Mastall M, Villars D, et al
Chimeric antigen receptor (CAR) T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma.
Neuro Oncol. 2023 Jun 19:noad108. doi: 10.1093.
PubMed Abstract available

RATLIFF M, Karimian-Jazi K, Hoffmann DC, Rauschenbach L, et al
Individual glioblastoma cells harbor both proliferative and invasive capabilities during tumor progression.
Neuro Oncol. 2023 Jun 19:noad109. doi: 10.1093.
PubMed Abstract available

KOCAKAVUK E, Johnson KC, Sabedot TS, Reinhardt HC, et al
Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas.
Neuro Oncol. 2023 Jun 17:noad095. doi: 10.1093.
PubMed

CHAN P, Rich JN, Kay SA
Watching the Clock in Glioblastoma.
Neuro Oncol. 2023 Jun 16:noad107. doi: 10.1093.
PubMed Abstract available

MUELLER S, Kline C, Stoller S, Lundy S, et al
PNOC015: Repeated convection enhanced delivery (CED) of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
Neuro Oncol. 2023 Jun 15:noad105. doi: 10.1093.
PubMed Abstract available

HOTCHKISS KM, Batich KA, Mohan A, Rahman R, et al
Dendritic cell vaccine trials in gliomas: Untangling the lines.
Neuro Oncol. 2023 Jun 8:noad088. doi: 10.1093.
PubMed Abstract available

KULIESIUTE U, Joseph K, Straehle J, Ravi VM, et al
Sialic acid metabolism orchestrates transcellular connectivity and signalling in glioblastoma.
Neuro Oncol. 2023 Jun 8:noad101. doi: 10.1093.
PubMed Abstract available

HUANG N, Chen Z, Yang X, Gao Y, et al
Upstream Open Reading Frame-encoded MP31 Disrupts the Mitochondrial Quality Control Process and Inhibits Tumorigenesis in Glioblastoma.
Neuro Oncol. 2023 Jun 6:noad099. doi: 10.1093.
PubMed Abstract available

XIN L, Tan Y, Zhu Y, Cui X, et al
EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.
Neuro Oncol. 2023 Jun 5:noad102. doi: 10.1093.
PubMed Abstract available

BAILLEUL J, Ruan Y, Abdulrahman L, Scott AJ, et al
PKM2 rewires glucose metabolism during radiation therapy to promote an antioxidant response and glioblastoma radioresistance.
Neuro Oncol. 2023 Jun 5:noad103. doi: 10.1093.
PubMed Abstract available

SAHM F, Brandner S, Bertero L, Capper D, et al
Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline.
Neuro Oncol. 2023 Jun 2:noad100. doi: 10.1093.
PubMed Abstract available

ALI UM, Withrow DR, Judge AD, Plaha P, et al
Temporal trends in the incidence of malignant and nonmalignant primary brain and central nervous system tumors by the method of diagnosis in England, 1993-2017.
Neuro Oncol. 2023;25:1177-1192.
PubMed Abstract available

SUN T, Wang Y, Liu X, Li Z, et al
Deep learning based on preoperative magnetic resonance (MR) images improves the predictive power of survival models in primary spinal cord astrocytomas.
Neuro Oncol. 2023;25:1157-1165.
PubMed Abstract available

ZAYTSEVA M, Valiakhmetova A, Yasko L, Samarin A, et al
Molecular heterogeneity of pediatric choroid plexus carcinomas determines the distinctions in clinical course and prognosis.
Neuro Oncol. 2023;25:1132-1145.
PubMed Abstract available

DEMIRDIZEN E, Al-Ali R, Narayanan A, Sun X, et al
TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing.
Neuro Oncol. 2023;25:1031-1043.
PubMed Abstract available

LAMBA N, Cagney DN, Catalano PJ, Kim D, et al
A Genomic Score to Predict Local Control among Patients with Brain Metastases Managed with Radiation.
Neuro Oncol. 2023 Jun 1:noad098. doi: 10.1093.
PubMed Abstract available

May 2023

KARSCHNIA P, Dono A, Young JS, Juenger ST, et al
Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.
Neuro Oncol. 2023 May 30:noad074. doi: 10.1093.
PubMed Abstract available

Correction to: Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
Neuro Oncol. 2023 May 29:noad091. doi: 10.1093.
PubMed

Corrigendum to: Identifying risk factors for recurrence/relapse in NF1 optic pathway gliomas: Moving forward by looking back.
Neuro Oncol. 2023 May 25:noad093. doi: 10.1093.
PubMed

Correction to: Progress for patients with melanoma brain metastases.
Neuro Oncol. 2023 May 19:noad089. doi: 10.1093.
PubMed

Corrigendum to: Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1.
Neuro Oncol. 2023 May 19:noad094. doi: 10.1093.
PubMed

NEHAMA D, Woodell AS, Maingi SM, Hingtgen SD, et al
Cell-based therapies for glioblastoma: Promising tools against tumor heterogeneity.
Neuro Oncol. 2023 May 14:noad092. doi: 10.1093.
PubMed Abstract available

Retraction of: PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitors.
Neuro Oncol. 2023 May 13:noad081. doi: 10.1093.
PubMed

HAASE S, Lowenstein PR, Castro MG
"Sabotaging the Protein Factory to Overcome Glioma Stem Cell Resistance".
Neuro Oncol. 2023 May 13:noad090. doi: 10.1093.
PubMed

DI NUNNO V, Gatto L, Tosoni A, Bartolini S, et al
Letter concerning "Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival": Toward surrogate endpoints for phase II trials in patients with recurrent gliobla
Neuro Oncol. 2023 May 12:noad071. doi: 10.1093.
PubMed

ELLINGSON BM, Wen PY, Cloughesy TF
Reply to Di Nunno et al. concerning objective response rates targets for recurrent glioblastoma clinical trials: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma.
Neuro Oncol. 2023 May 11:noad085. doi: 10.1093.
PubMed

BURGER MC, Forster MT, Romanski A, Strassheimer F, et al
Intracranial injection of NK cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.
Neuro Oncol. 2023 May 6:noad087. doi: 10.1093.
PubMed Abstract available

LAMBA N, Cagney DN, Catalano PJ, Elhalawani H, et al
Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries.
Neuro Oncol. 2023;25:973-983.
PubMed Abstract available

ALLEN BD, Alaghband Y, Kramar EA, Ru N, et al
Elucidating the neurological mechanism of the FLASH effect in juvenile mice exposed to hypofractionated radiotherapy.
Neuro Oncol. 2023;25:927-939.
PubMed Abstract available

HUANG J, Chan SC, Lok V, Zhang L, et al
Disease burden, risk factors, and trends of primary central nervous system (CNS) cancer: A global study of registries data.
Neuro Oncol. 2023;25:995-1005.
PubMed Abstract available

April 2023

JO J, Diaz M, Horbinski C, Mackman N, et al
Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review.
Neuro Oncol. 2023 Apr 26:noad059. doi: 10.1093.
PubMed Abstract available

MULE' TN, Hodges J, Wu S, Li Y, et al
Social Determinants of Cognitive Outcomes in Survivors of Pediatric Brain Tumors Treated with Conformal Radiation Therapy.
Neuro Oncol. 2023 Apr 26:noad080. doi: 10.1093.
PubMed Abstract available

KOEKKOEK JAF, van der Meer PB, Walbert T
Reply to the letter regarding "Palliative care and end-of-life care in adults with malignant brain tumors".
Neuro Oncol. 2023 Apr 25:noad069. doi: 10.1093.
PubMed

LIU G, Zhang P, Chen S, Chen Z, et al
FAM129A promotes self-renewal and maintains invasive status via stabilizing the Notch intracellular domain in glioma stem cells.
Neuro Oncol. 2023 Apr 21:noad079. doi: 10.1093.
PubMed Abstract available

MILLER AM, Karajannis MA
Cerebrospinal fluid: the new frontier for methylome-based diagnostic classification of brain tumors.
Neuro Oncol. 2023 Apr 20:noad075. doi: 10.1093.
PubMed

HARDIN EC, Schmid S, Sommerkamp A, Bodden C, et al
LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients.
Neuro Oncol. 2023 Apr 19:noad078. doi: 10.1093.
PubMed Abstract available

BARBIERI F, Bajetto A, Dellacasagrande I, Solari A, et al
Stem-like signatures in human meningioma cells are under the control of CXCL11/CXCL12 chemokine activity.
Neuro Oncol. 2023 Apr 19:noad076. doi: 10.1093.
PubMed Abstract available

CONTRERAS-ZARATE MJ, Alvarez-Eraso KLF, Jaramillo-Gomez JA, Littrell Z, et al
Short-term topiramate treatment prevents radiation-induced cytotoxic edema in preclinical models of breast-cancer brain metastasis.
Neuro Oncol. 2023 Apr 13:noad070. doi: 10.1093.
PubMed Abstract available

MISHIMA K, Nishikawa R, Narita Y, Mizusawa J, et al
Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C.
Neuro Oncol. 2023;25:687-698.
PubMed Abstract available

LI X, Moreira DC, Bag AK, Qaddoumi I, et al
The clinical and molecular characteristics of progressive hypothalamic/optic pathway pilocytic astrocytoma.
Neuro Oncol. 2023;25:750-760.
PubMed Abstract available

FU R, Norris GA, Willard N, Griesinger AM, et al
Spatial transcriptomic analysis delineates epithelial and mesenchymal subpopulations and transition stages in childhood ependymoma.
Neuro Oncol. 2023;25:786-798.
PubMed Abstract available

SELT F, Sigaud R, Valinciute G, Sievers P, et al
BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma.
Neuro Oncol. 2023;25:735-747.
PubMed Abstract available

STOLTZE UK, Foss-Skiftesvik J, van Overeem Hansen T, Byrjalsen A, et al
Genetic predisposition and evolutionary traces of pediatric cancer risk: a prospective 5-year population-based genome sequencing study of children with CNS tumors.
Neuro Oncol. 2023;25:761-773.
PubMed Abstract available

Corrigendum to: NCOG-45. DIFFERENTIAL AND DOSE-DEPENDENT EFFECTS OF CRANIAL IRRADIATION ON BRAIN STRUCTURES AND NEUROPSYCHOLOGICAL OUTCOMES IN CHILDREN WITH POSTERIOR FOSSA BRAIN TUMORS TREATED WITH DIFFERENT MODALITIES.
Neuro Oncol. 2023 Apr 1:noad058. doi: 10.1093.
PubMed

March 2023

Corrigendum to: Association of circulating markers with cognitive decline after radiation therapy for brain metastasis.
Neuro Oncol. 2023 Mar 29:noad062. doi: 10.1093.
PubMed

GOENKA A, Song X, Tiek D, Iglesia RP, et al
Oncogenic Long Non-coding RNA LINC02283 Enhances PDGF Receptor A mediated Signaling and Drives Glioblastoma Tumorigenesis.
Neuro Oncol. 2023 Mar 29:noad065. doi: 10.1093.
PubMed Abstract available

XIE J, Kuriakose T, Bianski B, Twarog N, et al
ATM inhibition enhances the efficacy of radiation across distinct molecular subgroups of pediatric high-grade glioma.
Neuro Oncol. 2023 Mar 27:noad064. doi: 10.1093.
PubMed Abstract available

WERNER JM, Wollring MM, Tscherpel C, Rosen EK, et al
Multimodal imaging findings in patients with glioblastoma with extensive coagulative necrosis related to regorafenib.
Neuro Oncol. 2023 Mar 24:noad051. doi: 10.1093.
PubMed

Corrigendum to: IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.
Neuro Oncol. 2023 Mar 21:noad048. doi: 10.1093.
PubMed

GU D, Zhou F, You H, Gao J, et al
SREBP2 maintains glioblastoma stem cells through keeping the balance between cholesterol biosynthesis and uptake.
Neuro Oncol. 2023 Mar 19:noad060. doi: 10.1093.
PubMed Abstract available

BAUCHET L, Sanson M
Deciphering gliomagenesis from GWAS.
Neuro Oncol. 2023 Mar 14:noad057. doi: 10.1093.
PubMed

KUMTHEKAR PU, Avram MJ, Lassman AB, Lin NU, et al
A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics.
Neuro Oncol. 2023;25:557-565.
PubMed Abstract available

VOLLMUTH P, Foltyn M, Huang RY, Galldiks N, et al
Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study.
Neuro Oncol. 2023;25:533-543.
PubMed Abstract available

SPERDUTO PW, Salama AKS, Anders C
Progress for Patients with Melanoma Brain Metastases.
Neuro Oncol. 2023 Mar 8:noad050. doi: 10.1093.
PubMed

GROSSMAN SA
Using Historical Objective Response Rates to Design Single Arm Phase II Trials in Patients with Recurrent Glioblastoma.
Neuro Oncol. 2023 Mar 7:noad046. doi: 10.1093.
PubMed

YANG Y, Brown MC, Zhang G, Stevenson K, et al
Polio Virotherapy Targets the Malignant Glioma Myeloid Infiltrate with Diffuse Microglia Activation Engulfing the CNS.
Neuro Oncol. 2023 Mar 2:noad052. doi: 10.1093.
PubMed Abstract available

DREXLER R, Gottsche J, Sauvigny T, Schuller U, et al
Targeted anticonvulsive treatment of IDH-wildtype glioblastoma based on DNA methylation subclasses.
Neuro Oncol. 2023 Mar 1:noad014. doi: 10.1093.
PubMed

February 2023

ROMO CG, Piotrowski AF, Campian JL, Diarte J, et al
Clinical, Histological and Molecular Features of Gliomas in Adults with Neurofibromatosis Type 1.
Neuro Oncol. 2023 Feb 25:noad033. doi: 10.1093.
PubMed Abstract available

FOSS-SKIFTESVIK J, Li S, Rosenbaum A, Hagen CM, et al
Multi-ancestry genome-wide association study of 4,069 children with glioma identifies 9p21.3 risk locus.
Neuro Oncol. 2023 Feb 22:noad042. doi: 10.1093.
PubMed Abstract available

MULKEARNS-HUBERT EE, Lathia JD
DUB-ling down on the epigenetic regulation of cancer stem cells in glioblastoma.
Neuro Oncol. 2023 Feb 22:noad040. doi: 10.1093.
PubMed

DE ROECK L, Gillebert RC, van Aert RCM, Vanmeenen A, et al
Cognitive outcomes after multimodal treatment in adult glioma patients: A meta-analysis.
Neuro Oncol. 2023 Feb 21:noad045. doi: 10.1093.
PubMed Abstract available

Corrigendum to: Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas.
Neuro Oncol. 2023 Feb 21:noac267. doi: 10.1093.
PubMed

BHATTACHARYYA S, Oblinger JL, Beauchamp RL, Yin Z, et al
Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma.
Neuro Oncol. 2023 Feb 20:noad037. doi: 10.1093.
PubMed Abstract available

ROTTGERING JG, Klein M, Douw L
Letter regarding "Palliative care and end-of-life care in adults with malignant brain tumors".
Neuro Oncol. 2023 Feb 18:noad006. doi: 10.1093.
PubMed

LASSMAN AB, van den Bent MJ
What is a glioblastoma?
Neuro Oncol. 2023 Feb 15:noad044. doi: 10.1093.
PubMed

BAGLEY SJ
Phase 2 trials in the era of glioblastoma immunotherapy: New mechanisms of action, familiar challenges in trial design and tumor response assessment.
Neuro Oncol. 2023 Feb 15:noad043. doi: 10.1093.
PubMed

CHANG SM
Launch of an Editorial Scholars Program for Neuro-Oncology.
Neuro Oncol. 2023;25:219-220.
PubMed

GAO T, Zhang S, Li M
Intrathecal trastuzumab: What else do we need to consider?
Neuro Oncol. 2023;25:418-419.
PubMed

OBERKAMPF F, Gutierrez M, Trabelsi Grati O, Rhun EL, et al
Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis.
Neuro Oncol. 2023;25:365-374.
PubMed Abstract available

MCAFEE SS, Zhang S, Zou P, Conklin HM, et al
Fastigial nuclei surgical damage and focal midbrain disruption implicate PAG survival circuits in cerebellar mutism syndrome.
Neuro Oncol. 2023;25:375-385.
PubMed Abstract available

UPADHYAYA SA, Campagne O, Billups CA, Orr BA, et al
Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor.
Neuro Oncol. 2023;25:386-397.
PubMed Abstract available

LIM YC, Jensen KE, Aguilar-Morante D, Vardouli L, et al
Non-metabolic functions of phosphofructokinase-1 orchestrate tumor cellular invasion and genome maintenance under bevacizumab therapy.
Neuro Oncol. 2023;25:248-260.
PubMed Abstract available

GREGORY TA, Williford GL, Maronge JM, Alfaro K, et al
An expedited strategy for accurate and timely integrated molecular diagnosis of gliomas.
Neuro Oncol. 2023 Feb 1:noad007. doi: 10.1093.
PubMed

PATEL RV, Yao S, Huang RY, Bi WL, et al
Application of radiomics to meningiomas: a systematic review.
Neuro Oncol. 2023 Feb 1:noad028. doi: 10.1093.
PubMed Abstract available

January 2023

ALEMANY M, Todeschini FA, Vidal N, Pons A, et al
The impact of health system crises on glioblastoma management and outcomes.
Neuro Oncol. 2023 Jan 30:noac266. doi: 10.1093.
PubMed

TONN S, Korshunov A, Obrecht D, Sill M, et al
Risk prediction in early childhood SHH medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than two subgroups.
Neuro Oncol. 2023 Jan 30:noad027. doi: 10.1093.
PubMed Abstract available

CHEN CH, Chin RL, Hartley GP, Lea ST, et al
Novel Murine Glioblastoma Models That Reflect the Immunotherapy Resistance Profile of Human Disease.
Neuro Oncol. 2023 Jan 27:noad025. doi: 10.1093.
PubMed Abstract available

AQUILANTI E, Kageler L, Watson J, Baird DM, et al
Telomerase inhibition is an effective therapeutic strategy in TERT promoter mutant-glioblastoma models with low tumor volume.
Neuro Oncol. 2023 Jan 24:noad024. doi: 10.1093.
PubMed Abstract available

LIU H, Xu C, Diplas BH, Brown A, et al
Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
Neuro Oncol. 2023 Jan 23:noad022. doi: 10.1093.
PubMed Abstract available

AJAIB S, Lodha D, Pollock S, Hemmings G, et al
GBMdeconvoluteR accurately infers proportions of neoplastic and immune cell populations from bulk glioblastoma transcriptomics data.
Neuro Oncol. 2023 Jan 23:noad021. doi: 10.1093.
PubMed Abstract available

WANG Z, Wang Y, Chang M, Wang Y, et al
Single-cell transcriptomic analyses provide insights into the cellular origins and drivers of brain metastasis from lung adenocarcinoma.
Neuro Oncol. 2023 Jan 19:noad017. doi: 10.1093.
PubMed Abstract available

ALEJO S, Palacios BE, Venkata PP, He Y, et al
Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double strand break repair and augments efficacy of temozolomide in glioblastoma.
Neuro Oncol. 2023 Jan 18:noad018. doi: 10.1093.
PubMed Abstract available

KOTECHA R, Mehta MP
Rethinking Classification and Categorization of Resection Extent and its Impact on Patient Survival in Glioblastoma: Was Walter Dandy Ahead of His Time?
Neuro Oncol. 2023 Jan 16:noad013. doi: 10.1093.
PubMed

SAMPSON JH, Singh Achrol A, Aghi MK, Bankiewiecz K, et al
Targeting the IL4 Receptor with MDNA55 in Patients with Recurrent Glioblastoma: Results of a Phase 2b Trial.
Neuro Oncol. 2023 Jan 14:noac285. doi: 10.1093.
PubMed Abstract available

STERN E, Ben-Ami M, Gruber N, Toren A, et al
Hypothalamic-Pituitary-Gonadal Function, Pubertal Development and Fertility Outcomes in Male and Female Medulloblastoma Survivors: A Single Centre Experience.
Neuro Oncol. 2023 Jan 12:noad009. doi: 10.1093.
PubMed Abstract available

CAPPER D, Reifenberger G, French PJ, Schweizer L, et al
EANO guideline on rational molecular testing of gliomas, glioneuronal and neuronal tumors in adults for targeted therapy selection.
Neuro Oncol. 2023 Jan 12:noad008. doi: 10.1093.
PubMed Abstract available

LIGON JA, Sayour EJ
Spotlighting cellular therapies to advance the treatment of medulloblastoma.
Neuro Oncol. 2023 Jan 11:noad005. doi: 10.1093.
PubMed

LIU X, Kang C
Bridging deep sequencing to precision oncology in meningiomas.
Neuro Oncol. 2023 Jan 10:noad004. doi: 10.1093.
PubMed

Retraction of: A novel fully automated MRI-based deep-learning method for classification of IDH mutation status in brain gliomas.
Neuro Oncol. 2023 Jan 10:noac260. doi: 10.1093.
PubMed

ZHANG H, Liu K, Ba R, Zhang Z, et al
Histological and Molecular Classifications of Pediatric Glioma with Time-dependent Diffusion MRI based Microstructural Mapping.
Neuro Oncol. 2023 Jan 7:noad003. doi: 10.1093.
PubMed Abstract available

ELLINGSON BM, Wen PY, Chang SM, van den Bent M, et al
Objective response rate (ORR) targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival.
Neuro Oncol. 2023 Jan 7:noad002. doi: 10.1093.
PubMed Abstract available

KOEKKOEK JAF, van der Meer PB, Pace A, Hertler C, et al
Corrigendum to: Palliative care and end-of-life care in adults with malignant brain tumors.
Neuro Oncol. 2023;25:212.
PubMed

FORTIN ENSIGN SP, Jenkins RB, Giannini C, Sarkaria JN, et al
Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.
Neuro Oncol. 2023;25:28-36.
PubMed Abstract available

HOANG-XUAN K, Deckert M, Ferreri AJM, Furtner J, et al
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL).
Neuro Oncol. 2023;25:37-53.
PubMed Abstract available

DE RUITER MB, Groot PFC, Deprez S, Pullens P, et al
Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small cell lung cancer reduces hippocampal atrophy compared to conventional PCI.
Neuro Oncol. 2023;25:167-176.
PubMed Abstract available

DE ALMEIDA MAGALHAES T, Alencastro Veiga Cruzeiro G, Ribeiro de Sousa G, Englinger B, et al
Activation of Hedgehog signaling by the oncogenic RELA fusion reveals a primary cilia-dependent vulnerability in supratentorial ependymoma.
Neuro Oncol. 2023;25:185-198.
PubMed Abstract available

GUERRA G, McCoy L, Hansen HM, Rice T, et al
Antibodies to varicella-zoster virus and three other herpesviruses and survival in adults with glioma.
Neuro Oncol. 2023 Jan 4:noac283. doi: 10.1093.
PubMed Abstract available

XIE Y, He L, Zhang Y, Huang H, et al
Wnt Signaling Regulates MFSD2A-dependent Drug Delivery through Endothelial Transcytosis in Glioma.
Neuro Oncol. 2023 Jan 2:noac288. doi: 10.1093.
PubMed Abstract available

December 2022

ZISI A, Kanellis DC, Moussaud S, Karlsson I, et al
Small Molecule-mediated Disruption of Ribosome Biogenesis Synergizes With FGFR Inhibitors to Suppress Glioma Cell Growth.
Neuro Oncol. 2022 Dec 30:noac286. doi: 10.1093.
PubMed Abstract available

APPS JR, Martinez-Barbera JP
A promising future for hypothalamic dysfunction in craniopharyngioma.
Neuro Oncol. 2022 Dec 27:noac284. doi: 10.1093.
PubMed

PREUSSER M, van den Bent MJ
Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination (DCVax-L) in glioblastoma: breakthrough or fata morgana?
Neuro Oncol. 2022 Dec 23:noac281. doi: 10.1093.
PubMed

ALPEN K, Vajdic CM, MacInnis RJ, Milne RL, et al
Australian genome-wide association study confirms higher female risk for adult glioma associated with variants in the region of CCDC26.
Neuro Oncol. 2022 Dec 20:noac279. doi: 10.1093.
PubMed Abstract available

STUNDON JL, Ijaz H, Gaonkar KS, Kaufman RS, et al
ALT in Pediatric High-Grade Gliomas Can Occur without ATRX Mutation and is Enriched in Patients with Pathogenic Germline MMR Variants.
Neuro Oncol. 2022 Dec 20:noac278. doi: 10.1093.
PubMed Abstract available

IORGULESCU JB, Sun C, Neff C, Cioffi G, et al
Corrigendum to: Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.
Neuro Oncol. 2022 Dec 19:noac270. doi: 10.1093.
PubMed

Corrigendum to: Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-beta signaling in recurrent tumors.
Neuro Oncol. 2022 Dec 16:noac265. doi: 10.1093.
PubMed

MILLER JJ, Arrillaga-Romany I
IDH-mutant glioma: A new IDH1 inhibitor moves forward.
Neuro Oncol. 2022 Dec 16:noac275. doi: 10.1093.
PubMed

TAO W, Lei H, Luo W, Huang Z, et al
NIR Drives Glioblastoma Growth by Promoting Ribosomal DNA Transcription in Glioma Stem Cells.
Neuro Oncol. 2022 Dec 15:noac272. doi: 10.1093.
PubMed Abstract available

HAO X, Bahia R, Cseh O, Bozek D, et al
BI-907828, a novel potent MDM2 inhibitor, inhibits GBM brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
Neuro Oncol. 2022 Dec 15:noac271. doi: 10.1093.
PubMed Abstract available

BARNHOLTZ-SLOAN JS
Expanding our knowledge of brain tumor overall survival trends at a global scale.
Neuro Oncol. 2022 Dec 14:noac268. doi: 10.1093.
PubMed

HASANOV M, Milton DR, Bea Davies A, Sirmans E, et al
Changes In Outcomes And Factors Associated With Survival In Melanoma Patients With Brain Metastases.
Neuro Oncol. 2022 Dec 13:noac251. doi: 10.1093.
PubMed Abstract available

HUNTOON K, Anderson SK, Ballman KV, Twohy E, et al
Association of Circulating Markers with Cognitive Decline After Radiation Therapy for Brain Metastasis.
Neuro Oncol. 2022 Dec 6:noac262. doi: 10.1093.
PubMed Abstract available

MORENO V, Sepulveda JM, Reardon DA, Perez-Nunez A, et al
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, "windowofopportunity" study.
Neuro Oncol. 2022 Dec 1:noac263. doi: 10.1093.
PubMed Abstract available

WANG C, Zhang H, Fan J, Li Q, et al
Inhibition of integrated stress response protects against lipid-induced senescence in hypothalamic neural stem cells in adamantinomatous craniopharyngioma.
Neuro Oncol. 2022 Dec 1:noac261. doi: 10.1093.
PubMed Abstract available

November 2022

GONZALEZ CASTRO LN, Liu I, Filbin M
Erratum to: Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods.
Neuro Oncol. 2022 Nov 29:noac257. doi: 10.1093.
PubMed

PRINS RM, Everson RG
Commentary on "Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.".
Neuro Oncol. 2022 Nov 29:noac256. doi: 10.1093.
PubMed

GERRITSEN JKW, Zwarthoed RH, Kilgallon JL, Nawabi NL, et al
Impact of maximal extent of resection on postoperative deficits, patient functioning and survival within clinically important glioblastoma subgroups.
Neuro Oncol. 2022 Nov 24:noac255. doi: 10.1093.
PubMed Abstract available

LIN B, Ziebro J, Smithberger E, Skinner KR, et al
Corrigendum to: EGFR, the Lazarus target for precision oncology in glioblastoma.
Neuro Oncol. 2022 Nov 23:noac254. doi: 10.1093.
PubMed

DEAN JA, Tanguturi SK, Cagney D, Shin KY, et al
Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity.
Neuro Oncol. 2022 Nov 19:noac253. doi: 10.1093.
PubMed Abstract available

ZHANG IY, Liu S, Zhang L, Liang R, et al
RAGE Ablation Attenuates Glioma Progression and Enhances Tumor Immune Responses by Suppressing Galectin-3 Expression.
Neuro Oncol. 2022 Nov 17. pii: 6832182. doi: 10.1093.
PubMed Abstract available

FORRY S, Hubbard L, Espey MG, Vikram B, et al
The NCI Glioblastoma Therapeutics Network (GTN).
Neuro Oncol. 2022 Nov 11. pii: 6822421. doi: 10.1093.
PubMed

GIRARDI F, Matz M, Stiller C, You H, et al
Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3).
Neuro Oncol. 2022 Nov 10. pii: 6819785. doi: 10.1093.
PubMed Abstract available

Corrigendum to: Influence of county-level geographic/ancestral origin on glioma incidence and outcomes in US Hispanics.
Neuro Oncol. 2022 Nov 8. pii: 6809298. doi: 10.1093.
PubMed

CHEN L, Xie X, Wang T, Xu L, et al
ARL13B promotes angiogenesis and glioma growth by activating VEGFA-VEGFR2 signaling.
Neuro Oncol. 2022 Nov 2. pii: 6794117. doi: 10.1093.
PubMed Abstract available

SMITH K, Nakaji P, Thomas T, Pinnaduwage D, et al
Safety and patterns of survivorship in recurrent GBM following resection and surgically targeted radiation therapy: Results from a prospective trial.
Neuro Oncol. 2022;24.
PubMed Abstract available

MCCRACKEN DJ, Schupper AJ, Lakomkin N, Malcolm J, et al
Turning on the light for brain tumor surgery: A 5-aminolevulinic acid story.
Neuro Oncol. 2022;24.
PubMed Abstract available

ODIA Y, Gutierrez AN, Kotecha R
Stereotactic targeted radiation therapy (STaRT) trials for brain neoplasms: A comprehensive review.
Neuro Oncol. 2022;24.
PubMed Abstract available

SCHUPPER AJ, Chanenchuk T, Racanelli A, Price G, et al
Laser hyperthermia: Past, present, and future.
Neuro Oncol. 2022;24.
PubMed Abstract available

WU A, Wu JY, Lim M
Updates in intraoperative strategies for enhancing intra-axial brain tumor control.
Neuro Oncol. 2022;24.
PubMed Abstract available

HADDAD AF, Aghi MK, Butowski N
Novel intraoperative strategies for enhancing tumor control: Future directions.
Neuro Oncol. 2022;24.
PubMed Abstract available

HOOGENDIJK R, van der Lugt J, Hoving E, Kremer L, et al
The fifth edition of the World Health Organization Classification of Tumors of the Central Nervous System: Implications for cancer registries.
Neuro Oncol. 2022;24:1811-1814.
PubMed

GALLDIKS N, Langen KJ, Albert NL, Law I, et al
Investigational PET tracers in neuro-oncology-What's on the horizon? A report of the PET/RANO group.
Neuro Oncol. 2022;24:1815-1826.
PubMed Abstract available

YEO KK, MacDonald SM
CNS non-germinomatous germ cell tumor (NGGCT): Lessons from the recent past.
Neuro Oncol. 2022;24:1962-1963.
PubMed

FONSECA A, Faure-Conter C, Murray MJ, Fangusaro J, et al
Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials.
Neuro Oncol. 2022;24:1950-1961.
PubMed Abstract available

October 2022

NAKATA S, Murai J, Okada M, Takahashi H, et al
Epigenetic upregulation of Schlafen11 renders WNT- and SHH- activated medulloblastomas sensitive to cisplatin.
Neuro Oncol. 2022 Oct 23. pii: 6770101. doi: 10.1093.
PubMed Abstract available

ZHAO J, Yang S, Cui X, Wang Q, et al
A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma.
Neuro Oncol. 2022 Oct 22. pii: 6770036. doi: 10.1093.
PubMed Abstract available

KOEKKOEK JAF, van der Meer PB, Pace A, Hertler C, et al
Palliative care and end-of-life care in adults with malignant brain tumors.
Neuro Oncol. 2022 Oct 22. pii: 6769915. doi: 10.1093.
PubMed Abstract available

SHORT SC
EV packing allows meningioma tracking in blood.
Neuro Oncol. 2022 Oct 21. pii: 6765271. doi: 10.1093.
PubMed

RUDA R
Optimize Treatment Approaches In Isocitrate Dehydrogenase (Idh) Mutant Gliomas: Open Issues.
Neuro Oncol. 2022 Oct 17. pii: 6761819. doi: 10.1093.
PubMed

CHANG G, Xie GS, Ma L, Li P, et al
USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5.
Neuro Oncol. 2022 Oct 14. pii: 6761025. doi: 10.1093.
PubMed Abstract available

GREEN K, Panagopoulou P, D'Arco F, O'Hare P, et al
A Nationwide Evaluation of Bevacizumab-based Treatments in Paediatric Low-Grade Glioma in the UK: Safety. Efficacy, Visual Morbidity and Outcomes.
Neuro Oncol. 2022 Oct 14. pii: 6761018. doi: 10.1093.
PubMed Abstract available

AWADA H, Paris F, Pecqueur C
Exploiting Radiation Immunostimulatory Effects To Improve Glioblastoma Outcome.
Neuro Oncol. 2022 Oct 14. pii: 6761020. doi: 10.1093.
PubMed Abstract available

CHOUDHURY A, Chen WC, Lucas CG, Bayley JC, et al
Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features.
Neuro Oncol. 2022 Oct 13. pii: 6760303. doi: 10.1093.
PubMed Abstract available

MILLER JJ, Gonzalez Castro LN, McBrayer S, Weller M, et al
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
Neuro Oncol. 2022 Oct 12. pii: 6761148. doi: 10.1093.
PubMed Abstract available

KOROVINA I, Vehlow A, Temme A, Cordes N, et al
Targeting integrin alpha2 as potential strategy for radiochemosensitization of glioblastoma.
Neuro Oncol. 2022 Oct 11. pii: 6758417. doi: 10.1093.
PubMed Abstract available

SCHAKELAAR MY, Monnikhof M, Crnko S, Pijnappel E, et al
Cellular Immunotherapy for Medulloblastoma.
Neuro Oncol. 2022 Oct 11. pii: 6758415. doi: 10.1093.
PubMed Abstract available

WOLLRING MM, Werner JM, Bauer EK, Tscherpel C, et al
Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.
Neuro Oncol. 2022 Oct 10. pii: 6755441. doi: 10.1093.
PubMed Abstract available

YANG R, Zhang G, Dong Z, Wang S, et al
HOXA3 and KDM6A cooperate in transcriptional control of aerobic glycolysis and glioblastoma progression.
Neuro Oncol. 2022 Oct 10. pii: 6755443. doi: 10.1093.
PubMed Abstract available

GIRARDI F, Di Carlo V, Stiller C, Gatta G, et al
Global survival trends for brain tumours, by histology: analysis of individual records for 67,776 children diagnosed in 61 countries during 2000-2014 (CONCORD-3).
Neuro Oncol. 2022 Oct 10. pii: 6755369. doi: 10.1093.
PubMed Abstract available

GONZALEZ CASTRO LN, Liu I, Filbin M
Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods.
Neuro Oncol. 2022 Oct 5. pii: 6748723. doi: 10.1093.
PubMed Abstract available

OSTROM QT, Price M, Neff C, Cioffi G, et al
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.
Neuro Oncol. 2022;24.
PubMed Abstract available

KUMTHEKAR P, Nagpal S
Preclinical modeling in leptomeningeal disease: Starting at the foundation to tackle a difficult disease.
Neuro Oncol. 2022;24:1687-1688.
PubMed

LUKAS RV
Leptomeningeal metastases-What outcomes should we measure and how?
Neuro Oncol. 2022;24:1736-1737.
PubMed

BOCKMAYR M, Harnisch K, Pohl LC, Schweizer L, et al
Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease.
Neuro Oncol. 2022;24:1689-1699.
PubMed Abstract available

LAW V, Chen Z, Vena F, Smalley I, et al
A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma.
Neuro Oncol. 2022;24:1673-1686.
PubMed Abstract available

LE RHUN E, Devos P, Winklhofer S, Lmalem H, et al
Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.
Neuro Oncol. 2022;24:1726-1735.
PubMed Abstract available

September 2022

LIN B, Ziebro J, Smithberger E, Skinner KR, et al
EGFR, the Lazarus target for precision oncology in glioblastoma.
Neuro Oncol. 2022 Sep 19. pii: 6705404. doi: 10.1093.
PubMed Abstract available

HOFFMAN LM, Jaimes C, Mankad K, Mirsky DM, et al
Response assessment in pediatric craniopharyngioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.
Neuro Oncol. 2022 Sep 17. pii: 6702540. doi: 10.1093.
PubMed Abstract available

KASHANI E, Schnidrig D, Hashemi Gheinani A, Ninck MS, et al
Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-beta signaling in recurrent tumors.
Neuro Oncol. 2022 Sep 17. pii: 6702539. doi: 10.1093.
PubMed Abstract available

OSTROM QT, Price M, Ryan K, Edelson J, et al
CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.
Neuro Oncol. 2022;24.
PubMed Abstract available

STEJEREAN-TODORAN I, Gimotty PA, Watters A, Brafford P, et al
A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells.
Neuro Oncol. 2022 Sep 2. pii: 6687782. doi: 10.1093.
PubMed Abstract available

INDELICATO DJ
No question: Proton therapy is safe.
Neuro Oncol. 2022;24:1582-1583.
PubMed

August 2022

YU K, Kong K, Lozzi B, Luna-Figueroa E, et al
In Vivo Functional Characterization of EGFR Variants Identifies Novel Drivers of Glioblastoma.
Neuro Oncol. 2022 Aug 31. pii: 6679484. doi: 10.1093.
PubMed Abstract available

BEDDOK A, Scher N, Alapetite C, Baussart B, et al
Protontherapy for adult craniopharyngioma: experience of a single institution in 91 consecutive patients.
Neuro Oncol. 2022 Aug 25. pii: 6674791. doi: 10.1093.
PubMed Abstract available

OSTROM QT, Shoaf ML, Cioffi G, Waite K, et al
National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
Neuro Oncol. 2022 Aug 22. pii: 6673397. doi: 10.1093.
PubMed Abstract available

YOUNGBLOOD MW, Tran AN, Wang W, An S, et al
Docetaxel Targets Aggressive Methylation Profiles and Serves as a Radiosensitizer in High-Risk Meningiomas.
Neuro Oncol. 2022 Aug 17. pii: 6670614. doi: 10.1093.
PubMed Abstract available

SHI DD, Youssef GC, Nassar AH, Lim-Fat MJ, et al
Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma.
Neuro Oncol. 2022 Aug 16. pii: 6668736. doi: 10.1093.
PubMed

VAN OPIJNEN MP, Tesileanu CMS, Dirven L, van der Meer PB, et al
IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas.
Neuro Oncol. 2022 Aug 16. pii: 6668487. doi: 10.1093.
PubMed Abstract available

KARSCHNIA P, Young JS, Dono A, Hani L, et al
Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group.
Neuro Oncol. 2022 Aug 12. pii: 6664041. doi: 10.1093.
PubMed Abstract available

SEYVE A, Dehais C, Chinot O, Djelad A, et al
Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: a POLA network study.
Neuro Oncol. 2022 Aug 12. pii: 6661438. doi: 10.1093.
PubMed Abstract available

LUO X, Yang Y, Yin S, Li H, et al
False-negative and false-positive outcomes of computer aided detection on brain metastasis: secondary analysis of a multicenter, multireader study.
Neuro Oncol. 2022 Aug 9. pii: 6658946. doi: 10.1093.
PubMed Abstract available

RUDA R, Capper D, Waldman AD, Pallud J, et al
Eano-Euracan-Sno Guidelines on Circumscribed Astrocytic GLIOMAS, Glioneuronal and Neuronaltumors.
Neuro Oncol. 2022 Aug 1. pii: 6652587. doi: 10.1093.
PubMed Abstract available

BOELE FW, den Otter PWM, Reijneveld JC, de Witt Hamer PC, et al
Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers: a longitudinal study spanning two decades.
Neuro Oncol. 2022 Aug 1. pii: 6652588. doi: 10.1093.
PubMed Abstract available

VARADHARAJAN S, Mack SC
Leveraging epigenomic patterns to resolve the heterogeneity and origins of CNS germ cell tumors.
Neuro Oncol. 2022;24:1259-1260.
PubMed

DESJARDINS A
Improving survival in neuro-oncology is a struggle; we cannot allow ourselves to also struggle with issues of diversity.
Neuro Oncol. 2022;24:1350-1351.
PubMed

YAO H, Xie W, Dai Y, Liu Y, et al
TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT.
Neuro Oncol. 2022;24:1286-1297.
PubMed Abstract available

TAKAMI H, Elzawahry A, Mamatjan Y, Fukushima S, et al
Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts.
Neuro Oncol. 2022;24:1246-1258.
PubMed Abstract available

KOH KN, Wong RX, Lee DE, Han JW, et al
Outcomes of intracranial germinoma-A retrospective multinational Asian study on effect of clinical presentation and differential treatment strategies.
Neuro Oncol. 2022;24:1389-1399.
PubMed Abstract available

July 2022

HERTLER C, Seystahl K, Le Rhun E, Wirsching HG, et al
Improved seizure control in patients with recurrent glioblastoma treated with bevacizumab.
Neuro Oncol. 2022 Jul 30. pii: 6652283. doi: 10.1093.
PubMed

Erratum to: Environmental and sex-specific molecular signatures of glioma causation.
Neuro Oncol. 2022 Jul 29. pii: 6651886. doi: 10.1093.
PubMed

CHEN AT, Xiao Y, Tang X, Baqri M, et al
Cross-platform analysis reveals cellular and molecular landscape of glioblastoma invasion.
Neuro Oncol. 2022 Jul 28. pii: 6651351. doi: 10.1093.
PubMed Abstract available

SIGAUD R, Rosch L, Gatzweiler C, Benzel J, et al
The first-in-class ERK inhibitor ulixertinib shows promising activity in MAPK-driven pediatric low-grade glioma models.
Neuro Oncol. 2022 Jul 27. pii: 6650335. doi: 10.1093.
PubMed Abstract available

DREXLER R, Schuller U, Eckhardt A, Filipski K, et al
DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.
Neuro Oncol. 2022 Jul 22. pii: 6648783. doi: 10.1093.
PubMed Abstract available

WALSH KM, Neff C, Bondy ML, Kruchko C, et al
Influence of county-level geographic/ancestral origin on glioma incidence and outcomes in US Hispanics.
Neuro Oncol. 2022 Jul 22. pii: 6648782. doi: 10.1093.
PubMed Abstract available

KOSTI A, Chiou J, Guardia GDA, Lei X, et al
ELF4 is a critical component of a miRNA-transcription factor network and is a bridge regulator of glioblastoma receptor signaling and lipid dynamics.
Neuro Oncol. 2022 Jul 21. pii: 6648020. doi: 10.1093.
PubMed Abstract available

LASSMAN AB, Pugh SL, Wang TJC, Aldape K, et al
Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial.
Neuro Oncol. 2022 Jul 15. pii: 6645128. doi: 10.1093.
PubMed Abstract available

BUEHLER M, Yi X, Ge W, Blattmann P, et al
Quantitative proteomic landscapes of primary and recurrent glioblastoma reveal a protumorigeneic role for FBXO2-dependent glioma-microenvironment interactions.
Neuro Oncol. 2022 Jul 8. pii: 6634186. doi: 10.1093.
PubMed Abstract available

REYES-GONZALEZ J, Barajas-Olmos F, Garcia-Ortiz H, Magraner-Pardo L, et al
Brain Radiotoxicity-Related 15CAcBRT Gene Expression Signature Predicts Survival Prognosis of Glioblastoma Patients.
Neuro Oncol. 2022 Jul 8. pii: 6634161. doi: 10.1093.
PubMed Abstract available

VAN DER VOORT SR, Incekara F, Wijnenga MMJ, Kapsas G, et al
Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning.
Neuro Oncol. 2022 Jul 5. pii: 6631283. doi: 10.1093.
PubMed Abstract available

HUSE JT
A Promising Preclinical Model For Tert Promoter Mutation In Glioblastoma.
Neuro Oncol. 2022 Jul 3. pii: 6628220. doi: 10.1093.
PubMed

DONAHUE BR, MacDonald S
Protons for pediatric ependymoma: Where are we now?
Neuro Oncol. 2022;24:1203-1204.
PubMed

MILLWARD CP, Armstrong TS, Barrington H, Brodbelt AR, et al
Opportunities and challenges for the development of "core outcome sets" in neuro-oncology.
Neuro Oncol. 2022;24:1048-1055.
PubMed Abstract available

HERRGOTT GA, Asmaro KP, Wells M, Sabedot TS, et al
Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
Neuro Oncol. 2022;24:1126-1139.
PubMed Abstract available

PETERS S, Merta J, Schmidt L, Jazmati D, et al
Evaluation of dose, volume, and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study.
Neuro Oncol. 2022;24:1193-1202.
PubMed Abstract available

June 2022

PALMER JD, Prasad RN, Cioffi G, Kruchtko C, et al
Exposure to Radon and Heavy Particulate Pollution and Incidence of Brain Tumors.
Neuro Oncol. 2022 Jun 28. pii: 6618967. doi: 10.1093.
PubMed Abstract available

AIZER AA, Lamba N, Ahluwalia MS, Aldape K, et al
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.
Neuro Oncol. 2022 Jun 28. pii: 6618874. doi: 10.1093.
PubMed Abstract available

NOBRE L, Bouffet E
BRAF inhibitors in BRAFV600E mutated pediatric high-grade gliomas: upfront or at recurrence?
Neuro Oncol. 2022 Jun 24. pii: 6617660. doi: 10.1093.
PubMed

WEISHAUPT H, Cancer M, Rosen G, Holmberg KO, et al
Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas.
Neuro Oncol. 2022 Jun 23. pii: 6615415. doi: 10.1093.
PubMed Abstract available

CHEN X, Niu W, Fan X, Yang H, et al
Oct4A palmitoylation modulates tumorigenicity and stemness in human glioblastoma cells.
Neuro Oncol. 2022 Jun 21. pii: 6612239. doi: 10.1093.
PubMed Abstract available

WANG Y, Wang K, Fu J, Zhang Y, et al
FRK inhibits glioblastoma progression via phosphorylating YAP and inducing its ubiquitylation and degradation by Siah1.
Neuro Oncol. 2022 Jun 20. pii: 6611687. doi: 10.1093.
PubMed Abstract available

NATSUME A, Arakawa Y, Narita Y, Sugiyama K, et al
The first-in-human phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.
Neuro Oncol. 2022 Jun 20. pii: 6611503. doi: 10.1093.
PubMed Abstract available

LIU XP, Jin X, Ahmadian SS, Yang X, et al
Clinical Significance and Molecular Annotation of Cellular Morphometric Subtypes in Lower Grade Gliomas discovered by Machine Learning.
Neuro Oncol. 2022 Jun 18. pii: 6611075. doi: 10.1093.
PubMed Abstract available

OSTROM QT, Lu D, Lu R, Baker MC, et al
Prevalence of autoimmunity and atopy in US adults with glioblastoma and meningioma.
Neuro Oncol. 2022 Jun 17. pii: 6609733. doi: 10.1093.
PubMed

SARAF A, Yock TI, Niemierko A, Oh KS, et al
Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: a contemporary single-institution experience.
Neuro Oncol. 2022 Jun 7. pii: 6603917. doi: 10.1093.
PubMed Abstract available

LEE-CHANG C
Understanding the relationship between gliomas and T cells: Paving the way for effective immunotherapy.
Neuro Oncol. 2022 Jun 6. pii: 6602133. doi: 10.1093.
PubMed

ROGERS CL, Pugh SL, Vogelbaum MA, Perry A, et al
Low-Risk Meningioma: Initial Outcomes from NRG Oncology/RTOG 0539.
Neuro Oncol. 2022 Jun 3. pii: 6601387. doi: 10.1093.
PubMed Abstract available

TAYLOR JW, Weyer-Jamora C, Hervey-Jumper S
Molecularly determining cognition in glioma: New insights as the plot thickens.
Neuro Oncol. 2022 Jun 3. pii: 6601533. doi: 10.1093.
PubMed

POON MTC, Brennan PM, Jin K, Sudlow CLM, et al
Standardizing reporting of brain and central nervous system tumors in the United Kingdom.
Neuro Oncol. 2022;24:1032-1033.
PubMed

MANGUM R, Parsons DW
TRK inhibition for pediatric and adult central nervous system tumors: Early promise and future questions.
Neuro Oncol. 2022;24:1008-1009.
PubMed

FAROUK SAIT S, Karajannis MA
Chemotherapy plus focal radiation therapy for localized intracranial germinoma: How little is enough?
Neuro Oncol. 2022;24:984-985.
PubMed

CAI F, Chen S, Yu X, Zhang J, et al
Transcription factor GTF2B regulates AIP protein expression in growth hormone-secreting pituitary adenomas and influences tumor phenotypes.
Neuro Oncol. 2022;24:925-935.
PubMed Abstract available

BARTELS U, Onar-Thomas A, Patel SK, Shaw D, et al
Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study.
Neuro Oncol. 2022;24:974-983.
PubMed Abstract available

PARK AK, Waheed A, Forst DA, Al-Samkari H, et al
Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies.
Neuro Oncol. 2022;24:964-973.
PubMed Abstract available

May 2022

Erratum to: Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma.
Neuro Oncol. 2022 May 27. pii: 6594729. doi: 10.1093.
PubMed

NOBRE L, Hawkins C
Liquid biopsy for pediatric brain tumor patients: is it prime time yet?
Neuro Oncol. 2022 May 27. pii: 6593987. doi: 10.1093.
PubMed

VERPLOEGH ISC, Conidi A, Brouwer RWW, Balcioglu HE, et al
Comparative single-cell RNA-sequencing profiling of BMP4-treated primary glioma cultures reveals therapeutic markers.
Neuro Oncol. 2022 May 26. pii: 6593858. doi: 10.1093.
PubMed Abstract available

DE LA FUENTE MI, Colman H, Rosenthal M, Van Tine BA, et al
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial.
Neuro Oncol. 2022 May 25. pii: 6593129. doi: 10.1093.
PubMed Abstract available

FRIEDRICH M, Hahn M, Michel J, Sankowski R, et al
Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
Neuro Oncol. 2022 May 24. pii: 6591514. doi: 10.1093.
PubMed Abstract available

GRIGUOLO G, Tosi A, Dieci MV, Fineberg S, et al
A comprehensive profiling of the immune microenvironment of breast cancer brain metastases.
Neuro Oncol. 2022 May 24. pii: 6591493. doi: 10.1093.
PubMed Abstract available

MESSINGER D, Harris MK, Cummings JR, Thomas C, et al
Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma.
Neuro Oncol. 2022 May 23. pii: 6590903. doi: 10.1093.
PubMed Abstract available

YEO KK, Alexandrescu S, Cotter JA, Vogelzang J, et al
Multi-institutional study of the frequency, genomic landscape and outcome of IDH-mutant glioma in paediatrics.
Neuro Oncol. 2022 May 23. pii: 6590765. doi: 10.1093.
PubMed Abstract available

GIRARDI F, Coleman MP, Allemani C
Reply to "Reporting pediatric brain tumors according to their behavior code can result in biased survival estimates-A European perspective to Girardi et al".
Neuro Oncol. 2022 May 21. pii: 6590321. doi: 10.1093.
PubMed

HOOGENDIJK R, van der Lugt J, van Vuurden DG, Visser O, et al
Reporting pediatric brain tumors according to their behavior code can result in biased survival estimates-A European perspective to Girardi et al.
Neuro Oncol. 2022 May 21. pii: 6590318. doi: 10.1093.
PubMed

EDMONSTON DY, Wu S, Li Y, Khan RB, et al
Limited Surgery and Conformal Photon Radiation Therapy for Pediatric Craniopharyngioma: Long-term Results from the RT1 Protocol.
Neuro Oncol. 2022 May 12. pii: 6585053. doi: 10.1093.
PubMed Abstract available

SAMPETREAN O, Saya H
What can metabolites tell us about gliomas?
Neuro Oncol. 2022 May 12. pii: 6584800. doi: 10.1093.
PubMed

BARTLETT A, Lane A, Chaney B, Escorza NY, et al
Characteristics of Children
Neuro Oncol. 2022 May 12. pii: 6585024. doi: 10.1093.
PubMed Abstract available

RICKLEFS FL, Maire CL, Wollmann K, Duhrsen L, et al
Diagnostic potential of extracellular vesicles in meningioma patients.
Neuro Oncol. 2022 May 12. pii: 6585054. doi: 10.1093.
PubMed Abstract available

REED-GUY L, Desai AS, Phillips RE, Croteau D, et al
Risk of intracranial hemorrhage with direct oral anticoagulants versus low molecular weight heparin in glioblastoma: A retrospective cohort study.
Neuro Oncol. 2022 May 12. pii: 6585055. doi: 10.1093.
PubMed Abstract available

ROESLER R, de Farias CB, Brunetto AT, Gregianin L, et al
Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma.
Neuro Oncol. 2022 May 11. pii: 6584501. doi: 10.1093.
PubMed

Erratum to: path-03. Ferroptosis-related long non-coding rna signatures predict prognosis in patients with glioma.
Neuro Oncol. 2022 May 9. pii: 6583332. doi: 10.1093.
PubMed

WINKLER F
Understanding epilepsy in IDH-mutated gliomas: towards a targeted therapy.
Neuro Oncol. 2022 May 9. pii: 6582767. doi: 10.1093.
PubMed

GALLDIKS N, Lohmann P, Langen KJ
The role of 11C-methionine PET in patients with newly diagnosed WHO grade 2 or 3 gliomas.
Neuro Oncol. 2022 May 5. pii: 6581471. doi: 10.1093.
PubMed

CASES-CUNILLERA S, van Loo KMJ, Pitsch J, Quatraccioni A, et al
Heterogeneity and excitability of BRAFV600E-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss.
Neuro Oncol. 2022;24:741-754.
PubMed Abstract available

SATOMI K, Takami H, Fukushima S, Yamashita S, et al
12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors.
Neuro Oncol. 2022;24:834-846.
PubMed Abstract available

LAZOW MA, Fuller C, DeWire M, Lane A, et al
Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry.
Neuro Oncol. 2022;24:821-833.
PubMed Abstract available

RUDA R, Bruno F, Ius T, Silvani A, et al
IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups.
Neuro Oncol. 2022;24:809-820.
PubMed Abstract available

FELIX M, Friedel D, Jayavelu AK, Filipski K, et al
HIP1R and Vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
Neuro Oncol. 2022 May 3. pii: 6578556. doi: 10.1093.
PubMed Abstract available

RICKLEFS FL, Drexler R, Wollmann K, Eckhardt A, et al
DNA Methylation subclass Receptor Tyrosine Kinase II (RTK II) is predictive for seizure development in glioblastoma patients.
Neuro Oncol. 2022 May 2. pii: 6577052. doi: 10.1093.
PubMed Abstract available

LIM M, Weller M, Idbaih A, Steinbach J, et al
Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter.
Neuro Oncol. 2022 May 2. pii: 6577049. doi: 10.1093.
PubMed Abstract available

April 2022

PERSSON ML, Douglas AM, Alvaro F, Faridi P, et al
The intrinsic and microenvironmental features of diffuse midline glioma; implications for the development of effective immunotherapeutic treatment strategies.
Neuro Oncol. 2022 Apr 27. pii: 6575144. doi: 10.1093.
PubMed Abstract available

MERCHANT TE, Edmonston DY, Wu S, Li Y, et al
Endocrine Outcomes after Limited Surgery and Conformal Photon Radiation Therapy for Pediatric Craniopharyngioma: Long-term Results from the RT1 Protocol.
Neuro Oncol. 2022 Apr 27. pii: 6575137. doi: 10.1093.
PubMed Abstract available

DING J, Li X, Khan S, Zhang C, et al
EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a non-canonical regulatory axis between EGFR and wild-type p53 in glioblastoma.
Neuro Oncol. 2022 Apr 26. pii: 6574563. doi: 10.1093.
PubMed Abstract available

GUTIERREZ-VALENCIA E, Kalyvas A, Villafuerte CJ, Millar BA, et al
Factors Correlating with Survival Following Adjuvant or Definitive Radiosurgery for Large Brain Metastases.
Neuro Oncol. 2022 Apr 26. pii: 6574580. doi: 10.1093.
PubMed Abstract available

JAIN B, Dee EC, Jain U, Aizer AA, et al
Trends in location of death for individuals with primary brain tumors in the United States.
Neuro Oncol. 2022 Apr 26. pii: 6574444. doi: 10.1093.
PubMed

SCHONROCK A, Heinzelmann E, Steffl B, Demirdizen E, et al
MEOX2 homeobox gene promotes growth of malignant gliomas.
Neuro Oncol. 2022 Apr 25. pii: 6573906. doi: 10.1093.
PubMed Abstract available

MA R, Rei M, Woodhouse I, Ferris K, et al
Decitabine increases neoantigen and cancer testis antigen expression to enhance T cell-mediated toxicity against glioblastoma.
Neuro Oncol. 2022 Apr 25. pii: 6573935. doi: 10.1093.
PubMed Abstract available

MINAMI N, Hong D, Stevers N, Barger CJ, et al
Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma.
Neuro Oncol. 2022 Apr 23. pii: 6573305. doi: 10.1093.
PubMed Abstract available

IORGULESCU JB, Sun C, Neff C, Cioffi G, et al
Molecular Biomarker-Defined Brain Tumors: Epidemiology, Validity, and Completeness in the United States.
Neuro Oncol. 2022 Apr 23. pii: 6573306. doi: 10.1093.
PubMed Abstract available

CHUNG C, Brown PD, Wefel JS
Lessons learned from proton vs photon radiation therapy for glioblastoma signal-finding trial.
Neuro Oncol. 2022 Apr 23. pii: 6573235. doi: 10.1093.
PubMed

PUROW B
ONC201 and ONC206: metabolically ClipPing the wings of diffuse midline glioma.
Neuro Oncol. 2022 Apr 23. pii: 6573255. doi: 10.1093.
PubMed

OMURO A, Brandes AA, Carpentier AF, Idbaih A, et al
Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.
Neuro Oncol. 2022 Apr 14. pii: 6568419. doi: 10.1093.
PubMed Abstract available

COUTURIER CP, Nadaf J, Li Z, Baig S, et al
Glioblastoma scRNAseq Shows Treatment-induced, Immune-dependent Rise In Mesenchymal Cancer Cells, and Structural Variants in Distal Neural Stem Cells.
Neuro Oncol. 2022 Apr 13. pii: 6567757. doi: 10.1093.
PubMed Abstract available

COOMANS M, Dirven L, Aaronson N, Baumert BG, et al
Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period.
Neuro Oncol. 2022 Apr 11. pii: 6566436. doi: 10.1093.
PubMed Abstract available

GHOSH S
Breaking the DLG shackles in glioblastoma.
Neuro Oncol. 2022 Apr 11. pii: 6566243. doi: 10.1093.
PubMed

ROSENBERG T, Yeo KK, Mauguen A, Alexandrescu S, et al
Upfront Molecular Targeted Therapy for the Treatment of BRAF-Mutant Pediatric High-Grade Glioma.
Neuro Oncol. 2022 Apr 9. pii: 6566011. doi: 10.1093.
PubMed Abstract available

ZHANG L, Nesvick CL, Day CA, Choi J, et al
STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
Neuro Oncol. 2022 Apr 9. pii: 6566009. doi: 10.1093.
PubMed Abstract available

KANMOUNYE US, Karekezi C, Nyalundja AD, Awad AK, et al
Adult brain tumors in Sub-Saharan Africa: A scoping review.
Neuro Oncol. 2022 Apr 9. pii: 6566010. doi: 10.1093.
PubMed Abstract available

ZHANG Y, Lucas CG, Young JS, Morshed RA, et al
Prospective genomically-guided identification of 'early/evolving' and 'undersampled' IDH-wildtype glioblastoma leads to improved clinical outcomes.
Neuro Oncol. 2022 Apr 8. pii: 6565639. doi: 10.1093.
PubMed Abstract available

BIEGEL JA
Meeting the high expectations for liquid biopsy assays for pediatric brain tumors: progress and challenges.
Neuro Oncol. 2022 Apr 5. pii: 6563880. doi: 10.1093.
PubMed

ELLINGSON BM, Gerstner ER, Lassman AB, Chung C, et al
Hypothetical Generalized Framework for a New Imaging Endpoint of Therapeutic Activity in Early Phase Clinical Trials in Brain Tumors.
Neuro Oncol. 2022 Apr 5. pii: 6563738. doi: 10.1093.
PubMed Abstract available

TESILEANU CMS, Gorlia T, Golfinopoulos V, French PJ, et al
MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas.
Neuro Oncol. 2022;24:665-667.
PubMed

FRAPPAZ D, Dhall G, Murray MJ, Goldman S, et al
EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults.
Neuro Oncol. 2022;24:516-527.
PubMed Abstract available

NAKAMURA H, Takami H, Yanagisawa T, Kumabe T, et al
The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors.
Neuro Oncol. 2022;24:503-515.
PubMed Abstract available

WU Z, Abdullaev Z, Pratt D, Chung HJ, et al
Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics.
Neuro Oncol. 2022;24:571-581.
PubMed Abstract available

March 2022

SARAN F, Eisenstat DD
The relapse doesn't fall far from the radiotherapy field: Lessons to be learned for the future of radiotherapy in medulloblastoma from the relapse patterns of SJMB03.
Neuro Oncol. 2022 Mar 24. pii: 6553345. doi: 10.1093.
PubMed

PIOTROWSKI AF, Jackson S
Identifying risk factors for recurrence/relapse in NF1 optic pathway gliomas: Moving forward by looking back.
Neuro Oncol. 2022 Mar 23. pii: 6553267. doi: 10.1093.
PubMed

CORDELL EC, Alghamri MS, Castro MG, Gutmann DH, et al
T lymphocytes as dynamic regulators of glioma pathobiology.
Neuro Oncol. 2022 Mar 23. pii: 6553145. doi: 10.1093.
PubMed Abstract available

OSUKA S
Targeting adaptive radioresistance in Glioblastoma.
Neuro Oncol. 2022 Mar 22. pii: 6552309. doi: 10.1093.
PubMed

BLOBNER J, Tonn JC
Resection of glioma - Feeding the beast?
Neuro Oncol. 2022 Mar 22. pii: 6552311. doi: 10.1093.
PubMed

AZAD TD, Bettegowda C
Longitudinal monitoring of diffuse midline glioma using liquid biopsy.
Neuro Oncol. 2022 Mar 22. pii: 6552310. doi: 10.1093.
PubMed

LE RHUN E, Oppong FB, Vanlancker M, Stupp R, et al
Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
Neuro Oncol. 2022 Mar 21. pii: 6551573. doi: 10.1093.
PubMed Abstract available

ZHAN Q, Yi K, Cui X, Li X, et al
Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy.
Neuro Oncol. 2022 Mar 21. pii: 6551550. doi: 10.1093.
PubMed Abstract available

QIN N, Paisana E, Langini M, Picard D, et al
Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis.
Neuro Oncol. 2022 Mar 21. pii: 6551011. doi: 10.1093.
PubMed Abstract available

FANGUSARO JR, Onar-Thomas A, Poussaint TY, Wu S, et al
Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.
Neuro Oncol. 2022 Mar 21. pii: 6551018. doi: 10.1093.
PubMed

FERDOSI SR, Taylor B, Lee M, Tang N, et al
PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitors.
Neuro Oncol. 2022 Mar 19. pii: 6550856. doi: 10.1093.
PubMed Abstract available

BOUFFET E, Lafay-Cousin L
Infant brain tumor trials: Beyond feasibility.
Neuro Oncol. 2022 Mar 14. pii: 6548388. doi: 10.1093.
PubMed

ZHOU Y, Meng X, He W, Li XY, et al
USF1/CD90 signaling in maintaining glioblastoma stem cells and tumor-associated macrophages adhesion.
Neuro Oncol. 2022 Mar 14. pii: 6548387. doi: 10.1093.
PubMed Abstract available

MOHAMED E, Kumar A, Zhang Y, Wang AS, et al
PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.
Neuro Oncol. 2022 Mar 14. pii: 6548389. doi: 10.1093.
PubMed Abstract available

FOREMAN NK
Outcomes after first relapse of children with intracranial ependymoma treated on the second l'Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) protocol.
Neuro Oncol. 2022;24:480-481.
PubMed

MILLER JJ, Wang N
Body imaging for newly diagnosed CNS lymphoma: Evaluating the utility of the evaluation.
Neuro Oncol. 2022;24:492-493.
PubMed

MASSIMINO M, Barretta F, Modena P, Johann P, et al
Treatment and outcome of intracranial ependymoma after first relapse in the 2nd AIEOP protocol.
Neuro Oncol. 2022;24:467-479.
PubMed Abstract available

BURGENSKE DM, Talele S, Pokorny JL, Mladek AC, et al
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
Neuro Oncol. 2022;24:384-395.
PubMed Abstract available

MILLER JJ, Cahill DP, Arrillaga-Romany I
Enhancing demethylation-induced differentiation in IDH-mutant glioma.
Neuro Oncol. 2022 Mar 3. pii: 6542042. doi: 10.1093.
PubMed

MLADEK AC, Yan H, Tian S, Decker PA, et al
RBBP4-p300 Axis Modulates Expression of Genes Essential for Cell Survival and is a Potential Target for Therapy in Glioblastoma.
Neuro Oncol. 2022 Mar 1. pii: 6540482. doi: 10.1093.
PubMed Abstract available

February 2022

BADODI S, Pomella N, Lim YM, Brandner S, et al
Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma.
Neuro Oncol. 2022 Feb 25. pii: 6537125. doi: 10.1093.
PubMed Abstract available

PAPUSHA L, Zaytseva M, Panferova A, Druy A, et al
Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib.
Neuro Oncol. 2022 Feb 23. pii: 6535118. doi: 10.1093.
PubMed

FERRARESE R, Carro MS
Neural networks help zebrafish to step up as a model for efficient drug screening in glioblastoma.
Neuro Oncol. 2022 Feb 19. pii: 6532496. doi: 10.1093.
PubMed

NINATTI G, Sollini M, Bono B, Gozzi N, et al
Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas.
Neuro Oncol. 2022 Feb 16. pii: 6529477. doi: 10.1093.
PubMed Abstract available

UPADHYAY R, Liao K, Grosshans DR, McGovern SL, et al
Quantifying the risk and dosimetric variables of symptomatic brainstem injury after proton beam radiation in pediatric brain tumors.
Neuro Oncol. 2022 Feb 14. pii: 6528473. doi: 10.1093.
PubMed Abstract available

PRZYSTAL JM, Cosentino CC, Yadavilli S, Zhang J, et al
Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.
Neuro Oncol. 2022 Feb 14. pii: 6528446. doi: 10.1093.
PubMed Abstract available

BJORKBLOM B, Wibom C, Eriksson M, Bergenheim AT, et al
Distinct metabolic hallmarks of WHO classified adult glioma subtypes.
Neuro Oncol. 2022 Feb 14. pii: 6528465. doi: 10.1093.
PubMed Abstract available

LIU T, Zhu C, Chen X, Guan G, et al
Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance.
Neuro Oncol. 2022 Feb 11. pii: 6527229. doi: 10.1093.
PubMed Abstract available

MILLER AM, Szalontay L, Bouvier N, Hill K, et al
Next-generation Sequencing of Cerebrospinal Fluid for Clinical Molecular Diagnostics in Pediatric, Adolescent and Young Adult (AYA) Brain Tumor Patients.
Neuro Oncol. 2022 Feb 11. pii: 6527231. doi: 10.1093.
PubMed Abstract available

VAN KESSEL E, Berendsen S, Baumfalk AE, Venugopal H, et al
Tumor-related molecular determinants of neurocognitive deficits in patients with diffuse glioma.
Neuro Oncol. 2022 Feb 11. pii: 6527233. doi: 10.1093.
PubMed Abstract available

LAZOW MA, Nievelstein MT, Lane A, Bandopadhayhay P, et al
Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry.
Neuro Oncol. 2022 Feb 11. pii: 6527234. doi: 10.1093.
PubMed Abstract available

REBCHUK AD, Chaharyn BM, Alam A, Hounjet CD, et al
The Impact of Brain Invasion Criteria on the Incidence and Distribution of WHO Grade 1, 2 and 3 Meningiomas.
Neuro Oncol. 2022 Feb 9. pii: 6525422. doi: 10.1093.
PubMed Abstract available

JO J, van den Bent MJ, Nabors B, Wen PY, et al
Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.
Neuro Oncol. 2022 Feb 8. pii: 6524653. doi: 10.1093.
PubMed Abstract available

CANTOR E, Wierzbicki K, Tarapore RS, Ravi K, et al
Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.
Neuro Oncol. 2022 Feb 6. pii: 6523277. doi: 10.1093.
PubMed Abstract available

January 2022

YIN S, Luo X, Yang Y, Shao Y, et al
Development and validation of a deep-learning model for detecting brain metastases on 3D post-contrast MRI: a multi-center multi-reader evaluation study.
Neuro Oncol. 2022 Jan 31. pii: 6518101. doi: 10.1093.
PubMed Abstract available

ALVAREZ-BRECKENRIDGE CA, Cahill DP, Brastianos PK
Trabectedin for recurrent WHO grade 2 or 3 meningiomas-paving the road for new opportunities.
Neuro Oncol. 2022 Jan 31. pii: 6518099. doi: 10.1093.
PubMed

READ RD
Repurposing the drug verteporfin as anti-neoplastic therapy for glioblastoma.
Neuro Oncol. 2022 Jan 31. pii: 6518098. doi: 10.1093.
PubMed

BROWN CE, Rodriguez A, Palmer J, Ostberg JR, et al
Off-the-shelf, Steroid Resistant, IL13Ralpha2-Specific CAR T Cells for Treatment of Glioblastoma.
Neuro Oncol. 2022 Jan 31. pii: 6518100. doi: 10.1093.
PubMed Abstract available

LOWE SR, Wang CP, Brisco A, Whiting J, et al
Surgical and Anatomic Factors Predict Development of Leptomeningeal Disease in Patients with Melanoma Brain Metastases.
Neuro Oncol. 2022 Jan 29. pii: 6517353. doi: 10.1093.
PubMed Abstract available

TAGLANG C, Batsios G, Mukherjee J, Tran M, et al
Deuterium magnetic resonance spectroscopy enables non-invasive metabolic imaging of tumor burden and response to therapy in low-grade gliomas.
Neuro Oncol. 2022 Jan 29. pii: 6517050. doi: 10.1093.
PubMed Abstract available

GERSTNER ER
Volumetric Measurements in Low Grade Glioma: Are we there yet?
Neuro Oncol. 2022 Jan 28. pii: 6516793. doi: 10.1093.
PubMed

KOEKKOEK JAF, van der Meer PB, Taphoorn MJB, Dirven L, et al
Letter regarding "SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors".
Neuro Oncol. 2022 Jan 25. pii: 6515357. doi: 10.1093.
PubMed

PICCA A, Desjardins C, Bihan K, Weiss N, et al
Progressive multifocal leukoencephalopathy after first-line radiotherapy and temozolomide for glioblastoma.
Neuro Oncol. 2022 Jan 17. pii: 6509380. doi: 10.1093.
PubMed

RAHMAN R, Huang RY
Deep learning approaches to non-invasively assess molecular features of gliomas.
Neuro Oncol. 2022 Jan 13. pii: 6507359. doi: 10.1093.
PubMed

VOGELIUS IR, Bentzen SM
Proton vs photon radiation therapy for glioblastoma: Maximizing information from trial.
Neuro Oncol. 2022 Jan 13. pii: 6506534. doi: 10.1093.
PubMed

BECKER KN, Eisenmann KM
New Targets in the Glioblastoma Tumor Microtube Multiverse: Emerging Roles for the TGF-beta/TSP1 Signaling Axis.
Neuro Oncol. 2022 Jan 10. pii: 6502470. doi: 10.1093.
PubMed

TRAN AN
Targeting glutamine addiction in meningioma.
Neuro Oncol. 2022 Jan 10. pii: 6502476. doi: 10.1093.
PubMed

ESPINOZA FI, Walker PR
Untangling macrophage/microglia complexity in glioblastoma subtypes to elucidate the impact of CSF1R inhibition.
Neuro Oncol. 2022 Jan 10. pii: 6502489. doi: 10.1093.
PubMed

VOGELBAUM MA
Balancing Maximal Resection and Functional Preservation in Surgery for Low Grade Glioma.
Neuro Oncol. 2022 Jan 10. pii: 6502479. doi: 10.1093.
PubMed

KOTCH C, Avery R, Getz KD, Bouffet E, et al
Risk Factors for Treatment Refractory and Relapsed Optic Pathway Glioma in Children with Neurofibromatosis Type 1.
Neuro Oncol. 2022 Jan 9. pii: 6501465. doi: 10.1093.
PubMed Abstract available

MAEGAWA S, Gopalakrishnan V
PLK inhibitors come of age in pediatric brain tumors.
Neuro Oncol. 2022 Jan 7. pii: 6499977. doi: 10.1093.
PubMed

SOFFIETTI R, Bettegowda C, Mellinghoff IK, Warren KE, et al
Liquid biopsy in gliomas: a RANO review and proposals for clinical applications.
Neuro Oncol. 2022 Jan 6. pii: 6499389. doi: 10.1093.
PubMed Abstract available

MORTAZAVI A, Fayed I, Bachani M, Dowdy T, et al
IDH Mutated Gliomas Promote Epileptogenesis through D-2-Hydroxyglutarate Dependent mTOR Hyperactivation.
Neuro Oncol. 2022 Jan 5. pii: 6498134. doi: 10.1093.
PubMed Abstract available

FURLAN JC, Wilson JR, Massicotte EM, Sahgal A, et al
Recent advances and new discoveries in the pipeline of the treatment of primary spinal tumors and spinal metastases: a scoping review of registered clinical studies from 2000 to 2020.
Neuro Oncol. 2022;24:1-13.
PubMed Abstract available

JUHNKE BO, Gessi M, Gerber NU, Friedrich C, et al
Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial.
Neuro Oncol. 2022;24:127-137.
PubMed Abstract available

LAMBA N, Catalano PJ, Bi WL, Wen PY, et al
Predictors of long-term survival among patients with brain metastases.
Neuro Oncol. 2022 Jan 4. pii: 6497420. doi: 10.1093.
PubMed

KUNDU S, Nandhu MS, Longo SL, Longo JA, et al
The scaffolding protein DLG5 promotes glioblastoma growth by controlling Sonic Hedgehog signaling in tumor stem cells.
Neuro Oncol. 2022 Jan 4. pii: 6497518. doi: 10.1093.
PubMed Abstract available

PAGES M, Rotem D, Gydush G, Reed S, et al
Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine.
Neuro Oncol. 2022 Jan 4. pii: 6497435. doi: 10.1093.
PubMed Abstract available

December 2021

DE BILLY E, Pellegrino M, Orlando D, Pericoli G, et al
Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
Neuro Oncol. 2021 Dec 29. pii: 6489024. doi: 10.1093.
PubMed Abstract available

KNUDSEN AM, Halle B, Cedile O, Burton M, et al
Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors.
Neuro Oncol. 2021 Dec 29. pii: 6489042. doi: 10.1093.
PubMed Abstract available

HU C, Wang K, Damon C, Fu Y, et al
ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma.
Neuro Oncol. 2021 Dec 24. pii: 6482823. doi: 10.1093.
PubMed Abstract available

MEISSNER AK, Gutsche R, Galldiks N, Kocher M, et al
Radiomics for the non-invasive prediction of the BRAF mutation status in patients with melanoma brain metastases.
Neuro Oncol. 2021 Dec 22. pii: 6478897. doi: 10.1093.
PubMed Abstract available

LEARY SES, Lindsay K, Geyer JR, Mehmet K, et al
Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026).
Neuro Oncol. 2021 Dec 22. pii: 6478443. doi: 10.1093.
PubMed Abstract available

DESHPANDE K, Martirosian V, Nakamura BN, Iyer M, et al
Neuronal exposure induces neurotransmitter signaling and synaptic mediators in tumors early in brain metastasis.
Neuro Oncol. 2021 Dec 21. pii: 6473228. doi: 10.1093.
PubMed Abstract available

YABO YA, Niclou SP, Golebiewska A
Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma.
Neuro Oncol. 2021 Dec 21. pii: 6472977. doi: 10.1093.
PubMed Abstract available

GU J, Mu N, Jia B, Guo Q, et al
Targeting radiation-tolerant persister cells as a strategy for inhibiting radioresistance and recurrence in glioblastoma.
Neuro Oncol. 2021 Dec 14. pii: 6461092. doi: 10.1093.
PubMed Abstract available

LUCAS JT, Tinkle CL, Huang J, Onar-Thomas A, et al
Revised clinical and molecular risk strata define the incidence and pattern of failure in Medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study.
Neuro Oncol. 2021 Dec 11. pii: 6459719. doi: 10.1093.
PubMed Abstract available

LIM-FAT MJ, Youssef GC, Touat M, Iorgulescu JB, et al
Clinical utility of targeted next generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.
Neuro Oncol. 2021 Dec 8. pii: 6456497. doi: 10.1093.
PubMed Abstract available

GARZIA L
Faraway, so close: intratumoral heterogeneity of medulloblastoma subgroups.
Neuro Oncol. 2021 Dec 4. pii: 6449209. doi: 10.1093.
PubMed

HAGIWARA A, Oughourlian TC, Cho NS, Schlossman J, et al
Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.
Neuro Oncol. 2021 Dec 2. pii: 6448328. doi: 10.1093.
PubMed Abstract available

GUPTA T, Manjali JJ, Purandare N, Bagal B, et al
Bone marrow biopsy in PCNSL: Relevant or redundant?
Neuro Oncol. 2021;23:2117-2118.
PubMed

MARGOLD M, Schlegel U
Reply to letter to the editor by Gupta et al: Bone marrow biopsy in patients with PCNSL: relevant or redundant?
Neuro Oncol. 2021;23:2119.
PubMed

MOUDGIL-JOSHI J, Kaliaperumal C
Letter regarding Louis et al: The 2021 WHO Classification of Tumors of the Central Nervous System: A summary.
Neuro Oncol. 2021;23:2120-2121.
PubMed

ECKEL-PASSOW JE, Kitange GJ, Decker PA, Kosel ML, et al
Experimental design of preclinical experiments: number of PDX lines vs subsampling within PDX lines.
Neuro Oncol. 2021;23:2066-2075.
PubMed Abstract available

MARNER L, Lundemann M, Sehested A, Nysom K, et al
Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors.
Neuro Oncol. 2021;23:2107-2116.
PubMed Abstract available

November 2021

CHAREST A
Optimizing an effective combination of the new microtubule targeting agent Lisavanbulin with standard of care therapy for glioblastoma in patient-derived xenograft pre-clinical models.
Neuro Oncol. 2021 Nov 27. pii: 6444804. doi: 10.1093.
PubMed

TAYLOR JW
Treat the VTE and worry less about the hemorrhage: A sigh of relief or is the jury still out for therapeutic anticoagulation in high grade glioma?
Neuro Oncol. 2021 Nov 27. pii: 6444703. doi: 10.1093.
PubMed

LEMAITRE AL, Herbet G, Ng S, Moritz-Gasser S, et al
Cognitive preservation following awake mapping-based neurosurgery for low-grade gliomas: a longitudinal, within-patient design study.
Neuro Oncol. 2021 Nov 26. pii: 6444171. doi: 10.1093.
PubMed Abstract available

ABDULLAH KG, Bird CE, Buehler JD, Gattie LC, et al
Establishment of patient-derived organoid models of lower grade glioma.
Neuro Oncol. 2021 Nov 26. pii: 6444299. doi: 10.1093.
PubMed Abstract available

CHIOCCA EA, Gelb AB, Chen CC, Rao G, et al
Combined immunotherapy with controlled Interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase 1 trial.
Neuro Oncol. 2021 Nov 26. pii: 6444298. doi: 10.1093.
PubMed Abstract available

DA COSTA ROSA M, Yamashita AS, Riggins GJ
Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas.
Neuro Oncol. 2021 Nov 26. pii: 6440681. doi: 10.1093.
PubMed Abstract available

DE JOODE K, Taal W, Snijders TJ, Hanse M, et al
Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium.
Neuro Oncol. 2021 Nov 24. pii: 6437945. doi: 10.1093.
PubMed

KIELISZEK AM, Aghaei N, Bassey-Archibong B, Singh SK, et al
Low and steady wins the race: for melanoma-brain metastases, is prevention better than a cure?
Neuro Oncol. 2021 Nov 24. pii: 6438512. doi: 10.1093.
PubMed

WU J
Targeting nicotinamide adenosine dinucleotide (NAD) in diffuse gliomas.
Neuro Oncol. 2021 Nov 22. pii: 6433381. doi: 10.1093.
PubMed

ALMSTEDT E, Rosen E, Gloger M, Stockgard R, et al
Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts.
Neuro Oncol. 2021 Nov 19. pii: 6432157. doi: 10.1093.
PubMed Abstract available

NASSIRI F, Wang JZ, Au K, Barnholtz-Sloan J, et al
Consensus core clinical data elements for meningiomas.
Neuro Oncol. 2021 Nov 17. pii: 6430437. doi: 10.1093.
PubMed Abstract available

BALIGA S, Gallotto S, Bajaj B, Lewy J, et al
Decade Long Disease, Secondary Malignancy, and Brainstem Injury Outcomes in Pediatric and Young Adult Medulloblastoma Patients Treated with Proton Radiotherapy.
Neuro Oncol. 2021 Nov 12. pii: 6425899. doi: 10.1093.
PubMed Abstract available

KACHURI L, Walsh KM
Long telomeres in need of a SNP: Germline contributions of telomere maintenance to glioma.
Neuro Oncol. 2021 Nov 10. pii: 6425113. doi: 10.1093.
PubMed

ELLINGSON BM, Kim GHJ, Brown M, Lee J, et al
Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of Ivosidenib.
Neuro Oncol. 2021 Nov 9. pii: 6424025. doi: 10.1093.
PubMed Abstract available

ARAKAKI AKS, Szulzewsky F, Gilbert MR, Gujral TS, et al
Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers.
Neuro Oncol. 2021;23.
PubMed Abstract available

PRATT D, Sahm F, Aldape K
DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncology.
Neuro Oncol. 2021;23.
PubMed Abstract available

ARMSTRONG TS, Gilbert MR
Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors.
Neuro Oncol. 2021;23.
PubMed Abstract available

PENAS-PRADO M
Rare central nervous system tumors: the path to progress.
Neuro Oncol. 2021;23.
PubMed

ASA SL, Mete O
Single-cell transcriptome and genome analysis: A much-needed tool for pituitary neuroendocrine tumor studies.
Neuro Oncol. 2021;23:1803-1804.
PubMed

CUI Y, Li C, Jiang Z, Zhang S, et al
Single-cell transcriptome and genome analyses of pituitary neuroendocrine tumors.
Neuro Oncol. 2021;23:1859-1871.
PubMed Abstract available

October 2021

MOLINARO AM
External Controls to Improve on Glioblastoma Clinical Trials.
Neuro Oncol. 2021 Oct 29. pii: 6414401. doi: 10.1093.
PubMed

ANDREWS LJ, Thornton ZA, Saincher SS, Yao IY, et al
Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.
Neuro Oncol. 2021 Oct 28. pii: 6413773. doi: 10.1093.
PubMed Abstract available

SCHWARTZBAUM J, Harris R
Age at diagnosis and sex interact to modify primary malignant glioma incidence and survival.
Neuro Oncol. 2021 Oct 25. pii: 6409990. doi: 10.1093.
PubMed

VACHHA BA, Huang RY
BOLD Asynchrony: An imaging biomarker of tumor burden in IDH-mutated gliomas.
Neuro Oncol. 2021 Oct 25. pii: 6409977. doi: 10.1093.
PubMed

PREUSSER M, Silvani A, Le Rhun E, Soffietti R, et al
Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG).
Neuro Oncol. 2021 Oct 21. pii: 6406919. doi: 10.1093.
PubMed Abstract available

BARRETTE AM, Ronk H, Joshi T, Mussa Z, et al
Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor Verteporfin in preclinical glioblastoma models.
Neuro Oncol. 2021 Oct 17. pii: 6398692. doi: 10.1093.
PubMed Abstract available

CLUCERU J, Interian Y, Phillips JJ, Molinaro AM, et al
Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging.
Neuro Oncol. 2021 Oct 15. pii: 6398212. doi: 10.1093.
PubMed Abstract available

PANT A, Lim M
Checkpoint blockade in recurrent meningiomas: Lessons for future management.
Neuro Oncol. 2021 Oct 9. pii: 6385431. doi: 10.1093.
PubMed

HOOGSTRATE Y, Ghisai SA, de Wit M, de Heer I, et al
The EGFRvIII transcriptome in glioblastoma, a meta-omics analysis.
Neuro Oncol. 2021 Oct 5. pii: 6381406. doi: 10.1093.
PubMed Abstract available

OSTROM QT, Cioffi G, Waite K, Kruchko C, et al
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.
Neuro Oncol. 2021;23.
PubMed Abstract available

STROWD RE
Etched in Code: Revisiting glioma risk factors through the exome.
Neuro Oncol. 2021 Oct 4. pii: 6380799. doi: 10.1093.
PubMed

FRIEDMAN GK, Dhall G
Potential Role of Carbon Ion Radiotherapy in Chromothripsis-induced Medulloblastoma and Other Malignancies.
Neuro Oncol. 2021 Oct 4. pii: 6380754. doi: 10.1093.
PubMed

WU J, Gupta R, Barreto J, Doo P, et al
Tumor DNA requirements for accurate epigenetic-based classification of CNS neoplasia.
Neuro Oncol. 2021;23:1798-1800.
PubMed

PERTZ M, Schlegel U
Tracking the neurobiology of cognitive dysfunction in primary CNS lymphoma?
Neuro Oncol. 2021;23:1623-1624.
PubMed

MILDE T, Rodriguez FJ, Barnholtz-Sloan JS, Patil N, et al
Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas.
Neuro Oncol. 2021;23:1634-1646.
PubMed Abstract available

GENG H, Tsang M, Subbaraj L, Cleveland J, et al
Tumor metabolism and neurocognition in CNS lymphoma.
Neuro Oncol. 2021;23:1668-1679.
PubMed Abstract available

September 2021

DEL BENE M, Osti D, Faletti S, Beznousenko GV, et al
Extracellular vesicles: the key for precision medicine in glioblastoma.
Neuro Oncol. 2021 Sep 28. pii: 6377304. doi: 10.1093.
PubMed Abstract available

RAO R, Han R, Ogurek S, Xue C, et al
Glioblastoma Genetic Drivers Dictate the Function of Tumor-Associated Macrophages/Microglia and Responses to CSF1R Inhibition.
Neuro Oncol. 2021 Sep 25. pii: 6375369. doi: 10.1093.
PubMed Abstract available

PENG J, Kim DD, Patel JB, Zeng X, et al
Corrigendum to: Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors.
Neuro Oncol. 2021 Sep 22. pii: 6374130. doi: 10.1093.
PubMed

JOSEPH JV, Magaut CR, Storevik S, Geraldo LH, et al
TGF- promotes microtube formation in glioblastoma through Thrombospondin 1.
Neuro Oncol. 2021 Sep 20. pii: 6372853. doi: 10.1093.
PubMed Abstract available

LUCAS CG, Mueller S, Reddy A, Taylor JW, et al
Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy.
Neuro Oncol. 2021 Sep 14. pii: 6370137. doi: 10.1093.
PubMed

WANG W, He H, Marin-Ramos NI, Zeng S, et al
Corrigendum to: Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.
Neuro Oncol. 2021 Sep 14. pii: 6370123. doi: 10.1093.
PubMed

BORNHORST M
New insights into low grade glioma tumor microenvironment for improved patient management.
Neuro Oncol. 2021 Sep 13. pii: 6369407. doi: 10.1093.
PubMed

ABOUNADER R, Schiff D
The blood-brain barrier limits the therapeutic efficacy of antibody drug conjugates in glioblastoma.
Neuro Oncol. 2021 Sep 13. pii: 6369406. doi: 10.1093.
PubMed

ZHANG W, Talele S, Sarkaria JN, Elmquist WF, et al
Changes in the vasculature of human brain tumors: Implications for treatment.
Neuro Oncol. 2021 Sep 13. pii: 6369378. doi: 10.1093.
PubMed

IJARE OB, Hambarde S, Brasil da Costa FH, Lopez S, et al
Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas.
Neuro Oncol. 2021 Sep 13. pii: 6369334. doi: 10.1093.
PubMed Abstract available

MAROSI C
Will mastering ferroptosis allow treating refractory meningiomas?
Neuro Oncol. 2021 Sep 13. pii: 6369228. doi: 10.1093.
PubMed

DRIVER J, Hoffman SE, Tavakol S, Woodward E, et al
A Molecularly Integrated Grade for Meningioma.
Neuro Oncol. 2021 Sep 11. pii: 6368844. doi: 10.1093.
PubMed Abstract available

TOM MC, Kotecha R
Beating a Benchmark: Boron Neutron Capture Therapy for Recurrent and Refractory Meningiomas.
Neuro Oncol. 2021 Sep 11. pii: 6368846. doi: 10.1093.
PubMed

IUS T, Ng S, Young JS, Tomasino B, et al
The benefit of early surgery on overall survival in incidental low grade glioma patients: a multicenter study.
Neuro Oncol. 2021 Sep 8. pii: 6366593. doi: 10.1093.
PubMed Abstract available

SAUNDERS CN, Kinnersley B, Culliford R, Cornish AJ, et al
Relationship between genetically determined telomere length and glioma risk.
Neuro Oncol. 2021 Sep 3. pii: 6363706. doi: 10.1093.
PubMed Abstract available

WANG D, Veo B, Pierce A, Fosmire S, et al
A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
Neuro Oncol. 2021 Sep 3. pii: 6363671. doi: 10.1093.
PubMed Abstract available

BANDOPADHAYAY P, Chi SN
The challenges in treating Embryonal Tumors with Multilayered Rosettes (ETMR) and other infant brain tumors.
Neuro Oncol. 2021 Sep 3. pii: 6363655. doi: 10.1093.
PubMed

AQUILANTI E, Kageler L, Wen PY, Meyerson M, et al
Telomerase as a therapeutic target in glioblastoma.
Neuro Oncol. 2021 Sep 2. pii: 6362724. doi: 10.1093.
PubMed Abstract available

BRANDNER S, McAleenan A, Kelly C, Spiga F, et al
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
Neuro Oncol. 2021;23:1457-1469.
PubMed Abstract available

THACKER N, Bouffet E
Posterior fossa syndrome-time to unmute the silence on cerebellar mutism.
Neuro Oncol. 2021;23:1427-1428.
PubMed

VON HOFF K, Haberler C, Schmitt-Hoffner F, Schepke E, et al
Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study.
Neuro Oncol. 2021;23:1597-1611.
PubMed Abstract available

KHAN RB, Patay Z, Klimo P, Huang J, et al
Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study.
Neuro Oncol. 2021;23:1586-1596.
PubMed Abstract available

August 2021

CHUNG C, Brown PD, Wefel JS
Short reply to "Proton therapy for newly diagnosed glioblastoma: More room for investigation" by R. Press et al.
Neuro Oncol. 2021 Aug 28. pii: 6359127. doi: 10.1093.
PubMed

PRESS RH, Chhabra AM, Choi JI, Hasan S, et al
Proton therapy for newly diagnosed glioblastoma: more room for investigation.
Neuro Oncol. 2021 Aug 28. pii: 6359128. doi: 10.1093.
PubMed

CICONE F, Cascini GL, Minniti G
Reply to: "Letter to the Editor: Assessment of imaging biomarkers in the follow-up of brain metastases after SRS".
Neuro Oncol. 2021 Aug 24. pii: 6357080. doi: 10.1093.
PubMed

DERKS SHAE, Jongen JLM, van den Bent MJ, van der Veldt AAM, et al
Assessment of imaging biomarkers in the follow-up of brain metastases after SRS.
Neuro Oncol. 2021 Aug 24. pii: 6357079. doi: 10.1093.
PubMed

RONSLEY R, Bouffet E
COVID-19 in pediatric cancer: Where are the brain tumors?
Neuro Oncol. 2021 Aug 20. pii: 6355395. doi: 10.1093.
PubMed

WANG GM, Cioffi G, Patil N, Waite KA, et al
Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas.
Neuro Oncol. 2021 Aug 13. pii: 6350590. doi: 10.1093.
PubMed Abstract available

JO J, Donahue J, Sarai G, Petroni G, et al
Management of Venous Thromboembolism in High-Grade Glioma: Does Low Molecular Weight Heparin Increase Intracranial Bleeding Risk?
Neuro Oncol. 2021 Aug 12. pii: 6348905. doi: 10.1093.
PubMed Abstract available

YANG WC, Chen YF, Yang CC, Wu PF, et al
Erratum to: Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial.
Neuro Oncol. 2021 Aug 7. pii: 6345198. doi: 10.1093.
PubMed

LAMBA N, Aizer AA
The evolving role of systemic therapy and local, brain-directed treatment in patients with melanoma and brain metastases.
Neuro Oncol. 2021 Aug 5. pii: 6341089. doi: 10.1093.
PubMed

WINKLER F
Silencing glioblastoma networks to make temozolomide more effective.
Neuro Oncol. 2021 Aug 4. pii: 6339977. doi: 10.1093.
PubMed

SU JM, Kilburn LB, Mansur DB, Krailo M, et al
Phase 1/2 Trial of Vorinostat and Radiation and Maintenance Vorinostat in Children with Diffuse Intrinsic Pontine Glioma: A Children's Oncology Group Report.
Neuro Oncol. 2021 Aug 4. pii: 6339987. doi: 10.1093.
PubMed Abstract available

HUANG H, Georganaki M, Conze LL, Lavina B, et al
ELTD1-deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.
Neuro Oncol. 2021 Aug 4. pii: 6339962. doi: 10.1093.
PubMed Abstract available

WEN PY, Packer RJ
The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications.
Neuro Oncol. 2021;23:1215-1217.
PubMed

LOUIS DN, Perry A, Wesseling P, Brat DJ, et al
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
Neuro Oncol. 2021;23:1231-1251.
PubMed Abstract available

CORREA DD
Neurocognitive functions in primary CNS lymphoma.
Neuro Oncol. 2021;23:1220-1221.
PubMed

MOSELLA MS, Sabedot TS, Silva TC, Malta TM, et al
DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features.
Neuro Oncol. 2021;23:1292-1303.
PubMed Abstract available

VAN DER MEULEN M, Dirven L, Habets EJJ, Bakunina K, et al
Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial.
Neuro Oncol. 2021;23:1315-1326.
PubMed Abstract available

July 2021

MUNOZ PINTO MF, Campbell SJ, Simoglou Karali C, Johanssen VA, et al
Selective blood-brain barrier permeabilisation of brain metastases by a type-1 receptor selective tumour necrosis factor mutein.
Neuro Oncol. 2021 Jul 23. pii: 6326734. doi: 10.1093.
PubMed Abstract available

RICHARDSON S, Hill RM, Kui C, Lindsey JC, et al
Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse.
Neuro Oncol. 2021 Jul 17. pii: 6323243. doi: 10.1093.
PubMed Abstract available

SHIH HA
An early foray with targeted therapy and inspiring novel approaches to combat adult medulloblastoma.
Neuro Oncol. 2021 Jul 16. pii: 6323026. doi: 10.1093.
PubMed

HULSBERGEN AFC, Abunimer AM, Ida F, Kavouridis VK, et al
Neurosurgical resection for locally recurrent brain metastasis.
Neuro Oncol. 2021 Jul 16. pii: 6322695. doi: 10.1093.
PubMed Abstract available

SHARMA P, Xu J, Williams K, Easley M, et al
Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
Neuro Oncol. 2021 Jul 14. pii: 6321319. doi: 10.1093.
PubMed Abstract available

LUDWIG N, Rao A, Sandlesh P, Yerneni SS, et al
Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles.
Neuro Oncol. 2021 Jul 13. pii: 6320007. doi: 10.1093.
PubMed Abstract available

RAMASWAMY V, Bartels U
Selumetinib for optic pathway glioma: Seeing through the fog, (not yet) the end of the tunnel?
Neuro Oncol. 2021 Jul 12. pii: 6319139. doi: 10.1093.
PubMed

BALANA C, Sun C, Vaz MA, Esteve A, et al
Reply to: Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
Neuro Oncol. 2021 Jul 9. pii: 6318238. doi: 10.1093.
PubMed

TERABE M, Wu J
Rethinking Immunotherapy in Meningiomas.
Neuro Oncol. 2021 Jul 9. pii: 6318447. doi: 10.1093.
PubMed

ZHAO B, Ma W
Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
Neuro Oncol. 2021 Jul 9. pii: 6318242. doi: 10.1093.
PubMed

BAGLEY SJ, Kline CN
Understanding the global impact of primary brain tumors: the untapped potential of population-based cancer registries.
Neuro Oncol. 2021 Jul 9. pii: 6318451. doi: 10.1093.
PubMed

LUKAS RV
Essential Oils for Blood-Brain Barrier Disruption: Preclinical Studies of NEO100 in Breast Cancer Brain Metastases.
Neuro Oncol. 2021 Jul 9. pii: 6318449. doi: 10.1093.
PubMed

ALHALABI OT, Fletcher MNC, Hielscher T, Kessler T, et al
A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma.
Neuro Oncol. 2021 Jul 7. pii: 6316731. doi: 10.1093.
PubMed Abstract available

TONOGAI EJ, Huang S, Botham RC, Berry MR, et al
Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.
Neuro Oncol. 2021 Jul 3. pii: 6314291. doi: 10.1093.
PubMed Abstract available

TEHRANIAN C, Fankhauser L, Harter PN, Ratcliffe CDH, et al
The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis.
Neuro Oncol. 2021 Jul 3. pii: 6314211. doi: 10.1093.
PubMed Abstract available

PETRIDIS PD, Horenstein C, Pereira B, Wu P, et al
BOLD Asynchrony Elucidates Tumor Burden in IDH-Mutated Gliomas.
Neuro Oncol. 2021 Jul 2. pii: 6313213. doi: 10.1093.
PubMed Abstract available

YAMAZAKI S, Ohka F, Hirano M, Shiraki Y, et al
Newly Established Patient-derived Organoid Model of Intracranial Meningioma.
Neuro Oncol. 2021 Jul 2. pii: 6313216. doi: 10.1093.
PubMed Abstract available

D'ALESSANDRIS QG, Della Pepa GM, Noya C, Olivi A, et al
Mesenchymal stem cells: are they the good or the bad?
Neuro Oncol. 2021;23:1203-1204.
PubMed

DANKNER M, Maritan SM
The relevance of surgical status in nodular leptomeningeal metastasis patient outcomes.
Neuro Oncol. 2021;23:1207.
PubMed

LE RHUN E, Devos P, Weller J, Seystahl K, et al
Prognostic factors in leptomeningeal metastases.
Neuro Oncol. 2021;23:1208-1209.
PubMed

BARAJAS RF, Politi LS, Anzalone N, Schoder H, et al
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).
Neuro Oncol. 2021;23:1056-1071.
PubMed Abstract available

LE RHUN E, Devos P, Weller J, Seystahl K, et al
Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors.
Neuro Oncol. 2021;23:1100-1112.
PubMed Abstract available

FORDE C, King AT, Rutherford SA, Hammerbeck-Ward C, et al
Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution.
Neuro Oncol. 2021;23:1113-1124.
PubMed Abstract available

June 2021

GOLDBRUNNER R, Stavrinou P, Jenkinson MD, Sahm F, et al
EANO guideline on the diagnosis and management of meningiomas.
Neuro Oncol. 2021 Jun 28. pii: 6310843. doi: 10.1093.
PubMed Abstract available

WALBERT T, Harrison RA, Schiff D, Avila EK, et al
SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.
Neuro Oncol. 2021 Jun 26. pii: 6310125. doi: 10.1093.
PubMed Abstract available

PENG J, Kim DD, Patel JB, Zeng X, et al
Deep Learning-Based Automatic Tumor Burden Assessment of Pediatric High-Grade Gliomas, Medulloblastomas, and Other Leptomeningeal Seeding Tumors.
Neuro Oncol. 2021 Jun 26. pii: 6310123. doi: 10.1093.
PubMed Abstract available

WIRSCHING HG, Steiner L, Becker D, Regli L, et al
Increase in contrast-enhancing volume of irradiated meningiomas reflects tumor progression and not pseudoprogression.
Neuro Oncol. 2021 Jun 19. pii: 6305986. doi: 10.1093.
PubMed

JOHNSON KC, Verhaak RGW
Serum cell-free DNA epigenetic biomarkers aid glioma diagnostics and monitoring.
Neuro Oncol. 2021 Jun 17. pii: 6302547. doi: 10.1093.
PubMed

HAU P
Dissecting adult SHH-activated medulloblastoma - molecularly defined tumor subsets reveal new prognostic biomarkers.
Neuro Oncol. 2021 Jun 17. pii: 6302543. doi: 10.1093.
PubMed

SHAH AH, Gilbert M, Ivan ME, Komotar RJ, et al
The role of human endogenous retroviruses in gliomas: from etiological perspectives and therapeutic implications.
Neuro Oncol. 2021 Jun 12. pii: 6297568. doi: 10.1093.
PubMed Abstract available

ERKER C, Lane A, Chaney B, Leary S, et al
Characteristics of Patients >/= 10 Years of Age with Diffuse Intrinsic Pontine Glioma: A Report from the International DIPG Registry.
Neuro Oncol. 2021 Jun 11. pii: 6296498. doi: 10.1093.
PubMed Abstract available

SHEEHAN J, Pikis S, Islim A, Chen CJ, et al
An International Multicenter Matched Cohort Analysis of Incidental Meningioma Progression During Active Surveillance or After Stereotactic Radiosurgery: The IMPASSE Study.
Neuro Oncol. 2021 Jun 9. pii: 6295369. doi: 10.1093.
PubMed Abstract available

KOTECHA R, Aboian M, Nabavizadeh SA, Parent EE, et al
Letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation.
Neuro Oncol. 2021 Jun 3. pii: 6291736. doi: 10.1093.
PubMed

GALLDIKS N, Niyazi M, Tonn JC, Langen KJ, et al
Reply to the letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation.
Neuro Oncol. 2021 Jun 3. pii: 6291737. doi: 10.1093.
PubMed

RIEMONDY KA, Venkataraman S, Willard N, Nellan A, et al
Neoplastic and immune single cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma.
Neuro Oncol. 2021 Jun 2. pii: 6291352. doi: 10.1093.
PubMed Abstract available

RITZMANN TA, Kilday JP, Grundy RG
Pediatric ependymomas: destined to recur?
Neuro Oncol. 2021;23:874-876.
PubMed

POON MTC, Brennan PM, Jin K, Sudlow CLM, et al
Might changes in diagnostic practice explain increasing incidence of brain and central nervous system tumors? A population-based study in Wales (United Kingdom) and the United States.
Neuro Oncol. 2021;23:979-989.
PubMed Abstract available

ADOLPH JE, Fleischhack G, Mikasch R, Zeller J, et al
Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study.
Neuro Oncol. 2021;23:1012-1023.
PubMed Abstract available

May 2021

PHILLIPS LM, Li S, Gumin J, Daou M, et al
An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
Neuro Oncol. 2021 May 31. pii: 6290257. doi: 10.1093.
PubMed Abstract available

MARIN BM, Porath KA, Jain S, Kim M, et al
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
Neuro Oncol. 2021 May 29. pii: 6288409. doi: 10.1093.
PubMed Abstract available

SCOCCIANTI S, Olmetto E, Pinzi V, Osti MF, et al
Immunotherapy in association with stereotactic radiotherapy for Non-Small Cell Lung Cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO.
Neuro Oncol. 2021 May 29. pii: 6288399. doi: 10.1093.
PubMed Abstract available

VERBURG N, Barthel FP, Anderson KJ, Johnson KC, et al
Spatial concordance of DNA methylation classification in diffuse glioma.
Neuro Oncol. 2021 May 28. pii: 6287958. doi: 10.1093.
PubMed Abstract available

SIMOVIC M, Bolkestein M, Moustafa M, Wong JKL, et al
Carbon ion radiotherapy eradicates medulloblastomas with chromothripsis in an orthotopic Li-Fraumeni patient-derived mouse model.
Neuro Oncol. 2021 May 28. pii: 6287957. doi: 10.1093.
PubMed Abstract available

DE ANDRADE COSTA A, Chatterjee J, Cobb O, Sanapala S, et al
RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth.
Neuro Oncol. 2021 May 27. pii: 6286081. doi: 10.1093.
PubMed Abstract available

LI Y, Wang X, Qi S, Gao L, et al
Spliceosome-regulated RSRP1-dependent NF-kappaB activation promotes the glioblastoma mesenchymal phenotype.
Neuro Oncol. 2021 May 27. pii: 6286882. doi: 10.1093.
PubMed Abstract available

LAPERRIERE NJ
Protons for the Management of Adult Patients with Glioblastoma.
Neuro Oncol. 2021 May 24. pii: 6283746. doi: 10.1093.
PubMed

MENDOZA TR
Especially for neuro-oncologists - minimally important differences for the EORTC QLQ-C30 in glioma patients.
Neuro Oncol. 2021 May 24. pii: 6283743. doi: 10.1093.
PubMed

CHONGSATHIDKIET P, Fecci PE
Cold-inducible RNA-binding protein (CIRBP) as a biomarker to predict recurrence of brain metastases.
Neuro Oncol. 2021 May 24. pii: 6283744. doi: 10.1093.
PubMed

BI WL, Nayak L, Meredith DM, Driver J, et al
Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results.
Neuro Oncol. 2021 May 20. pii: 6279078. doi: 10.1093.
PubMed Abstract available

GUSYATINER O, Bady P, Pham MDT, Lei Y, et al
BET inhibitors repress expression of Interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma.
Neuro Oncol. 2021 May 14. pii: 6275457. doi: 10.1093.
PubMed Abstract available

SIM HW, McDonald KL, Lwin Z, Barnes EH, et al
A randomized phase II trial of veliparib, radiotherapy and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
Neuro Oncol. 2021 May 13. pii: 6275307. doi: 10.1093.
PubMed Abstract available

DAHL NA, Vibhakar R
Converging evidence for inhibition of transcriptional control in high-grade gliomas.
Neuro Oncol. 2021 May 13. pii: 6275360. doi: 10.1093.
PubMed

TAKAI S, Wanibuchi M, Kawabata S, Takeuchi K, et al
Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up.
Neuro Oncol. 2021 May 13. pii: 6275296. doi: 10.1093.
PubMed Abstract available

BAO Z, Hua L, Ye Y, Wang D, et al
MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma.
Neuro Oncol. 2021 May 13. pii: 6275374. doi: 10.1093.
PubMed Abstract available

WANG Z, Gao L, Wang Y, Chang M, et al
Validation of the prognostic value of 9-gene ATE score for IDH wild-type glioblastoma.
Neuro Oncol. 2021 May 13. pii: 6275034. doi: 10.1093.
PubMed

NASSIRI F, Wang JZ, Singh O, Karimi S, et al
Loss of H3K27me3 in meningiomas.
Neuro Oncol. 2021 May 10. pii: 6273127. doi: 10.1093.
PubMed Abstract available

FELKER J, Agnihotri S
Not all mouse blood-brain barriers are created equal.
Neuro Oncol. 2021;23:705-706.
PubMed

SO J, Mamatjan Y, Zadeh G, Aldape K, et al
Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis.
Neuro Oncol. 2021;23:795-802.
PubMed Abstract available

MASSIMINO M, Barretta F, Modena P, Witt H, et al
Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up.
Neuro Oncol. 2021;23:848-857.
PubMed Abstract available

CLAUS EB, Cannataro VL, Gaffney SG, Townsend JP, et al
Environmental and sex-specific molecular signatures of glioma causation.
Neuro Oncol. 2021 May 4. pii: 6263733. doi: 10.1093.
PubMed Abstract available

April 2021

BRANDNER S, McAleenan A, Kelly C, Spiga F, et al
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Review.
Neuro Oncol. 2021 Apr 30. pii: 6263562. doi: 10.1093.
PubMed Abstract available

YEUNG J, Yaghoobi V, Miyagishima D, Vesely MD, et al
Targeting the CSF1/CSF1R Axis is a Potential Treatment Strategy for Malignant Meningiomas.
Neuro Oncol. 2021 Apr 29. pii: 6259024. doi: 10.1093.
PubMed Abstract available

TESILEANU CMS, van den Bent MJ, Sanson M, Wick W, et al
Prognostic significance of genome-wide DNA methylation profiles within the randomised, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
Neuro Oncol. 2021 Apr 29. pii: 6259004. doi: 10.1093.
PubMed Abstract available

LAMBA N, Wen PY, Aizer AA
Epidemiology of Brain Metastases and Leptomeningeal Disease.
Neuro Oncol. 2021 Apr 28. pii: 6256866. doi: 10.1093.
PubMed Abstract available

STROTHER D, Lafay-Cousin L
Adjuvant therapy for high risk medulloblastoma: More is better?
Neuro Oncol. 2021 Apr 27. pii: 6254485. doi: 10.1093.
PubMed

MARINELLI JP, Carlson ML
Potential for selection bias surrounding reporting of benign brain tumors in the United States.
Neuro Oncol. 2021 Apr 26. pii: 6253739. doi: 10.1093.
PubMed

TAWBI HA, Forsyth PA, Hodi FS, Lao CD, et al
Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204).
Neuro Oncol. 2021 Apr 21. pii: 6242717. doi: 10.1093.
PubMed Abstract available

NICLOU SP, Golebiewska A
Turning strength into weakness: protein degradation and autophagy as therapeutic targets in Glioblastoma?
Neuro Oncol. 2021 Apr 17. pii: 6231737. doi: 10.1093.
PubMed

SCHNEIDER M, Vollmer L, Potthoff AL, Ravi VM, et al
Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma.
Neuro Oncol. 2021 Apr 17. pii: 6231712. doi: 10.1093.
PubMed Abstract available

VISWANATH P, Batsios G, Ayyappan V, Taglang C, et al
Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas.
Neuro Oncol. 2021 Apr 17. pii: 6231711. doi: 10.1093.
PubMed Abstract available

VOLMAR MNM, Cheng J, Alenezi H, Richter S, et al
Cannabidiol converts NFkappaB into a tumor suppressor in glioblastoma with defined antioxidative properties.
Neuro Oncol. 2021 Apr 17. pii: 6231710. doi: 10.1093.
PubMed Abstract available

KATSUSHIMA K, Lee B, Kunhiraman H, Zhong C, et al
The long noncoding RNA lnc-HLX-2-7 is oncogenic in Group 3 medulloblastomas.
Neuro Oncol. 2021;23:572-585.
PubMed Abstract available

THOMAS C, Soschinski P, Zwaig M, Oikonomopoulos S, et al
The genetic landscape of choroid plexus tumors in children and adults.
Neuro Oncol. 2021;23:650-660.
PubMed Abstract available

WANIS HA, Moller H, Ashkan K, Davies EA, et al
The incidence of major subtypes of primary brain tumours in adults in England 1995-2017.
Neuro Oncol. 2021 Apr 9. pii: 6218679. doi: 10.1093.
PubMed Abstract available

HORBINSKI C, McCortney K, Stupp R
MGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas.
Neuro Oncol. 2021 Apr 8. pii: 6217333. doi: 10.1093.
PubMed

MUKHERJEE S, Schiltz G, Clutter M, Mishra R, et al
Erratum to: DDIS-27. TARGETING ATP DOCKING AND P35/P25 BINDING OF CDK5 IN GLIOMA STEM CELLS USING SYNTHETIC INHIBITORS.
Neuro Oncol. 2021 Apr 7. pii: 6214067. doi: 10.1093.
PubMed

MUKHERJEE S, Olson C, Dundar B, Sharma N, et al
Erratum to: STEM-19. RESISTANCE IS FUTILE: UNDERSTANDING AND TARGETING THE CDK5-CREB1-MCL1 AXIS TO PREVENT RADIATION RESISTANCE IN GLIOMA STEM CELLS.
Neuro Oncol. 2021 Apr 7. pii: 6214066. doi: 10.1093.
PubMed

FRAPPAZ D, Barritault M, Montane L, Laigle-Donadey F, et al
MEVITEM - A Phase I/II of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
Neuro Oncol. 2021 Apr 7. pii: 6213882. doi: 10.1093.
PubMed Abstract available

YU Y, Villanueva-Meyer J, Grimmer MR, Hilz S, et al
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
Neuro Oncol. 2021 Apr 5. pii: 6211336. doi: 10.1093.
PubMed Abstract available

SANTAGATA S, Ligon KL
Prognostication for meningiomas: H3K27me3 to the rescue?
Neuro Oncol. 2021 Apr 3. pii: 6209863. doi: 10.1093.
PubMed

TSANG DS, Schulte F
Beyond the brain: Socioeconomic status and race in pediatric brain tumor survivorship.
Neuro Oncol. 2021 Apr 3. pii: 6209877. doi: 10.1093.
PubMed

LEE EQ, Selig W, Meehan C, Bacha J, et al
Report of National Brain Tumor Society Roundtable Workshop on Innovating Brain Tumor Clinical Trials: Building on Lessons Learned from COVID-19 Experience.
Neuro Oncol. 2021 Apr 2. pii: 6209406. doi: 10.1093.
PubMed Abstract available

March 2021

PERKINS S, Acharya S
Radiation therapy to the developing brain: advanced technology is ready for robust optimization parameters.
Neuro Oncol. 2021;23:350-351.
PubMed

LASSMAN AB, Cloughesy TF
Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?
Neuro Oncol. 2021;23:347-349.
PubMed

KUMTHEKAR P, Dunbar EM, Peters KB, Brastianos PK, et al
A broad perspective on evaluating bias in the neuro-oncology workplace.
Neuro Oncol. 2021;23:498-499.
PubMed

GILBERT MR, Yuan Y, Wu J, Mendoza T, et al
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
Neuro Oncol. 2021;23:468-477.
PubMed Abstract available

JAECKLE KA, Ballman KV, van den Bent M, Giannini C, et al
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
Neuro Oncol. 2021;23:457-467.
PubMed Abstract available

BOURDEAUT F
Are B7-H3 CAR-T cells the future universal treatment for pediatric brain tumors?
Neuro Oncol. 2021 Mar 23. pii: 6182498. doi: 10.1093.
PubMed

LU SL, Xiao FR, Cheng JC, Yang WC, et al
Randomized Multi-Reader Evaluation of Automated Detection and Segmentation of Brain Tumors in Stereotactic Radiosurgery with Deep Neural Networks.
Neuro Oncol. 2021 Mar 23. pii: 6180141. doi: 10.1093.
PubMed Abstract available

LATHIA JD
Fountain of chaos: cerebrospinal fluid enhancement of cancer stem cells in glioblastoma.
Neuro Oncol. 2021 Mar 22. pii: 6179836. doi: 10.1093.
PubMed

NOBRE L, Ramaswamy V
Medulloblastoma (cross)talk through extracellular vesicles.
Neuro Oncol. 2021 Mar 22. pii: 6179837. doi: 10.1093.
PubMed

OSTROM QT, Edelson J, Byun J, Han Y, et al
Partitioned glioma heritability shows subtype-specific enrichment in immune cells.
Neuro Oncol. 2021 Mar 20. pii: 6179266. doi: 10.1093.
PubMed Abstract available

GIRARDI F, Rous B, Stiller CA, Gatta G, et al
The histology of brain tumours for 67,331 children and 671,085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3).
Neuro Oncol. 2021 Mar 19. pii: 6178525. doi: 10.1093.
PubMed Abstract available

VERKOUTEREN BJA, Cosgun B, Vermeulen RJ, Reinders MGHC, et al
Prevalence of medulloblastoma in basal cell nevus syndrome patients with a PTCH1 mutation.
Neuro Oncol. 2021 Mar 17. pii: 6231902. doi: 10.1093.
PubMed

TSIEN C
Stereotactic radiation therapy with concurrent immunotherapy for recurrent glioblastoma-hope or hype?
Neuro Oncol. 2021 Mar 12. pii: 6168946. doi: 10.1093.
PubMed

WINKLER F
In glioma, all endothelial cells are not created the same.
Neuro Oncol. 2021 Mar 11. pii: 6168415. doi: 10.1093.
PubMed

SAIT SF, Karajannis MA
Pediatric spinal cord gliomas - low grade but high risk for recurrence: should we treat them differently from intracranial low-grade gliomas?
Neuro Oncol. 2021 Mar 11. pii: 6168346. doi: 10.1093.
PubMed

TRIFILETTI DM, Brown PD
Cognitive outcomes in patients with low-grade glioma.
Neuro Oncol. 2021 Mar 11. pii: 6168225. doi: 10.1093.
PubMed

FONSECA A, Bouffet E
Brainstem Gliomas... The Devil is in the Details.
Neuro Oncol. 2021 Mar 11. pii: 6168340. doi: 10.1093.
PubMed

BAUMERT BG, Pesce GA
Elderly patients with brain metastases: new support for the balancing act in treatment decision making.
Neuro Oncol. 2021 Mar 11. pii: 6168221. doi: 10.1093.
PubMed

MENG Y, Pople CB, Suppiah S, Llinas M, et al
MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors.
Neuro Oncol. 2021 Mar 10. pii: 6167330. doi: 10.1093.
PubMed Abstract available

LIM-FAT MJ, Maralani PJ
Is there an optimal MRI surveillance schedule for patients with high grade glioma after standard of care therapy?
Neuro Oncol. 2021 Mar 1. pii: 6155531. doi: 10.1093.
PubMed

SPERDUTO PW, Lou E
The Past, Current and Future Management of Brain Metastases in EGFR-Mutant Non-Small Cell Lung Cancer.
Neuro Oncol. 2021 Mar 1. pii: 6155599. doi: 10.1093.
PubMed

February 2021

GIANNINI C, Giangaspero F
TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH-wildtype glioblastoma?
Neuro Oncol. 2021 Feb 28. pii: 6154503. doi: 10.1093.
PubMed

WANG W, He H, Marin-Ramos NI, Zeng S, et al
Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.
Neuro Oncol. 2021 Feb 28. pii: 6154448. doi: 10.1093.
PubMed Abstract available

BROWN PD, Chung C, Liu DD, McAvoy S, et al
A Prospective Phase II Randomized Trial of Proton Radiotherapy vs. Intensity Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma.
Neuro Oncol. 2021 Feb 27. pii: 6154000. doi: 10.1093.
PubMed Abstract available

JESSURUN CAC, Hulsbergen AFC, de Wit AE, Tewarie IA, et al
The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis.
Neuro Oncol. 2021 Feb 25. pii: 6150018. doi: 10.1093.
PubMed Abstract available

FANGUSARO J, Onar-Thomas A, Poussaint TY, Wu S, et al
A Phase 2 Trial of Selumetinib in Children with Recurrent Optic Pathway and Hypothalamic Low-Grade Glioma without NF1: A Pediatric Brain Tumor Consortium Study.
Neuro Oncol. 2021 Feb 25. pii: 6149924. doi: 10.1093.
PubMed Abstract available

TSCHERNICHOVSKY R, Katz LH, Derazne E, Berliner MB, et al
Height in Adolescence as a Risk Factor for Glioma Subtypes: a Nationwide Retrospective Cohort Study of 2.2 Million Subjects.
Neuro Oncol. 2021 Feb 25. pii: 6149925. doi: 10.1093.
PubMed Abstract available

JAIN R, Chi AS
Radiogenomics identifying important biological pathways in gliomas.
Neuro Oncol. 2021;23:177-178.
PubMed

ELLINGSON BM, Brown MS, Boxerman JL, Gerstner ER, et al
Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials.
Neuro Oncol. 2021;23:189-198.
PubMed Abstract available

KANAMORI M, Takami H, Yamaguchi S, Sasayama T, et al
So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma?
Neuro Oncol. 2021;23:295-303.
PubMed Abstract available

CANNON-ALBRIGHT LA, Farnham JM, Stevens J, Teerlink CC, et al
Genome-wide analysis of high-risk primary brain cancer pedigrees identifies PDXDC1 as a candidate brain cancer predisposition gene.
Neuro Oncol. 2021;23:277-283.
PubMed Abstract available

MATHEN P, Smart DK
Reimagining External Beam Radiotherapy for Glioblastoma: "Old Beam, New Trick".
Neuro Oncol. 2021 Feb 22. pii: 6146614. doi: 10.1093.
PubMed

KIM MM, Aryal MP, Sun Y, Parmar HA, et al
Response assessment during chemoradiation using a hypercellular/hyperperfused imaging phenotype predicts survival in patients with newly diagnosed glioblastoma.
Neuro Oncol. 2021 Feb 18. pii: 6144576. doi: 10.1093.
PubMed Abstract available

DIRVEN L, Musoro JZ, Coens C, Reijneveld JC, et al
Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.
Neuro Oncol. 2021 Feb 18. pii: 6142946. doi: 10.1093.
PubMed Abstract available

KORSHUNOV A, Okonechnikov K, Stichel D, Ryzhova M, et al
Integrated molecular analysis of adult Sonic Hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator.
Neuro Oncol. 2021 Feb 16. pii: 6137557. doi: 10.1093.
PubMed Abstract available

HUANG T, Cheng SY
Targeting phospholipid metabolism for glioblastoma therapy.
Neuro Oncol. 2021 Feb 9. pii: 6131652. doi: 10.1093.
PubMed

SCHAFFENRATH J, Wyss T, He L, Rushing EJ, et al
Blood-brain barrier alterations in human brain tumors revealed by genome-wide transcriptomic profiling.
Neuro Oncol. 2021 Feb 9. pii: 6131739. doi: 10.1093.
PubMed Abstract available

SABEDOT T, Malta T, Snyder J, Nelson K, et al
A serum-based DNA methylation assay provides accurate detection of glioma.
Neuro Oncol. 2021 Feb 9. pii: 6131768. doi: 10.1093.
PubMed Abstract available

GRAILLON T, Ferrer L, Siffre J, Sanson M, et al
Role of 3-D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study.
Neuro Oncol. 2021 Feb 8. pii: 6131353. doi: 10.1093.
PubMed Abstract available

GUO X, Wang S, Wang Y, Ma W, et al
Anti-PD-1 plus anti-VEGF therapy in multiple intracranial metastases of a hypermutated, IDH wild-type glioblastoma.
Neuro Oncol. 2021 Feb 8. pii: 6131355. doi: 10.1093.
PubMed

YAMAMOTO M, Sanomachi T, Suzuki S, Uchida H, et al
Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma.
Neuro Oncol. 2021 Feb 8. pii: 6131352. doi: 10.1093.
PubMed Abstract available

OTANI Y, Sur H, Rachaiah G, Namagiri S, et al
Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
Neuro Oncol. 2021 Feb 8. pii: 6131351. doi: 10.1093.
PubMed Abstract available

TORRES VA, Ashford JM, Wright E, Xu J, et al
The Impact of Socioeconomic Status (SES) on Cognitive Outcomes Following Radiotherapy for Pediatric Brain Tumors: A Prospective, Longitudinal Trial.
Neuro Oncol. 2021 Feb 5. pii: 6128895. doi: 10.1093.
PubMed Abstract available

LIAO Y, Luo Z, Deng Y, Zhang F, et al
OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes.
Neuro Oncol. 2021 Feb 4. pii: 6128721. doi: 10.1093.
PubMed Abstract available

GALLDIKS N, Niyazi M, Grosu AL, Kocher M, et al
Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group.
Neuro Oncol. 2021 Feb 4. pii: 6128548. doi: 10.1093.
PubMed Abstract available

January 2021

WEFEL JS, Armstrong TS, Pugh SL, Gilbert MR, et al
Neurocognitive, Symptom, and Health- Related Quality of Life Outcomes of a Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma (NRG/RTOG 0825).
Neuro Oncol. 2021 Jan 30. pii: 6124000. doi: 10.1093.
PubMed Abstract available

YANG TJ, Wijetunga NA, Yamada J, Wolden S, et al
Clinical trial of proton craniospinal irradiation for leptomeningeal metastases.
Neuro Oncol. 2021;23:134-143.
PubMed Abstract available

NARITA Y, Nagane M, Mishima K, Terui Y, et al
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
Neuro Oncol. 2021;23:122-133.
PubMed Abstract available

MAIRE CL, Fuh MM, Kaulich K, Fita KD, et al
Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification.
Neuro Oncol. 2021 Jan 28. pii: 6122789. doi: 10.1093.
PubMed Abstract available

GERRITSEN JKW, Vincent AJPE, De Vleeschouwer S
Maximizing extent of resection while minimizing the risk of neurological morbidity in glioma patients: a novel grading scale to translate these surgical goals into a merged onco-functional clinical outcome.
Neuro Oncol. 2021 Jan 20. pii: 6104892. doi: 10.1093.
PubMed

VARGAS LOPEZ AJ
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Neuro Oncol. 2021 Jan 20. pii: 6104916. doi: 10.1093.
PubMed

DIAMANDIS P
De-coding group 3 medulloblastoma biology with non-coding RNA.
Neuro Oncol. 2021 Jan 20. pii: 6104902. doi: 10.1093.
PubMed

KATAGI H, Takata N, Aoi Y, Zhang Y, et al
Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
Neuro Oncol. 2021 Jan 20. pii: 6104638. doi: 10.1093.
PubMed Abstract available

WEN PY, Weller M, Chiocca EA, Lim M, et al
Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez.
Neuro Oncol. 2021 Jan 20. pii: 6104896. doi: 10.1093.
PubMed

FULTS DW
Stemming the growth of pediatric gliomas through histone modification.
Neuro Oncol. 2021 Jan 20. pii: 6104497. doi: 10.1093.
PubMed

DMYTRIW AA, Huang RY
In search of predictive and response markers in antiangiogenic therapy of glioblastoma.
Neuro Oncol. 2021 Jan 20. pii: 6104491. doi: 10.1093.
PubMed

DANKNER M, Caron M, Al-Saadi T, Yu W, et al
Invasive growth associated with Cold-Inducible RNA-Binding Protein expression drives recurrence of surgically resected brain metastases.
Neuro Oncol. 2021 Jan 12. pii: 6089125. doi: 10.1093.
PubMed Abstract available

WU S, Li X, Gao F, de Groot JF, et al
PARP mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
Neuro Oncol. 2021 Jan 12. pii: 6089123. doi: 10.1093.
PubMed Abstract available

BENITEZ JA, Finlay D, Castanza A, Parisian AD, et al
Pten Deficiency Leads To Proteasome Addiction, A Novel Vulnerability In Glioblastoma.
Neuro Oncol. 2021 Jan 11. pii: 6081306. doi: 10.1093.
PubMed Abstract available

GUTMAN DC, Young RJ
IDH glioma radiogenomics in the era of deep learning.
Neuro Oncol. 2021 Jan 8. pii: 6068851. doi: 10.1093.
PubMed

SNUDERL M
Molecular classification and deconvolution of the immune microenvironment in glioblastoma.
Neuro Oncol. 2021 Jan 4. pii: 6062458. doi: 10.1093.
PubMed

SHOFUDA T, Kanemura Y
HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors?
Neuro Oncol. 2021 Jan 4. pii: 6062389. doi: 10.1093.
PubMed

December 2020

SHAHZAD U, Taccone MS, Kumar SA, Okura H, et al
Modeling human brain tumours in flies, worms, and zebrafish: From proof of principle to novel therapeutic targets.
Neuro Oncol. 2020 Dec 30. pii: 6055605. doi: 10.1093.
PubMed Abstract available

DUFOUR C, Foulon S, Geoffray A, Masliah-Planchon J, et al
Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase 2 trial PNET HR+5.
Neuro Oncol. 2020 Dec 30. pii: 6055191. doi: 10.1093.
PubMed Abstract available

CHUNTOVA P, Chow F, Watchmaker P, Galvez M, et al
Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology.
Neuro Oncol. 2020 Dec 24. pii: 6047273. doi: 10.1093.
PubMed Abstract available

BEHLING F, Fodi C, Gepfner-Tuma I, Kaltenbach K, et al
H3K27me3 loss indicates an increased risk of recurrence in the Tubingen meningioma cohort.
Neuro Oncol. 2020 Dec 24. pii: 6046432. doi: 10.1093.
PubMed Abstract available

KUKSIS M, Gao Y, Tran W, Hoey C, et al
The Incidence of Brain Metastases Among Patients with Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
Neuro Oncol. 2020 Dec 23. pii: 6046194. doi: 10.1093.
PubMed Abstract available

CARLSON JC, Cantu-Gutierrez M, Lozzi B, Huang-Hobbs E, et al
Identification of diverse tumor endothelial cell populations in malignant glioma.
Neuro Oncol. 2020 Dec 23. pii: 6046199. doi: 10.1093.
PubMed Abstract available

PATIL N, Kelly ME, Yeboa DN, Buerki RA, et al
Epidemiology of Brainstem High-Grade Gliomas in Children and Adolescents in the United States, 2000-2017.
Neuro Oncol. 2020 Dec 21. pii: 6042829. doi: 10.1093.
PubMed Abstract available

PERWEIN T, Benesch M, Kandels D, Pietsch T, et al
High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): Management strategies and results from the German LGG study group.
Neuro Oncol. 2020 Dec 21. pii: 6042812. doi: 10.1093.
PubMed Abstract available

BERNHARDT D, Combs SE
Reply to: "Call of duty: neuro-oncology outpatient management during the COVID-19 pandemic in Milan, Italy".
Neuro Oncol. 2020;22:1893.
PubMed

YANG Z, Zhang Y, Li R, Yisikandaer A, et al
Whole Brain Radiotherapy With and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a multicentre, open-label, randomized, controlled phase 3 Trial.
Neuro Oncol. 2020 Dec 17. pii: 6040795. doi: 10.1093.
PubMed Abstract available

LIU Y, Li Z, Zhang M, Zhou H, et al
Rolling-translated EGFR Variants Sustain EGFR Signaling and Promote Glioblastoma Tumorigenicity.
Neuro Oncol. 2020 Dec 16. pii: 6039055. doi: 10.1093.
PubMed Abstract available

HAYDAR D, Houke H, Chiang J, Yi Z, et al
Cell surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.
Neuro Oncol. 2020 Dec 15. pii: 6035165. doi: 10.1093.
PubMed Abstract available

XIE R, Kessler T, Grosch J, Hai L, et al
Tumor cell network integration in glioma represents a stemness feature.
Neuro Oncol. 2020 Dec 15. pii: 6035154. doi: 10.1093.
PubMed Abstract available

PUDUVALLI VK
Demystifying Demethylator Sensitivity in Gliomas: Role for TERT and DNMT1.
Neuro Oncol. 2020 Dec 2. pii: 6017324. doi: 10.1093.
PubMed

HUANG J, Mehta M
Can proton therapy reduce radiation-related lymphopenia in glioblastoma?
Neuro Oncol. 2020 Dec 2. pii: 6017294. doi: 10.1093.
PubMed

GENOVESI LA, Puttick S, Millar A, Kojic M, et al
Patient derived orthotopic xenograft models of Medulloblastoma lack a functional blood brain barrier.
Neuro Oncol. 2020 Dec 1. pii: 6015057. doi: 10.1093.
PubMed Abstract available

YUAN M, White D, Resar L, Bar E, et al
Conditional reprograming culture conditions facilitate growth of lower grade glioma models.
Neuro Oncol. 2020 Dec 1. pii: 6015051. doi: 10.1093.
PubMed Abstract available

November 2020

KHASRAW M, Walsh KM, Heimberger AB, Ashley DM, et al
What is the Burden of Proof for Tumor Mutational Burden in gliomas?
Neuro Oncol. 2020 Nov 30. pii: 6012765. doi: 10.1093.
PubMed Abstract available

LARA-VELAZQUEZ M, Zarco N, Carrano A, Phillipps J, et al
Alpha 1-antichymotrypsin contributes to stem cell characteristics and enhances tumorigenicity of Glioblastoma.
Neuro Oncol. 2020 Nov 29. pii: 6010432. doi: 10.1093.
PubMed Abstract available

ZHENG ZQ, Chen JT, Zheng MC, Yang LJ, et al
Nestin +/CD31 + Cells in the Hypoxic Perivascular Niche Regulate Glioblastoma Chemoresistance by Upregulating JAG1 and DLL4.
Neuro Oncol. 2020 Nov 29. pii: 6010441. doi: 10.1093.
PubMed Abstract available

NIU X, Yang Y, Zhou X, Zhang H, et al
A prognostic nomogram for patients with newly diagnosed adult thalamic glioma in a surgical cohort.
Neuro Oncol. 2020 Nov 27. pii: 6007003. doi: 10.1093.
PubMed

KAUFMANN TJ, Smits M, Boxerman J, Huang R, et al
Response to Letter to Editor.
Neuro Oncol. 2020;22:1706-1707.
PubMed

LE RHUN E, Weller M, Le Deley MC
DEPOSEIN-how meaningful was the benefit from intrathecal chemotherapy?
Neuro Oncol. 2020;22:1710-1711.
PubMed

VOGELBAUM MA, Krivosheya D, Borghei-Razavi H, Sanai N, et al
Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review.
Neuro Oncol. 2020;22:1568-1579.
PubMed Abstract available

OERMANN EK, Germano IM
In the pursuit of glioma diagnosis - the challenges and opportunities of deep neural network augmented analyses.
Neuro Oncol. 2020 Nov 12. pii: 5979500. doi: 10.1093.
PubMed

ALBERT TK, Interlandi M, Sill M, Graf M, et al
An extracellular vesicle-related gene expression signature identifies high-risk patients in medulloblastoma.
Neuro Oncol. 2020 Nov 11. pii: 5974128. doi: 10.1093.
PubMed Abstract available

MITCHELL K, Troike K, Silver DJ, Lathia JD, et al
The evolution of the cancer stem cell state in glioblastoma - emerging insights into the next-generation of functional interactions.
Neuro Oncol. 2020 Nov 11. pii: 5973946. doi: 10.1093.
PubMed Abstract available

BERZERO G, Di Stefano AL, Ronchi S, Bielle F, et al
IDH-wildtype lower grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.
Neuro Oncol. 2020 Nov 11. pii: 5973947. doi: 10.1093.
PubMed Abstract available

GRAMATZKI D, Felsberg J, Roth P, Kaulich K, et al
The molecular evolution of glioblastoma treated by gross total resection alone.
Neuro Oncol. 2020 Nov 11. pii: 5973944. doi: 10.1093.
PubMed

SAHEBJAM S, Forsyth PA, Tran ND, Arrington JA, et al
Hypofractionated Stereotactic Re-Irradiation with Pembrolizumab and Bevacizumab in Patients with Recurrent High Grade Gliomas: Results from a Phase 1 Study.
Neuro Oncol. 2020 Nov 11. pii: 5973945. doi: 10.1093.
PubMed Abstract available

YI K, Zhan Q, Wang Q, Tan Y, et al
PTRF/Cavin1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2.
Neuro Oncol. 2020 Nov 3. pii: 5952479. doi: 10.1093.
PubMed Abstract available

VITANZA NA, Biery MC, Myers C, Ferguson E, et al
Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naive diffuse midline glioma models.
Neuro Oncol. 2020 Nov 1. pii: 5948533. doi: 10.1093.
PubMed Abstract available

MANJUNATH M, Yan J, Youn Y, Drucker KL, et al
Functional analysis of low-grade glioma genetic variants predicts key target genes and transcription factors.
Neuro Oncol. 2020 Nov 1. pii: 5948532. doi: 10.1093.
PubMed Abstract available

DEJAEGHER J, Solie L, Hunin Z, Sciot R, et al
DNA Methylation based glioblastoma subclassification is related to tumoral T cell infiltration and patient survival.
Neuro Oncol. 2020 Nov 1. pii: 5948531. doi: 10.1093.
PubMed Abstract available

KLEIN M, Drijver AJ, van den Bent MJ, Bromberg JC, et al
Memory in low-grade glioma patients treated with radiotherapy or Temozolomide. A correlative analysis of EORTC study 22033-26033.
Neuro Oncol. 2020 Nov 1. pii: 5948535. doi: 10.1093.
PubMed Abstract available

SIEVERS P, Sill M, Schrimpf D, Stichel D, et al
A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR.
Neuro Oncol. 2020 Nov 1. pii: 5948536. doi: 10.1093.
PubMed Abstract available

JI SY, Lee J, Lee JH, Lee ST, et al
Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling.
Neuro Oncol. 2020 Nov 1. pii: 5948534. doi: 10.1093.
PubMed Abstract available

October 2020

OSTROM QT, Patil N, Cioffi G, Waite K, et al
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.
Neuro Oncol. 2020;22.
PubMed Abstract available

TENG J, Hejazi S, Hiddingh L, Carvalho L, et al
Corrigendum to: Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
Neuro Oncol. 2020 Oct 28. pii: 5942594. doi: 10.1093.
PubMed

CICONE F, Carideo L, Scaringi C, Romano A, et al
Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET.
Neuro Oncol. 2020 Oct 23. pii: 5936979. doi: 10.1093.
PubMed Abstract available

MYNAREK M, Rutkowski S
Young children with medulloblastoma: Important open questions and the high-risk dilemma.
Neuro Oncol. 2020 Oct 23. pii: 5936023. doi: 10.1093.
PubMed

GONDI V, Mehta MP
Radiotherapy Innovations to Optimize Brain Metastases Control.
Neuro Oncol. 2020 Oct 22. pii: 5934824. doi: 10.1093.
PubMed

BROSSIER NM, Thondapu S, Cobb OM, Dahiya S, et al
Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine Neurofibromatosis-1 optic glioma.
Neuro Oncol. 2020 Oct 20. pii: 5932401. doi: 10.1093.
PubMed Abstract available

CHO SJ, Sunwoo L, Baik SH, Bae YJ, et al
Brain Metastasis Detection using Machine Learning: A Systematic Review and Meta-analysis.
Neuro Oncol. 2020 Oct 19. pii: 5930826. doi: 10.1093.
PubMed Abstract available

GROSSMAN SA
The Duration of Adjuvant Temozolomide in Patients with Glioblastoma and the Law of Diminishing Returns.
Neuro Oncol. 2020 Oct 19. pii: 5930402. doi: 10.1093.
PubMed

SKINNER KR, Nabors LB, Miller CR
Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics.
Neuro Oncol. 2020 Oct 19. pii: 5930390. doi: 10.1093.
PubMed

ZHUANG H, Wang Y, Cheng C, Shi S, et al
The efficacy of anlotinib instead of glucocorticoids for edema induced by brain metastases in NSCLC patients with anti-PD1/PDL-1 immunotherapy.
Neuro Oncol. 2020 Oct 19. pii: 5930379. doi: 10.1093.
PubMed

YOUNGBLOOD MW, Miyagishima DF, Jin L, Gupte T, et al
Associations of Meningioma Molecular Subgroup and Tumor Recurrence.
Neuro Oncol. 2020 Oct 17. pii: 5928913. doi: 10.1093.
PubMed Abstract available

LAMBA N, Kearney RB, Catalano PJ, Hassett MJ, et al
Population-based estimates of survival among elderly patients with brain metastases.
Neuro Oncol. 2020 Oct 17. pii: 5929216. doi: 10.1093.
PubMed Abstract available

BEIG N, Singh S, Bera K, Prasanna P, et al
Sexually dimorphic radiogenomic models identify distinct imaging and biological pathways that are prognostic of overall survival in Glioblastoma.
Neuro Oncol. 2020 Oct 17. pii: 5929182. doi: 10.1093.
PubMed Abstract available

BINDRA RS
Penetrating the Brain Tumor Space with DNA Damage Response Inhibitors.
Neuro Oncol. 2020 Oct 16. pii: 5924496. doi: 10.1093.
PubMed

OPITZ CA, Turcan S
From anti-aging drugs to cancer therapy: Is there a potential for sirtuin activators in gliomas?
Neuro Oncol. 2020 Oct 16. pii: 5924499. doi: 10.1093.
PubMed

ALNAHHAS I, Rayi A, Ong S, Giglio P, et al
Management of gliomas in patients with Lynch Syndrome.
Neuro Oncol. 2020 Oct 16. pii: 5924485. doi: 10.1093.
PubMed

CHAMBERLAIN MC
Leptomeningeal metastases: how best to assess response.
Neuro Oncol. 2020;22:1417-1418.
PubMed

ROSSI M, Gay L, Ambrogi F, Nibali MC, et al
Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas.
Neuro Oncol. 2020 Oct 13. pii: 5922564. doi: 10.1093.
PubMed Abstract available

September 2020

DAS S
The ethics of neuro-oncology in the era of COVID-19: lessons to be learned.
Neuro Oncol. 2020;22:1399.
PubMed

XU W, Hu X, Zhang J
Letter regarding article "Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion".
Neuro Oncol. 2020;22:1400-1401.
PubMed

KOTECHA R, Yomo S, Suh JH
Response to letter regarding "Stereotactic radiosurgery for nonfunctioning pituitary adenomas: meta-analysis and International Society of Stereotactic Radiosurgery (ISRS) practice opinion".
Neuro Oncol. 2020;22:1402-1403.
PubMed

TSANG DS, Kim L, Liu ZA, Janzen L, et al
Intellectual changes after radiation for children with brain tumors: which brain structures are most important?
Neuro Oncol. 2020 Sep 16. pii: 5906521. doi: 10.1093.
PubMed Abstract available

August 2020

GUERREIRO STUCKLIN AS, Mueller S
Opportunities for the treatment of NF1-associated low-grade gliomas: how to decide on the best treatment options for patients?
Neuro Oncol. 2020 Aug 25. pii: 5896906. doi: 10.1093.
PubMed

BOHM AK, DePetro J, Binding CE, Gerber A, et al
In vitro modeling of glioblastoma initiation using PDGF-AA and p53-null neural progenitors.
Neuro Oncol. 2020;22:1150-1161.
PubMed Abstract available

SHI C, Ye Z, Han J, Ye X, et al
BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma.
Neuro Oncol. 2020;22:1114-1125.
PubMed Abstract available

WICK A, Kessler T, Platten M, Meisner C, et al
Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.
Neuro Oncol. 2020;22:1162-1172.
PubMed Abstract available

July 2020

KARREMAN MA, Winkler F
Targeting an adhesion molecule to prevent brain colonization of lung cancer.
Neuro Oncol. 2020;22:899-900.
PubMed

GEURTS M, van den Bent MJ
Fast-growing oligodendrogliomas are aggressive tumors-the real life biomarker?
Neuro Oncol. 2020;22:907-908.
PubMed

COLO F, Larrouquere L, Rivoirard R, Loiseau H, et al
Bevacizumab in progressive disseminated atypical choroid plexus papilloma in adults.
Neuro Oncol. 2020;22:1046-1047.
PubMed

JAIN R, Johnson DR, Patel SH, Castillo M, et al
"Real world" use of a highly reliable imaging sign: "T2-FLAIR mismatch" for identification of IDH mutant astrocytomas.
Neuro Oncol. 2020;22:936-943.
PubMed Abstract available

ROUX A, Tauziede-Espariat A, Zanello M, Peeters S, et al
Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults.
Neuro Oncol. 2020;22:993-1005.
PubMed Abstract available

June 2020

BENNETT J, Bouffet E
Neuro-oncology in adolescents and young adults-an unmet need.
Neuro Oncol. 2020;22:752-753.
PubMed

HU LS, Swanson KR
Roadmap for the clinical integration of radiomics in neuro-oncology.
Neuro Oncol. 2020;22:743-745.
PubMed

March 2020

KOTECHA R, Sahgal A, Rubens M, De Salles A, et al
Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion.
Neuro Oncol. 2020;22:318-332.
PubMed Abstract available

LASOCKI A, Khoo C, Lau PKH, Kok DL, et al
High-resolution MRI demonstrates that more than 90% of small intracranial melanoma metastases develop in close relationship to the leptomeninges.
Neuro Oncol. 2020;22:423-432.
PubMed Abstract available

February 2020

OSTROM QT, Kruchko C, Barnholtz-Sloan JS
Pilocytic astrocytomas: where do they belong in cancer reporting?
Neuro Oncol. 2020;22:298-300.
PubMed

January 2020

TEW BY, Legendre C, Schroeder MA, Triche T, et al
Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones.
Neuro Oncol. 2020;22:70-83.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.